Form 10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-17-247725.txt : 20170804 0001193125-17-247725.hdr.sgml : 20170804 20170803185258 ACCESSION NUMBER: 0001193125-17-247725 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170804 DATE AS OF CHANGE: 20170803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: T2 Biosystems, Inc. CENTRAL INDEX KEY: 0001492674 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 204827488 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36571 FILM NUMBER: 171006487 BUSINESS ADDRESS: STREET 1: 101 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-457-1200 MAIL ADDRESS: STREET 1: 101 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 10-Q 1 d411451d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2017

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 001-36571

T2 Biosystems, Inc.

(Exact name of registrant as specified in its charter)


Delaware		20-4827488
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

101 Hartwell Avenue Lexington, Massachusetts		02421
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (781) 761-4646

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant of Section 13(a) of the Exchange Act ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of August 2, 2017, the registrant had 30,764,319 shares of common stock outstanding.

T2 BIOSYSTEMS, INC.

TABLE OF CONTENTS


		Page

	PART I FINANCIAL INFORMATION

Item 1.	Financial Statements (unaudited)		1

	Condensed Consolidated Balance Sheets as of June 30, 2017 and December 31, 2016		1

	Condensed Consolidated Statements of Operations and Comprehensive Loss for three and six months ended June 30, 2017 and June 30, 2016		2

	Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2017 and June 30, 2016		3

	Notes to Condensed Consolidated Financial Statements		4

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		18

Item 3.	Quantitative and Qualitative Disclosures about Market Risk		32

Item 4.	Controls and Procedures		32

	PART II OTHER INFORMATION

Item 1.	Legal Proceedings		32

Item 1A.	Risk Factors		33

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		33

Item 3.	Defaults Upon Senior Securities		33

Item 4.	Mine Safety Disclosures		33

Item 5.	Other Information		33

Item 6.	Exhibits, Financial Statement Schedules		34

SIGNATURES			35

PART I.

FINANCIAL INFORMATION

Item 1. Financial Statements

T2 BIOSYSTEMS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

(Unaudited)


	June 30, 2017			December 31, 2016
Assets
Current assets:
Cash and cash equivalents	$	46,134		$	73,488
Accounts receivable		981			327
Prepaid expenses and other current assets		660			820
Inventories, net		1,014			803

Total current assets		48,789			75,438
Property and equipment, net		14,510			13,589
Restricted cash		260			260
Other assets		218			281

Total assets	$	63,777		$	89,568

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	1,660		$	962
Accrued expenses and other current liabilities		4,701			4,908
Current portion of notes payable		1,365			1,269
Deferred revenue		2,494			2,445
Current portion of lease incentives		248			301

Total current liabilities		10,468			9,885
Notes payable, net of current portion		39,908			39,504
Lease incentives, net of current portion		771			792
Other liabilities		305			49
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at June 30, 2017 and December 31, 2016		—			—
Common stock, $0.001 par value; 200,000,000 shares authorized; 30,763,919 and 30,482,712 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively		32			30
Additional paid-in capital		246,141			242,997
Accumulated deficit		(233,848	)		(203,689	)

Total stockholders’ equity		12,325			39,338

Total liabilities and stockholders’ equity	$	63,777		$	89,568

See accompanying notes to condensed consolidated financial statements.

T2 BIOSYSTEMS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share data)

(Unaudited)


	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
Revenue:
Product revenue	$	735		$	151		$	1,366		$	588
Research revenue		221			839			531			1,498

Total revenue		956			990			1,897			2,086
Costs and expenses:
Cost of product revenue		1,989			1,781			3,617			2,807
Research and development		7,112			6,369			13,697			12,958
Selling, general and administrative		5,759			6,143			11,633			12,347

Total costs and expenses		14,860			14,293			28,947			28,112

Loss from operations		(13,904	)		(13,303	)		(27,050	)		(26,026	)
Interest expense, net		(1,654	)		(805	)		(3,291	)		(1,540	)
Other income, net		102			62			181			94

Net loss and comprehensive loss	$	(15,456	)	$	(14,046	)	$	(30,160	)	$	(27,472	)

Net loss per share — basic and diluted	$	(0.50	)	$	(0.58	)	$	(0.99	)	$	(1.13	)

Weighted-average number of common shares used in computing net loss per share — basic and diluted		30,661,200			24,321,310			30,595,933			24,270,041

See accompanying notes to condensed consolidated financial statements.

T2 BIOSYSTEMS, INC.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(In thousands)

(Unaudited)


	Six Months Ended June 30,
	2017			2016
Cash flows from operating activities
Net loss	$	(30,160	)	$	(27,472	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		1,432			1,068
Stock-based compensation expense		2,550			2,527
Loss on sale of T2 owned equipment		107			—
Non-cash interest expense		1,291			308
Deferred rent		(74	)		(123	)
Changes in operating assets and liabilities:
Accounts receivable		(654	)		81
Prepaid expenses and other assets		225			276
Inventories, net		(212	)		(752	)
Accounts payable		698			(49	)
Accrued expenses and other liabilities		(230	)		228
Deferred revenue		48			(879	)

Net cash used in operating activities		(24,979	)		(24,787	)
Cash flows from investing activities
Purchases and manufacture of property and equipment		(2,468	)		(3,173	)

Net cash used in investing activities		(2,468	)		(3,173	)
Cash flows from financing activities
Payment of offering costs for issuance of common stock in public offering		—			(385	)
Proceeds from issuance of common stock and stock options exercises, net		713			700
Proceeds from notes payable, net of issuance costs		—			4,593
Repayments of note payable		(620	)		(392	)

Net cash provided by financing activities		93			4,516

Net decrease in cash and cash equivalents		(27,354	)		(23,444	)
Cash and cash equivalents at beginning of period		73,488			73,662

Cash and cash equivalents at end of period	$	46,134		$	50,218

Supplemental disclosures of cash flow information
Cash paid for interest	$	1,981		$	1,146

Supplemental disclosures of noncash investing and financing activities
Accrued property and equipment	$	51		$	184

See accompanying notes to condensed consolidated financial statements.

T2 BIOSYSTEMS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Nature of Business

T2 Biosystems, Inc. (the “Company”) was incorporated on April 27, 2006 as a Delaware corporation with operations based in Lexington, Massachusetts. The Company is an in vitro diagnostics company that has developed an innovative and proprietary technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company is using its T2 Magnetic Resonance technology (“T2MR”) to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (“CFU/mL”). The Company’s initial development efforts target sepsis and lyme disease, which are areas of significant unmet medical need in which existing therapies could be more effective with improved diagnostics. On September 22, 2014, the Company received market clearance from the U.S. Food and Drug Administration (“FDA”) for its first two products, the T2Dx Instrument (the “T2Dx”) and T2Candida Panel (“T2Candida”). On June 30, 2017 the Company received CE Mark for its T2Bacteria Panel (“T2Bacteria”).

Liquidity

At June 30, 2017, the Company had cash and cash equivalents of $46.1 million and an accumulated deficit of $233.8 million. The future success of the Company is dependent on its ability to successfully commercialize its FDA approved products, obtain regulatory clearance for and successfully launch its future product candidates, including T2Bacteria, obtain additional capital and ultimately attain profitable operations. Historically, the Company has funded its operations primarily through its August 2014 initial public offering, its December 2015 secondary public offering, its September 2016 private investment in public equity (“PIPE”) financing, private placements of redeemable convertible preferred stock and through debt financing arrangements.

The Company is subject to a number of risks similar to other newly commercial life science companies, including, but not limited to commercially launching the Company’s products, development and market acceptance of the Company’s product candidates, development by its competitors of new technological innovations, protection of proprietary technology, and raising additional capital.

Having obtained authorization from the FDA to market T2Dx and T2Candida, the Company has incurred significant commercialization expenses related to product sales, marketing, manufacturing and distribution. In addition, the Company expects that costs and expenses may increase as it continues the research and development of other product candidates and maintains, expands and protects its intellectual property portfolio. The Company may seek to fund its operations through public equity or private equity or debt financings, as well as other sources. However, the Company may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. The Company’s failure to raise capital or enter into such other arrangements if and when needed would have a negative impact on the Company’s business, results of operations and financial condition and the Company’s ability to develop and commercialize T2Dx, T2Candida, T2Bacteria and other product candidates.

Management believes that its existing cash and cash equivalents at June 30, 2017, together with the additional remaining liquidity on the Company’s Term Loan Agreement of up to an additional $10.0 million, will be sufficient to allow the Company to fund its current operating plan for 12 months from the date the financial statements are issued. The borrowing on the Term Loan Agreement is available at any time through July 27, 2018, and is subject to certain conditions including that the Company receive 510(k) clearance for the marketing of T2Bacteria^TM by the U.S. Food and Drug Administration (“FDA”) by April 30, 2018 (see Note 5). Because certain elements of the Company’s plan are outside of the Company’s control they cannot be considered probable, as defined by ASU 2014-15, Presentation of Financial Statements - Going Concern. Should the Company’s current operating plan not materialize as expected, including the Company’s ability to draw additional borrowings on the Term Loan Agreement on a timely basis, the Company would delay certain research projects and capital expenditures and reduce or eliminate certain future operating expenses in order to fund operations at reduced levels for the Company to continue as a going concern for a period of 12 months from the date the financial statements are issued.

For more information, refer to the section titled “Liquidity and Capital Resources” in Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations and the section entitled “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2016, for additional risks associated with our capital needs.

2. Summary of Significant Accounting Policies

Basis of Presentation

The Company’s financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP as defined in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). The Company’s condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, T2 Biosystems Securities Corporation. All intercompany balances and transactions have been eliminated.

We have evaluated subsequent events from June 30, 2017 through the date of the issuance of these consolidated financial statements and have determined that no material subsequent events have occurred that would affect the information presented in these consolidated financial statements.

Unaudited Interim Financial Information

Certain information and footnote disclosures normally included in the Company’s annual financial statements have been condensed or omitted. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.

The accompanying interim condensed consolidated balance sheet as of June 30, 2017, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2017 and 2016, the condensed consolidated statements of cash flows for the three and six months ended June 30, 2017 and 2016 and the related financial data and other information disclosed in these notes are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual financial statements, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of June 30, 2017, and the results of its operations and its cash flows for the three and six months ended June 30, 2017 and 2016. The results for the three and six months ended June 30, 2017 are not necessarily indicative of the results to be expected for the year ending December 31, 2017, any other interim periods, or any future year or period.

Segment Information

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is the Chief Executive Officer. The Company views its operations and manages its business in one operating segment, which is the business of developing and, upon regulatory clearance, launching commercially its diagnostic products aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier.

Net Loss Per Share

Basic net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net loss per share calculation, stock options and unvested restricted stock are considered to be common stock equivalents, but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share applicable to common stockholders was the same for all periods presented.

Guarantees

As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while each such officer or director is, or was, serving at the Company’s request in such capacity. The term of the indemnification is the officer’s or director’s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors’ and officers’ liability insurance coverage that limits its exposure and enables the Company to recover a portion of any future amounts paid.

The Company leases office, laboratory and manufacturing space under noncancelable operating leases. The Company has standard indemnification arrangements under the leases that require it to indemnify the landlords against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation or nonperformance of any covenant or condition of the Company’s leases.

In the ordinary course of business, the Company enters into indemnification agreements with certain suppliers and business partners where the Company has certain indemnification obligations limited to the costs, expenses, fines, suits, claims, demands, liabilities and actions directly resulting from the Company’s gross negligence or willful misconduct, and in certain instances, breaches, violations or nonperformance of covenants or conditions under the agreements.

As of June 30, 2017 and December 31, 2016, the Company had not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.

Revenue Recognition

The Company generates revenue from product sales, which includes the sale of instruments, consumable diagnostic tests and related services, and research and development agreements with third parties. The Company recognizes revenue in accordance with FASB ASC Topic 605, Revenue Recognition (“ASC 605”). Accordingly, the Company recognizes revenue when all of the following criteria have been met:

Persuasive evidence of an arrangement exists

ii.

Delivery has occurred or services have been rendered

iii.

The seller’s price to the buyer is fixed or determinable

iv.

Collectability is reasonably assured

If any of the above criteria have not been met, the Company defers revenue until such time each of the criteria have been satisfied.

customers. The Company either sells instruments to customers and international distributors, or retains title and places the instrument at the customer site pursuant to a reagent rental agreement. When the instrument is directly purchased by a customer, the Company recognizes revenue when all applicable revenue recognition criteria are met. When the instrument is placed under a reagent rental agreement, the Company’s customers generally agree to fixed term agreements, which can be extended, certain of which may include minimum purchase commitments and/or incremental charges on each consumable diagnostic test purchased, which varies based on the volume of test cartridges purchased. Revenue from the sale of consumable diagnostic tests, which includes the incremental charge, is recognized upon delivery or shipment as a component of product revenue in the Company’s consolidated statements of operations and comprehensive loss.

Direct sales of instruments include warranty, maintenance and technical support services for one year following the installation of the purchased instrument (“Maintenance Services”). After the completion of the initial Maintenance Services period, customers have the option to renew the Maintenance Services for additional one year periods in exchange for additional consideration. In addition, the Company may provide training to customers. The Company defers revenue from the initial sale of the instrument equal to the relative fair value of the one year of Maintenance Services and training and recognizes the amounts ratably over the service delivery period.

The Company warrants that consumable diagnostic tests will be free from defects, when handled according to product specifications, for the stated life of the product. To fulfill valid warranty claims, the Company either provides a credit to its customers on future orders or provides a replacement product. Accordingly, the Company defers revenue associated with the estimated defect rates of the consumable diagnostic tests.

The Company does not offer rights of return for instruments or consumable diagnostic tests.

Shipping and handling costs incurred associated with products sold to customers are recorded as a cost of product revenue in the consolidated statement of operations and comprehensive loss. Shipping and handling costs billed to customers in connection with a product sale are recorded as a component of product revenue in the consolidated statements of operations and comprehensive loss.

For multiple-element arrangements, the Company identifies the deliverables included within each agreement and evaluates which deliverables represent separate units of accounting. The determination that multiple elements in an arrangement meet the criteria for separate units of accounting requires the Company’s management to exercise judgment. The Company accounts for those components as separate elements when the following criteria are met: (1) the delivered items have value to the customer on a stand-alone basis; and, (2) if there is a general right of return relative to the delivered items, delivery or performance of the undelivered items is considered probable and within its control.

The consideration received is allocated among the separate units of accounting based on a selling price hierarchy. The selling price hierarchy is based on: (1) vendor specific objective evidence (“VSOE”), if available; (2) third party evidence of selling price if VSOE is not available; or (3) best estimated selling price (“BESP”) if neither VSOE nor third party evidence is available. The Company generally expects that it will not be able to establish selling price using third-party evidence due to the nature of our products and the markets in which the Company competes, and, as such, the Company typically will determine selling price using VSOE or BESP.

When the Company establishes selling price using BESP, consideration is given to both market and Company-specific factors, including the cost to produce the deliverable and the anticipated margin on that deliverable, as well as the characteristics of markets in which the deliverable is sold.

Revenue earned from activities performed pursuant to research and development agreements is reported as research revenue in the consolidated statements of operations and comprehensive loss, using the proportional performance method as the work is completed, limited to payments earned, and the related costs are expensed as incurred as research and development expense. The timing of receipt of cash from the Company’s research and development agreements generally differs from when revenue is recognized.

Product Recall

In July 2016, the Company initiated a voluntary recall and replacement of its T2Candida cartridges at certain customer sites because T2Candida was experiencing higher than normal invalid test rates as the T2Candida cartridges aged. As of June 30, 2016, as a result of this voluntary recall, the Company deferred revenue totaling $149,000 and recorded additional costs of product revenue of $41,000 related to returned products, which are no longer usable. As of June 30, 2017, the Company had $20,000 of deferred revenue and $2,000 of warranty reserve remaining, both related to this voluntary recall. The impact of the voluntary recall on T2Candida cartridges in inventory was not material to the condensed consolidated financial statements.

Cost of Product Revenue

Cost of product revenue includes the cost of materials, direct labor and manufacturing overhead costs used in the manufacture of consumable diagnostic tests sold to customers and related license and royalty fees. Cost of product revenue also includes depreciation on revenue generating T2Dx systems that have been placed with customers under reagent rental agreements; costs of materials, direct labor and manufacturing overhead costs on the T2Dx systems sold to customers; and other costs such as customer support costs, royalties and license fees, warranty and repair and maintenance expense on the T2Dx systems that have been placed with customers under reagent rental agreements.

Research and Development Costs

Costs incurred in the research and development of the Company’s product candidates are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including activities associated with performing services under research revenue arrangements, and include salaries and benefits, stock compensation, research-related facility and overhead costs, laboratory supplies, equipment and contract services.

Recent Accounting Standards

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

Accounting Standards Adopted

In August 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” which is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its financial obligations as they become due within one year after the date that the financial statements are issued (or are available to be issued). ASU No. 2014-15 provides guidance to an organization’s management, with principles and definitions intended to reduce diversity in the timing and content of disclosures commonly provided by organizations in the footnotes of their financial statements. ASU No. 2014-15 was effective for annual reporting periods ending after December 15, 2016, and for annual and interim periods thereafter. This standard has been adopted and the Company does not believe it is required to make any additional disclosures.

In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory (“ASU 2015-11”). The standard simplifies the subsequent measurement of inventory by requiring inventory to be measured at the lower of cost and net realizable value for entities using the first-in-first out method of valuing inventory. ASU 2015-11 eliminates other measures required by current guidance to determine net realizable value. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016 and interim periods within those fiscal years and early adoption is permitted. The Company’s adoption of this standard did not have a material effect on its condensed consolidated financial statements.

which they occurred. The guidance is effective for public entities for fiscal years beginning after December 15, 2016, and interim periods within those years. Early adoption is permitted, however all of the guidance included in the update must be applied when adopted. The Company must use a modified retrospective transition method for adopting and record the cumulative effect of all unrecognized benefits and any change in valuation allowances at the end of the prior tax period as an adjustment to retained earnings. The Company’s adoption of this standard did not have a material effect on its condensed consolidated financial statements and prior periods have not been adjusted. As a result, the Company established a net operating loss deferred tax asset of $1.2 million to account for prior period excess tax benefits through retained earnings, however an offsetting valuation allowance of $1.2 million will also be established through retained earnings because it is not more likely than not that the deferred tax asset will be realized due to historical and expected future losses, such that there is no impact on the Company’s condensed consolidated financial statements. The Company also elected to maintain the use of estimated forfeitures in the calculation of stock based compensation.

In March 2016, the FASB issued ASU No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments (“ASU 2016-06”), which applies to all issuers of or investors in debt instruments with embedded call or put options. ASU 2016-06 clarifies the requirements for assessing whether contingent call or put options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts. Entities performing the assessment under the guidance of ASU 2016-06 are required to assess the embedded call or put options solely in accordance with the four-step decision process. In addition, ASU 2016-06 clarifies what steps are required when assessing whether the economic characteristics and risks of call or put options are clearly and closely related to the economic characteristics and risks of their debt hosts. ASU 2016-06 is effective for financial statements issued for fiscal years beginning after December 15, 2016 and interim periods within those fiscal years using the modified retrospective method for existing debt instruments. The Company’s adoption of this standard did not have a material effect on its condensed consolidated financial statements.

Accounting Standards Issued, Not Adopted

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASC 2016-15”), which provides guidance on the classification of certain specific cash flow issues including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of certain insurance claims and distributions received from equity method investees. The standard requires the use of a retrospective approach to all periods presented, but may be applied prospectively if retrospective application would be impracticable. The guidance is effective for public entities for fiscal years beginning after December 15, 2017, and interim periods within those years, and early application is permitted. The Company is currently evaluating the impact of its pending adoption of ASU 2016-15 on the Company’s consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases (“ASU 2016-02”), which applies to all leases. Under ASU 2016-02, a right-of-use asset and lease obligation will be recorded for all leases, whether operating or financing leases, while the statement of operations will reflect lease expense for operating leases and amortization and interest expense for financing leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 and interim periods within those years, which is the year ended December 31, 2019 for the Company. Entities are required to use a modified retrospective approach of adoption for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. Full retrospective application is prohibited. The Company is evaluating the new guidance and the expected effect on the Company’s consolidated financial statements.

In June 2014, the FASB issued amended guidance, ASU No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which is applicable to revenue recognition that will now be effective for the Company for the year ending December 31, 2018, as a result of the deferral of the effective date adopted by the FASB in July 2015. The new guidance must be adopted using either a full retrospective approach for all periods presented or a modified retrospective approach. Early adoption prior to the original adoption date of ASU 2014-09 is not permitted. The new guidance applies a more principles-based approach to revenue recognition. The Company currently anticipates adoption of the new standard effective January 1, 2018 under the modified retrospective method. The Company’s revenue is primarily comprised of product sales and research services, and the Company is in the process of determining the impact of the new standard on its financial statements.

3. Fair Value Measurements

The Company measures the following financial assets at fair value on a recurring basis. There were no transfers between levels of the fair value hierarchy during any of the periods presented. The following tables set forth the Company’s financial assets carried at fair value categorized using the lowest level of input applicable to each financial instrument as of June 30, 2017 and December 31, 2016 (in thousands):


	Balance at June 30, 2017		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash	$	2,953	$	2,953	$	—	$	—
Money market funds		43,181		43,181		—		—
Restricted cash		260		260		—		—

Total	$	46,394	$	46,394	$	—	$	—


	Balance at December 31, 2016		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash	$	16,887	$	16,887	$	—	$	—
Money market funds		56,601		56,601		—		—
Restricted cash		260		260		—		—

Total	$	73,748	$	73,748	$	—	$	—

For certain financial instruments, including accounts payable and accrued expenses, the carrying amounts approximate their fair values as of June 30, 2017 and December 31, 2016 because of their short-term nature. At June 30, 2017 and December 31, 2016, the carrying value of the Company’s debt approximated fair value, which was determined using Level 3 inputs, using market quotes from brokers and is based on current rates offered for similar debt (Note 5).

4. Supplemental Balance Sheet Information

Inventories

Inventories are stated at the lower of cost or net realizable value on a first-in, first-out basis and are comprised of the following (in thousands):


	June 30, 2017		December 31, 2016
Raw materials	$	463	$	389
Work-in-process		469		351
Finished goods		82		63

Total inventories, net	$	1,014	$	803

Property and Equipment

Property and equipment consists of the following (in thousands):


	June 30, 2017			December 31, 2016
Office and computer equipment	$	409		$	409
Software		743			708
Laboratory equipment		4,078			4,516
Furniture		200			200
Manufacturing equipment		910			897
Manufacturing tooling and molds		160			154
T2-owned instruments and components		10,933			9,119
Leasehold improvements		3,372			3,353
Construction in progress		1,488			1,299

		22,293			20,655
Less accumulated depreciation and amortization		(7,783	)		(7,066	)

Property and equipment, net	$	14,510		$	13,589

Construction in progress is primarily comprised of equipment and leasehold improvement construction projects that have not been placed in service. T2-owned instruments and components is comprised of raw materials and work-in-process inventory that are expected to be used or used to produce Company-owned instruments, based on our business model and forecast, and completed instruments that will be used for internal research and development, clinical studies or reagent rental agreements with customers. Completed T2-owned instruments are placed in service once installation procedures are completed and are depreciated over five years. The Company has approximately $7.8 million and $5.7 million of T2-owned instruments installed and depreciating as of June 30, 2017 and December 31, 2016, respectively. Depreciation expense for T2-owned instruments placed at customer sites pursuant to reagent rental agreements is recorded as a component of cost of product revenue and totaled approximately $0.2 million and $0.2 million for the three months ended June 30, 2017 and 2016, respectively, and $0.4 million and $0.2 million for the six months ended June 30, 2017 and 2016, respectively. Depreciation expense for T2-owned instruments used for internal research and development and clinical studies is recorded as a component of research and development expense.

Accrued Expenses

Accrued expenses consist of the following (in thousands):


	June 30, 2017		December 31, 2016
Accrued payroll and compensation	$	2,234	$	2,479
Accrued research and development expenses		1,205		846
Accrued professional services		545		884
Other accrued expenses		717		699

Total accrued expenses	$	4,701	$	4,908

5. Notes Payable

Future principal payments on the notes payable are as follows (in thousands):


	June 30, 2017			December 31, 2016
Term loan agreement, net of deferred issuance costs of $2.7 million and $3.0 million, respectively	$	38,141		$	37,031
Equipment lease credit facility, net of deferred issuance cost of $34 and $45 thousand, respectively		3,132			3,742

Total notes payable		41,273			40,773
Less: current portion of notes payable		(1,365	)		(1,269	)

Notes payable, net of current portion	$	39,908		$	39,504

Term Loan Agreement

In December 2016, the Company entered into a Term Loan Agreement (the “Term Loan Agreement”) with CRG Servicing LLC (“CRG”). The Company initially borrowed $40.0 million pursuant to the Term Loan Agreement and may borrow up to an additional $10.0 million at any time through and including July 27, 2018, provided that, among other conditions, the Company receives 510(k) clearance for the marketing of T2Bacteria^TM by the FDA on or before April 30, 2018 (the “Approval Milestone”). The Term Loan Agreement has a six-year term with three years (through December 30, 2019) of interest-only payments, which period shall be extended to four years (through December 30, 2020) if the Company achieves the Approval Milestone, after which quarterly principal and interest payments will be due through the December 30, 2022 maturity date. Interest on the amounts borrowed under the Term Loan Agreement accrues at an annual fixed rate of (a) prior to the Approval Milestone, 12.5%, 4.0% of which may be deferred during the interest-only period by adding such amount to the aggregate principal loan amount and (b) following the Approval Milestone, 11.5%, 3.5% of which may be deferred during the interest-only period by adding such amount to the aggregate principal loan amount. In addition, if the Company achieves certain financial performance metrics, the loan will convert to interest-only until the December 30, 2022 maturity, at which time all unpaid principal and accrued unpaid interest will be due and payable. The Company is required to pay CRG a financing fee based on the loan principal amount drawn. The Company is also required to pay a final payment fee of 8.0% of the principal outstanding upon repayment.

The Company may prepay all or a portion of the outstanding principal and accrued unpaid interest under the Term Loan Agreement at any time upon prior notice subject to a prepayment fee during the first five years of the term and no prepayment fee thereafter. As security for its obligations under the Term Loan Agreement the Company entered into a security agreement with CRG whereby the Company granted a lien on substantially all of its assets, including intellectual property. The Term Loan Agreement also contains customary affirmative and negative covenants for a credit facility of this size and type. The Term Loan Agreement also requires the Company to achieve certain revenue targets, whereby the Company is required to pay double the amount of any shortfall as an acceleration of principal payments. The Term Loan Agreement includes a subjective acceleration clause whereby an event of default, including a material adverse change in the business, operations, or conditions (financial or otherwise), could result in the acceleration of the obligations under the Term Loan Agreement. Under certain circumstances, a default interest rate of an additional 4.0% per annum will apply at the election of CRG on all outstanding obligations during the occurrence and continuance of an event of default. CRG has not exercised its right under this clause, as there have been no such events. The Company believes the likelihood of CRG exercising this right is remote.

The Company assessed the terms and features of the Term Loan Agreement in order to identify any potential embedded features that would require bifurcation or any beneficial conversion features. As part of this analysis, the Company assessed the economic characteristics and risks of the Term Loan Agreement, including put and call features. The Company determined that the features of the Term Loan Agreement are either clearly and closely associated with a debt host and do not require bifurcation as a derivative liability, or the fair value of the feature is immaterial. Included in these features are principal payment acceleration clauses triggered by a developmental milestone. Should the Company’s assessment of this milestone change, there could be a non-cash charge in operations. The Company will continue to reassess the features to determine if they require separate accounting on a quarterly basis.

In December 2016, pursuant to the Term Loan Agreement, the Company made an initial draw of $39.2 million, net of financing fees. The Company used approximately $28.0 million of the initial proceeds to repay approximately $27.5 million of outstanding debt pursuant to the Loan and Security Agreement and to repay approximately $0.5 million of outstanding debt pursuant to the Promissory Note. Upon the repayment of all amounts owed by the Company under these agreements, all commitments were terminated and all security interests granted by the Company were released.

In connection with the Term Loan Agreement entered into in December 2016, the Company issued to CRG four separate warrants to purchase a total of 528,958 shares of the Company’s common stock. The warrants are exercisable any time prior to December 30, 2026 at a price of $8.06 per share, with typical provisions for termination upon a change of control or a sale of all or substantially all of the assets of the Company. The warrants are classified within shareholders’ equity, and the proceeds were allocated between the debt and warrants based on their relative fair value. The fair value of the warrants was determined by the Black Scholes Merton option pricing model. The fair value of the warrants at issuance on December 30, 2016 was $1.8 million.

Equipment Lease Credit Facility

In October 2015, the Company signed a $10.0 million Credit Facility with Essex Capital Corporation (the “Lessor”) to fund capital equipment needs. As one of the conditions of the Term Loan Agreement, the Credit Facility is capped at a maximum of $5.0 million. Under the Credit Facility, Essex will fund capital equipment purchases presented by the Company. The Company will repay the amounts borrowed in 36 equal monthly installments from the date of the amount funded. At the end of the 36 month lease term, the Company has the option to (a) repurchase the leased equipment at the lesser of fair market value or 10% of the original equipment value, (b) extend the applicable lease for a specified period of time, which will not be less than one year, or (c) return the leased equipment to the Lessor.

In April 2016 and June 2016, the Company completed the first two draws under the Credit Facility, of $2.1 million and $2.5 million, respectively. The Company will make monthly payments of $67,000 under the first draw and $79,000 under the second draw. The borrowings under the Credit Facility are treated as capital leases. The amortization of the assets conveyed under the Credit Facility is included as a component of depreciation expense.

6. Stockholders’ Equity

Private Investment in Public Equity Financing

On September 21, 2016, Canon U.S.A., Inc. (“Canon”) became a related party when the Company sold 6,055,341 shares of its common stock (the “Canon Shares”) to Canon at $6.56 per share, the closing price on this date, for an aggregate cash purchase price of $39.7 million. As of September 21, 2016, the Canon Shares represented 19.9% of the outstanding shares of common stock of the Company. In connection with the sale of the Canon Shares, the Company agreed to grant Canon certain board designation rights, including the right to initially appoint a Class I director to the Company’s board of directors. On March 20, 2017, the Company filed with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-3 for purposes of registering the resale of the Canon Shares with the SEC.

7. Stock-Based Compensation

Stock Incentive Plans

2006 Stock Incentive Plan

The Company’s 2006 Stock Option Plan (“2006 Plan”) was established for granting stock incentive awards to directors, officers, employees and consultants of the Company. Upon closing of the Company’s IPO in August 2014, the Company ceased granting stock incentive awards under the 2006 Plan. The 2006 Plan provided for the grant of incentive and non-qualified stock options and restricted stock grants as determined by the Company’s board of directors. Under the 2006 Plan, stock options were generally granted with exercise prices equal to or greater than the fair value of the common stock as determined by the board of directors, expired no later than 10 years from the date of grant, and vest over various periods not exceeding 4 years.

2014 Stock Incentive Plan

The Company’s 2014 Plan (“2014 Plan”, and together with the 2006 Plan, the “Stock Incentive Plans”), provides for the issuance of shares of common stock in the form of stock options, awards of restricted stock, awards of restricted stock units, performance awards, dividend equivalent awards, stock payment awards and stock appreciation rights to directors, officers, employees and consultants of the Company. Since the establishment of the 2014 Plan, the Company has only granted stock options and restricted stock units. Generally, stock options are granted with exercise prices equal to or greater than the fair value of the common stock on the date of grant, expire no later than 10 years from the date of grant, and vest over various periods not exceeding 4 years.

The number of shares reserved for future issuance under the 2014 Plan is the sum of (1) 823,529 shares, (2) any shares that were granted under the 2006 Plan which are forfeited, lapsed unexercised or are settled in cash subsequent to the effective date of the 2014 Plan and (3) an annual increase on the first day of each calendar year beginning January 1, 2015 and ending on January 1, 2024, equal to the lesser of (A) 4% of the shares outstanding (on an as-converted basis) on the final day of the immediately preceding calendar year, and (B) such smaller number of shares determined by the Company’s Board of Directors. As of June 30, 2017 there were 960,529 shares available for future grant under the 2014 Plan.

Stock Options

During the six months ended June 30, 2017 and 2016, the Company granted stock options with an aggregate fair value of $2.3 million and $5.8 million, respectively, which are being amortized into compensation expense over the vesting period of the stock options as the services are being provided.

The following is a summary of stock option activity under the Plans (in thousands, except share and per share amounts):


	Number of Shares			Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term (In years)		Aggregate Intrinsic Value
Outstanding at December 31, 2016		4,042,627		$	8.20		7.05	$	4,091
Granted		743,200			5.30		6.00
Exercised		(193,630	)		2.33				500
Forfeited		(483,274	)		9.03
Cancelled		(102,775	)		14.93

Outstanding at June 30, 2017		4,006,148			7.67		6.98		918

Exercisable at June 30, 2017		2,309,906			7.25		5.54		918

Vested or expected to vest at June 30, 2017		3,761,002			7.69		6.83		918

Included in the stock options outstanding as of December 31, 2016 are 166,066 options to purchase common stock granted to certain executive officers of the Company that vest upon the achievement of certain performance conditions, which include the attainment of specified operating result and regulatory targets, by December 31, 2017, of which 20,000 options to purchase common stock upon the achievement of certain performance conditions were forfeited during the year ended December 31, 2016. There are 146,066 performance based stock options outstanding at June 30, 2017 and December 31, 2016. The Company will continually evaluate the probability of achievement of each performance condition and will commence recognition of stock-based compensation expense on these awards in the period the achievement of each performance condition is deemed probable, including a catch-up adjustment from the grant date.

The weighted-average fair values of stock options granted in the six month periods ended June 30, 2017 and 2016 were $3.11 per share and $4.90 per share, respectively, and were calculated using the following estimated assumptions:


	Six months ended
	June 30,
	2017			2016
Weighted-average risk-free interest rate		1.99	%		1.45	%
Expected dividend yield		—	%		—	%
Expected volatility		63	%		60	%
Expected terms		6.0 years			6.0 years

The total fair values of stock options that vested during the six months ended June 30, 2017 and 2016 were $2.0 million and $2.5 million, respectively.

As of June 30, 2017, there was $6.1 million of total unrecognized compensation cost related to unvested stock options granted under the Stock Incentive Plans, including the unrecognized compensation expense of stock options with performance conditions deemed probable of vesting. Total unrecognized compensation cost will be adjusted for future changes in the estimated forfeiture rate. The Company expects to recognize that cost over a remaining weighted-average period of 2.5 years as of June 30, 2017.

Restricted Stock Units

During the six months ended June 30, 2017, the Company awarded shares of restricted stock units to certain employees and directors at no cost to them, which cannot be sold, assigned, transferred or pledged during the restriction period. The restricted stock and restricted stock units vest through the passage of time, assuming continued employment. Restricted stock units are not included in issued and outstanding common stock until the shares are vested and released. The fair value of the award at the time of the grant is expensed on a straight line basis. The granted restricted stock units had an aggregate fair value of $1.8 million, which are being amortized into compensation expense over the vesting period of the options as the services are being provided.

The following is a summary of restricted stock unit activity under the 2014 Plan (in thousands, except share and per share amounts):


	Number of Shares			Weighted-Average Grant Date Fair Value
Nonvested at December 31, 2016		272,195			5.83
Granted		357,925			5.16
Vested		—			—
Forfeited		(32,900	)		5.80
Canceled		—			—

Nonvested at June 30, 2017		597,220			5.43

There was no vesting of restricted stock units during the six months ended June 30, 2017. As of June 30, 2017, there was $2.2 million of total unrecognized compensation cost related to unvested restricted stock units granted under the Stock Incentive Plans. Total unrecognized compensation cost will be adjusted for future forfeitures . The Company expects to recognize that cost over a remaining weighted-average period of 1.8 years as of June 30, 2017.

Stock-Based Compensation Expense

The following table summarizes the stock-based compensation expense resulting from awards granted under stock incentive plans, including the 2014 ESPP, that was recorded in the Company’s results of operations for the periods presented (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Cost of product revenue	$	36	$	33	$	65	$	59
Research and development		393		341		691		610
Selling, general and administrative		902		826		1,699		1,793

Total stock-based compensation expense	$	1,331	$	1,200	$	2,455	$	2,462

For the three months ended June 30, 2017 and 2016, $53,000 and $37,000 of stock-based compensation expenses was capitalized as part of inventory or T2 instruments and components, respectively. For the six months ended June 30, 2017 and 2016, $86,000 and $65,000 of stock-based compensation expenses was capitalized as part of inventory or T2 instruments and components, respectively.

8. Warrants

In connection with the Term Loan Agreement entered into in December 2016, the Company issued to CRG four separate warrants to purchase a total of 528,958 shares of the Company’s common stock. The warrants are exercisable any time prior to December 30, 2026 at a price of $8.06 per share, with typical provisions for termination upon a change of control or a sale of all or substantially all of the assets of the Company. The warrants are classified within shareholders’ equity, and the proceeds were allocated between the debt and warrants based on their relative fair value. The fair value of the warrants was determined by the Black-Scholes-Merton option pricing model. The fair value of the warrants at issuance on December 30, 2016 was $1.8 million.

9. Net Loss Per Share

The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock method, because their effect would have been anti-dilutive for the periods presented:


	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Options to purchase common shares		4,006,148		4,167,295		4,006,148		4,167,295
Restricted stock units		597,220		—		597,220		—
Warrants to purchase common stock		528,958		—		528,958		—

Total		5,132,326		4,167,295		5,132,326		4,167,295

10. Co-Development Agreements

Canon US Life Sciences

On September 21, 2016, Canon became a related party when the Company sold the Canon Shares for an aggregate cash purchase price of $39.7 million, which represented 19.9% of the outstanding shares of common stock of the Company. On February 3, 2015, the Company entered into a Co-Development Partnership Agreement (the “Co-Development Agreement”) with Canon U.S. Life Sciences, Inc. (“Canon US Life Sciences”) to develop a diagnostic test panel to rapidly detect Lyme disease. Under the terms of the Co-Development Agreement, the Company received an upfront payment of $2.0 million from Canon US Life Sciences, and the agreement includes an additional $6.5 million of consideration upon achieving certain development and regulatory milestones for total aggregate payments of up to $8.5 million. In October 2015, the Company achieved a specified technical requirement and received $1.5 million related to the achievement of the milestone. The Company is eligible to receive an additional $5.0 million under the arrangement, in two milestone payments of $2.0 million and $3.0 million, related to the achievement of additional development and regulatory milestones. All payments under the Co-

Development Agreement are non-refundable once received. The Company will retain exclusive worldwide commercialization rights of any products developed under the Co-Development Agreement, including sales, marketing and distribution and Canon US Life Sciences will not receive any commercial rights and will be entitled to only receive royalty payments on the sales of all products developed under the Co-Development Agreement. Either party may terminate the Co-Development Agreement upon the occurrence of a material breach by the other party (subject to a cure period).

The Company evaluated the deliverables under the Co-Development Agreement and determined that the Co-Development Agreement included one unit of accounting, the research and development services, as the joint research and development committee deliverable was deemed to be de minimis. The Company is recognizing revenue for research and development services as a component of research revenue in the condensed consolidated financial statements as the services are delivered using the proportional performance method of accounting, limited to payments earned. Costs incurred to deliver the services under the Co-Development Agreement are recorded as research and development expense in the condensed consolidated financial statements.

The Company recorded revenue of $0.0 and $0.6 million during the three months ended June 30, 2017 and June 30, 2016, respectively, and recorded revenue of $0.3 million and $1.1 million during the six months ended June 30, 2017 and 2016, under the Co-Development Agreement, and expects to record revenue over the next two years, provided development milestones are achieved.

Allergan Sales, LLC

On November 1, 2016, the Company entered into a Co-Development, Collaboration and Co-Marketing Agreement (the “Allergan Agreement”) with Allergan Sales, LLC (“Allergan Sales”) to develop (1) a direct detection diagnostic test panel that adds one additional bacteria species to the existing T2Bacteria product candidate (the “T2Bacteria II Panel”), and (2) a direct detection diagnostic test panel for testing drug resistance directly in whole blood (the “T2GNR Panel” and, together with the T2Bacteria II Panel, the “Developed Products”). In addition, both the Company and Allergan Sales will participate in a joint research and development committee and Allergan Sales will receive the right to cooperatively market the T2Candida, T2Bacteria, and the Developed Products under the Allergan Agreement to certain agreed-upon customers. On June 1, 2017 the Company and Allergan Sales entered into an Amendment to the Allergan Agreement which primarily modified the project plan to combine the T2Bacteria II Panel and T2GNR Panel into one test panel.

Under the terms of the Allergan Agreement, the Company received an upfront payment of $2.0 million from Allergan Sales and will receive additional milestone payments upon achieving certain developmental milestones for total aggregate payments of up to $4.0 million. All payments under the Allergan Agreement are non-refundable once received. The Company will retain exclusive worldwide commercialization rights of any products developed under the Allergan Agreement, including distribution, subject to Allergan Sales’ right to co-market the Developed Products. Allergan Sales, at its election, may co-market T2Candida, T2Bacteria and the Developed Products worldwide to certain agreed-upon customers and will receive royalty based on its sales for a period of time.

The Company evaluated the deliverables under the Allergan Agreement and determined that the Allergan Agreement included two units of accounting, the research and development services for the T2Bacteria II Panel and the research and development services for the T2GNR Panel, as the joint research and development committee and right to cooperatively market deliverables were deemed to be de minimus. The Company is recognizing revenue for research and development services as a component of research revenue in the consolidated financial statements as the services are delivered using the proportional performance method of accounting, limited to payments earned. Costs incurred to deliver the services under the Allergan Agreement are recorded as research and development expense in the consolidated financial statements.

The Company recorded revenue of $0.2 million for the three and six months ended June 30, 2017, under the Allergan Agreement and expects to record revenue over the next two years, provided development and regulatory milestones are achieved.

11. Subsequent Events.

None

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This Quarterly Report on Form 10-Q contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, and Section 21E of the Securities and Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, business strategy, prospective products and product candidates, their expected performance and impact on healthcare costs, marketing clearance from the U.S. Food and Drug Administration (“FDA”) regulatory clearance, reimbursement for our product candidates, research and development costs, timing of regulatory filings, timing and likelihood of success, plans and objectives of management for future operations, availability of funding for such operations and future results of anticipated products, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described under the sections in this Quarterly Report on Form 10-Q entitled “Item 1A.—Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this Quarterly Report on Form 10-Q. These forward looking statements are subject to numerous risks, including, without limitation, the following:

•

our expectation to incur losses in the future;

•

the market acceptance of our T2MR technology;

•

our ability to timely and successfully develop and commercialize our existing products and future product candidates;

•

the length of our anticipated sales cycle;

•

our ability to gain the support of leading hospitals and key thought leaders and publish the results of our clinical trials in peer-reviewed journals;

•

our ability to successfully manage our growth;

•

our future capital needs and our need to raise additional funds;

•

the performance of our diagnostics;

•

our ability to compete in the highly competitive diagnostics market;

•

our ability to obtain marketing clearance from the FDA or regulatory clearance for new product candidates in the United States or any other jurisdiction;

•

federal, state, and foreign regulatory requirements, including FDA regulation of our product candidates; and

•

our ability to protect and enforce our intellectual property rights, including our trade secret-protected proprietary rights in T2MR.

These forward-looking statements represent our estimates and assumptions only as of the date of this Quarterly Report on Form 10-Q. Unless required by U.S. federal securities laws, we do not intend to update any of these forward-looking statements to reflect circumstances or events that occur after the statement is made or to conform these statements to actual results. The following discussion should be read in conjunction with the financial statements and notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2016, as supplemented or amended from time to time under “Item 1A.—Risk Factors” in our Quarterly Reports on Form 10-Q, and elsewhere in this Quarterly Report on Form 10-Q.

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the “Item 1A.—Risk Factors” section of this Quarterly Report on Form 10-Q, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Business Overview

We are an in vitro diagnostics company that has developed an innovative and proprietary technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies. We are using our T2 Magnetic Resonance technology (“T2MR”) to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (“CFU/mL”). Our initial development efforts target sepsis and Lyme disease, which are areas of significant unmet medical need in which existing therapies could be more effective with improved diagnostics. On September 22, 2014, we received market clearance from the FDA for our first two products, the T2Dx Instrument (“the T2Dx”) and the T2Candida Panel (“T2Candida”), which have the ability to rapidly identify the five clinically relevant species of Candida, a fungal pathogen known to cause sepsis. In the United States, we have built a direct sales force that is primarily targeting the top 450 hospitals with the highest concentration of patients at risk for Candida infections. In Europe, we have partnered with distributors that target large hospitals in their respective European markets. Three additional diagnostic applications in development are called T2Bacteria, T2Resistance and T2Lyme, which are focused on bacterial sepsis infections and Lyme disease, respectively. In late 2015, we initiated the collection of patient blood samples to support the clinical trial for T2Bacteria, and in early 2017, we initiated a multi-site clinical trial for T2Bacteria. The T2Bacteria Panel is currently available in the United States for Research Use Only (RUO) and the Company is in the final stages of completing the FDA pivotal trial, after which a 510(k) application will be submitted to the FDA for clearance to market in the US. The T2 Bacteria panel received CE Mark on June 30, 2017 allowing for the sale and distribution of the product within the European Union and those countries accepting the CE Mark for sale in Europe. We expect that existing reimbursement codes will support our sepsis and Lyme disease product candidates, and that the anticipated economic savings associated with our sepsis products will be realized directly by hospitals.

another study published in Clinical Infectious Diseases in 2012, the delayed administration of appropriate antifungal therapy was associated with higher mortality among patients with septic shock attributed to Candida infection and, on that basis, the study concluded that more rapid and accurate diagnostic techniques are needed. Due to the high mortality rate associated with Candida infections, physicians often will place patients on antifungal drugs while they await blood culture diagnostic results which generally take at least five days to generate a negative test result. Antifungal drugs are toxic and may result in side effects and can cost over $50 per day. Our T2Candida Panel’s speed to result coupled with its superior sensitivity as compared to blood culture may help reduce the overuse of ineffective, or even unnecessary, antimicrobial therapy which may reduce side effects for patients, lower hospital costs and potentially counteract the growing resistance to antifungal therapy. The administration of inappropriate therapy is a driving force behind the spread of antimicrobial-resistant pathogens, which the United States Centers for Disease Control and Prevention (“CDC”) recently called “one of our most serious health threats.”

We compete with traditional blood culture-based diagnostic companies, including Becton Dickinson & Co. and bioMerieux, Inc., as well as companies offering post-culture species identification using both molecular and non-molecular methods, including bioMerieux, Inc. (and its affiliate, BioFire Diagnostics, Inc.), Bruker Corporation, Accelerate Diagnostics, Luminex, Genmark, Cepheid and Beckman Coulter, a Danaher company.

We have never been profitable and have incurred net losses in each year since inception. Our accumulated deficit at June 30, 2017 was $233.8 million. Substantially all of our net losses resulted from costs incurred in connection with our research and development programs and from selling, general and administrative costs associated with our operations. We have incurred significant commercialization expenses related to product sales, marketing, manufacturing and distribution of our FDA-cleared T2Dx and T2Candida. In addition, we expect that costs and expenses may increase as we continue to develop other product candidates, improve existing products and maintain, expand and protect our intellectual property portfolio. We may seek to fund our operations through public equity or private equity or debt financings, as well as other sources. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements if and when needed would have a negative impact on our business, results of operations and financial condition and our ability to develop, commercialize and drive adoption of the T2Dx, T2Candida, our product candidate, T2Bacteria, and future T2MR-based diagnostics.

Management believes that its existing cash and cash equivalents at June 30, 2017, together with the additional remaining liquidity on the Company’s Term Loan Agreement of up to an additional $10.0 million (which is available at any time through July 27, 2018, subject to certain conditions including that the Company receives 510(k) clearance for the marketing of T2Bacteria^TM by the FDA by April 30, 2018, see Note 5 for details) will be sufficient to allow the Company to fund its current operating plan for at least the next 12 months. Should the Company’s current operating plans not materialize as expected, or it is unable to obtain additional capital on a timely basis, or on acceptable terms, the Company will be required to change its current operating plans to reduce its future expenses in order to fund operations at reduced levels.

Our Commercial Products and the Unmet Clinical Need

Our initial FDA-cleared products, the T2Dx and T2Candida, utilize T2MR to detect species-specific Candida directly from whole blood in as few as three hours versus the one to six or more days typically required by blood culture-based diagnostics. This allows the patient to potentially receive the correct treatment in four to six hours versus 24 to 144 hours for blood culture. The T2Candida runs on the T2Dx and provides high sensitivity with a limit of detection as low as 1 CFU/mL, even in the presence of antimicrobial therapy.

Our T2Candida Panel

Our direcT2 pivotal clinical trial was designed to evaluate the sensitivity and specificity of T2Candida on the T2Dx. The direcT2 trial consisted of two patient arms: a prospective arm with 1,501 samples from patients with a possible infection and a seeded arm with 300 samples, also obtained from patients with a possible infection. T2Candida and the T2Dx

demonstrated a sensitivity of 91.1 percent and a specificity of 99.4 percent. In addition, the speed to a species-specific positive result with T2Candida was 4.4 hours versus 129 hours with blood culture. A negative result from T2Candida was obtained in just 4.2 hours versus greater than 120 hours with blood culture. The data and other information from the direcT2 pivotal clinical trial was published in January 2015 in Clinical Infectious Diseases.

Sepsis is one of the leading causes of death in the United States, claiming more lives annually than breast cancer, prostate cancer and AIDS combined, and it is the most expensive hospital-treated condition. Most commonly afflicting immunocompromised, critical care and elderly patients, sepsis is a severe inflammatory response to a bacterial or fungal infection with a mortality rate of approximately 30%. According to data published by the U.S. Department of Health and Human Services for 2016, the cost of sepsis was over $23 billion in the United States, or approximately 5% of the total aggregate costs associated with domestic hospital stays. Sepsis is typically caused by one or more of five Candida species or over 25 bacterial pathogens, and effective treatment requires the early detection and identification of these specific target pathogens in a patient’s bloodstream. Today, sepsis is typically diagnosed through a series of blood cultures followed by post-blood culture species identification. These methods have substantial diagnostic limitations that lead to a high rate of false negative test results, a delay of up to several days in administration of targeted treatment and the incurrence of unnecessary hospital expense. In addition, the Survey of Physicians’ Perspectives and Knowledge About Diagnostic Tests for Bloodstream Infections in 2015 reported that negative blood culture results are only trusted by 36% of those physicians. Without the ability to rapidly identify pathogens, physicians typically start treatment of at-risk patients with broad-spectrum antibiotics, which can be ineffective and unnecessary and have contributed to the spread of antimicrobial resistance. According to a study published by Critical Care Medicine in 2006, in sepsis patients with documented hypotension, administration of effective antimicrobial therapy within the first hour of detection was associated with a survival rate of 79.9% and, over the ensuing six hours, each hour of delay in initiation of treatment was associated with an average decrease in survival of 7.6%.

We believe our sepsis products, which include T2Candida and our product candidate, T2Bacteria, will redefine the standard of care in sepsis management while lowering healthcare costs by improving both the precision and the speed of detection of sepsis-causing pathogens. According to a study published in the Journal of Clinical Microbiology in 2010, targeted therapy for patients with bloodstream infections can be delayed up to 72 hours due to the wait time for blood culture results. In another study published in Clinical Infectious Diseases in 2012, the delayed administration of appropriate antifungal therapy was associated with higher mortality among patients with septic shock attributed to Candida infection and, on that basis, the study concluded that more rapid and accurate diagnostic techniques are needed. Our pivotal clinical trial demonstrated that T2Candida can deliver actionable results in as few as three hours, with an average time to result during the trial of 4.2 hours, compared to the average time to result of one to six or more days typically required for blood-culture-based diagnostics, which we believe will potentially enable physicians to make treatment decisions and administer targeted treatment to patients in four to six hours versus 24 to 144 hours for blood culture. We believe that T2Bacteria will also deliver actionable results in similar timeframes because this diagnostic panel operates similarly to T2Candida and is designed to run on the same instrument as T2Candida.

Candida is the fourth leading hospital-acquired bloodstream infection, afflicting more than 135,000 patients per year in the United States, and the most lethal form of common bloodstream infections that cause sepsis, with an average mortality rate of approximately 40%. This high mortality rate is largely due to a delay in providing targeted therapy to the patient due to the elapsed time from Candida infection to positive diagnosis. According to a study published in Antimicrobial Agents and Chemotherapy, the Candida mortality rate can be reduced to 11% with the initiation of targeted therapy within 12 hours of presentation of symptoms. Additionally, a typical patient with a Candida infection averages 40 days in the hospital, including nine days in intensive care, resulting in an average cost per hospital stay of more than $130,000 per patient. In a study published in the American Journal of Respiratory and Critical Care Medicine, providing targeted antifungal therapy within 24 hours of the presentation of symptoms decreased the length of hospital stay by approximately ten days and decreased the average cost of care by approximately $30,000 per patient. Furthermore, in April 2015, Future Microbiology published the results of an economic study regarding the use of T2Candida conducted by IMS Health, a healthcare economics agency. In that economic study, IMS demonstrated that an average hospital admitting 5,100 patients at risk for Candida infections could save approximately $5.8 million annually due to decreased hospital stays for patients, reduction in use of antifungal drugs, and other associated savings. The economic study further showed T2Candida can potentially reduce the costs of care by $26,887 per

Candida patient and that rapid detection of Candida reduces patient deaths by 60.6%. Results from a data analysis of T2Candida for the detection and monitoring of Candida infection and sepsis were published comparing aggregated results from the use of T2Candida to blood culture-based diagnostics for the detection of invasive candidiasis and candidemia. The analysis included samples acquired from more than 1,900 patients. Out of 55 prospective patient cases that were tested with T2Candida and blood culture and determined to be positive or likely to be positive for a Candida infection, T2Candida detected 96.4% of the patients (53 cases) compared to detection of 60% of the patients (33 cases) with blood culture. During 2016, a number of T2Candida users presented data on their experiences with the T2Candida Panel which demonstrated both the clinical and economic benefits of use of the T2Candida Panel in the diagnostic regimen. The Henry Ford Health System in Detroit, Michigan reported data on a pre- and post-T2Candida implementation analysis that covered 6 months of clinical experience. The data showed a statistically significant (p = 0.009) seven day reduction in median Intensive Care Unit (“ICU”) length of stay per positive patient that was identified as positive for Candida after implementation of the T2Candida test panel and a trend (p = 0.164) of total hospital length of stay reduction of four days. The data also showed significant reductions in use of antifungal drugs for negative patients tested with T2Candida. The overall economic savings resulting from these clinical benefits was projected to be approximately $2.3 million on an annualized basis. The Lee Health System in Fort Myers, Florida compared patient and economic experience before and after T2Candida implementation. The data demonstrated that in the post-T2Candida cohort, median length of stay for patients with Candida infections was reduced by 7 days when detected by T2Candida while unnecessary antifungal therapy was avoided in 41% of patients tested and was discontinued after one dose in another 15% of patients tested. The economic savings derived solely from reduction in antifungal drug use was $195 per patient tested, net of the cost of the T2Candida test panel. Huntsville Hospital in Huntsville, Alabama, reported that the use of the T2Candida test panel resulted in a reduction in the duration of therapy and time to de-escalation in patients that tested negative for Candida on the T2Candida test panel, yielding net pharmacy savings of approximately $280 per patient tested. T2Candida also detected 56% more positive patients than blood culture. Finally, Riverside Community Hospital in Riverside, California, demonstrated improvements in time to appropriate therapy, increased sensitivity, and rapid discontinuation of antifungal therapy when using T2Candida. Specifically, 83% of patients who tested positive with T2Candida received appropriate therapy within six hours of the blood draw and 100% of patients received appropriate therapy in under nine hours. None of the patients who tested positive had been identified to have been treated with antifungals prior to T2Candida testing. In addition, antifungal therapy was discontinued for 100% of the patients who tested negative with T2Candida.

Due to the high mortality rate associated with Candida infections, physicians often will place patients on antifungal drugs while they await blood culture diagnostic results which generally take at least five days to generate a negative test result. Antifungal drugs are toxic and may result in side effects and can cost over $50 per day. Our T2Candida Panel’s speed to result coupled with its superior sensitivity as compared to blood culture may help reduce the overuse of ineffective, or even unnecessary, antimicrobial therapy which may reduce side effects for patients, hospital costs and potentially, the growing resistance to antifungal therapy. This inappropriate therapy is a driving force behind the spread of antimicrobial-resistant pathogens, which the CDC recently called “one of our most serious health threats.”

Our T2Dx Instrument

Our FDA-cleared T2Dx is an easy-to-use, fully-automated, benchtop instrument utilizing T2MR for use in hospitals and labs for a broad range of diagnostic tests. To operate the system, a patient’s sample tube is snapped onto a disposable test cartridge, which is pre-loaded with all necessary reagents. The cartridge is then inserted into the T2Dx, which automatically processes the sample and then delivers a diagnostic test result. Test results are displayed on screen or directly through the lab information system.

By utilizing our proprietary T2MR technology for direct detection, the T2Dx eliminates the need for sample purification and analyte extraction, which are necessary for other optical-detection devices. Eliminating these sample processing steps increases diagnostic sensitivity and accuracy, enables a broad menu of tests to be run on a single platform, and greatly reduces the complexity of the consumables. The T2Dx incorporates a simple user interface and is designed to efficiently process up to seven specimens simultaneously.

Our T2Bacteria Panel

We are also developing a product candidate named T2Bacteria, a multiplex diagnostic panel that detects six major bacterial pathogens associated with sepsis and, in conjunction with T2Candida and standard empiric therapy regimens, may enable the early, appropriate treatment of 95% of sepsis patients. T2Bacteria, which will also run on the T2Dx, is expected to address the same approximately 6.75 million symptomatic high-risk patients as T2Candida and also a new population of patients who are at increased risk for bacterial infections, including an additional two million patients presenting with symptoms of infection in the emergency room setting. We expect that T2Bacteria will achieve similar performance capabilities and provide similar benefits as T2Candida, including similar time to results and limits of detection. The T2 Bacteria panel received CE Mark on June 30, 2017 allowing for the sale and distribution of the product within the European Union and those countries accepting the CE Mark for sale in Europe. The T2Bacteria Panel is currently available in the United States for Research Use Only (RUO) and the Company is in the final stages of completing the FDA pivotal trial, after which a 510(k) application for clearance to market in the US will be submitted to the FDA.

Our T2MR Platform

T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. For molecular and immunodiagnostics targets, T2MR utilizes advances in the field of magnetic resonance by deploying particles with magnetic properties that enhance the magnetic resonance signals of specific targets. When particles coated with target-specific binding agents are added to a sample containing the target, the particles bind to and cluster around the target. This clustering changes the microscopic environment of water in that sample, which in turn alters the magnetic resonance signal, or the T2 relaxation signal that we measure, indicating the presence of the target.

We believe that T2MR can also address the significant unmet need associated with Lyme disease, a tick-borne illness that can cause prolonged neurological disease and musculoskeletal disease. For patients with Lyme disease, early diagnosis and appropriate treatment significantly reduces both the likelihood of developing neurological and musculoskeletal disorders, as well as the significant costs associated with treating these complications. Our product candidate, T2Lyme, will identify the bacteria that cause Lyme disease directly from the patient’s blood, without the need for blood culture which, for the bacteria associated with Lyme disease, can take several weeks. Our Lyme product candidate is currently in pre-clinical development and we expect to initiate a T2Lyme clinical trial in 2018.

Another significant unmet clinical need is the diagnosis and management of impaired hemostasis, which is a life-threatening condition in which a patient is unable to promote the formation of blood clots to stabilize excessive bleeding. Within the broader population of patients with symptoms of impaired hemostasis, there are over ten million trauma patients in the United States annually. These trauma patients typically face life-threatening injuries or invasive surgical procedures. Approximately 25% of trauma patients have impaired hemostasis, which frequently goes undetected during the initial hospitalization. According to a study in the Journal of the American College of Surgeons, for trauma patients with symptoms of impaired hemostasis, mortality rates were reduced from 45% to 19% with more rapid delivery of therapy. The T2Plex and T2HemoStat are being designed to utilize T2MR and are designed to provide hemostasis measurements in less than 45 minutes. Our product candidate, T2HemoStat, is a comprehensive panel of diagnostic tests that can provide data across the hemostasis spectrum, including measurements of fibrinogen, platelet activity, and clot lysis. We believe that T2HemoStat may be the first panel capable of rapidly identifying key coagulation, platelet and other hematologic factors directly from whole blood on a single, easy-to-operate, compact instrument. We are exploring partnership opportunities to complete the development and commercialization of these products.

We believe T2MR is the first technology with the ability to detect directly from a clinical sample of whole blood, plasma, serum, saliva, sputum or urine, saving time and potentially improving sensitivity by eliminating the need for purification or the extraction of target pathogens. T2MR has been demonstrated to detect cellular targets at limits of detection as low as one colony-forming unit per milliliter (CFU/mL). More than 100 studies published in peer reviewed journals have featured T2MR in a breadth of applications.

Financial Overview

Revenue

We generate revenue from the sale of our products and from activities performed pursuant to research and development agreements.

Revenue earned from activities performed pursuant to research and development agreements is reported as research revenue using the proportional performance method as the work is completed, limited to payments earned, and the related costs are expensed as incurred as research and development expense.

Product revenue is derived from the sale of our instruments and related consumable diagnostic tests, predominantly through our direct sales force in the United States, and distributors in geographic regions outside the United States. We do not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to our customers, including our distributors. Payment terms granted to distributors are the same as those granted to end-user customers and payments are not dependent upon the distributors’ receipt of payment from their end-user customers. We recognize product revenue from the sale of our instruments as soon as all applicable revenue recognition criteria have been met. In the majority of cases, we expect to place our instruments, under reagent rental agreements, in hospitals, certain of which may include minimum commitments and/or an incremental charge on the purchase of our consumable diagnostic tests. Under this business model, we believe we will recover the cost of placing our instruments in hospitals through the margins realized from our consumable diagnostic tests. Our consumable diagnostic tests can only be used with our instruments, and accordingly, as the installed base of our instruments grows, we expect the following to occur:

•

recurring revenue from our consumable diagnostic tests will increase and become subject to less period-to-period fluctuation;

•

consumable revenue will become an increasingly predictable and important contributor to our total revenue; and

•

we will gain economies of scale through the growth in our sales, resulting in improving gross margins and operating margins.

Revenue from consumables is based on the volume of tests sold and the price of each consumable unit.

Cost of Product Revenue

Cost of product revenue includes the cost of materials, direct labor and manufacturing overhead costs used in the manufacture of our consumable diagnostic tests sold to customers and related license and royalty fees. Cost of product revenue also includes depreciation on the revenue-generating T2Dx Instruments that have been placed with our customers under reagent rental agreements; costs of materials, direct labor and manufacturing overhead costs on the T2Dx Instruments sold to customers; and other costs such as customer support costs, warranty and repair and maintenance expense on the T2Dx Instruments that have been placed with our customers under reagent rental agreements. We manufacture the T2Dx Instruments and part of our consumable diagnostic tests in our facilities. We outsource the manufacturing of components of our consumable diagnostic tests to contract manufacturers.

We expect cost of product revenue to continue to represent a high percentage of our product revenue as we continue to invest in our manufacturing capabilities, infrastructure and customer service organization and grow our installed customer base. We plan to continue to expand our capacity to support our growth, which will result in higher cost of revenue in absolute dollars. However, we expect cost of product revenue, as a percentage of revenue, to decline as revenue grows in the future.

Research and development expenses

Our research and development expenses consist primarily of costs incurred for the development of our technology and product candidates, technology improvements and enhancements, clinical trials to evaluate the clinical utility of our product candidates, and laboratory development and expansion, and include salaries and benefits, including stock-based compensation, research-related facility and overhead costs, laboratory supplies, equipment and contract services. Research and development expenses also include costs of delivering products or services associated with research revenue. We expense all research and development costs as incurred.

We anticipate our overall research and development expenses to continue to increase in absolute dollars to support research partnerships, clinical trials and new product development. We have committed, and expect to commit, significant resources toward developing additional product candidates, improving existing products, conducting ongoing and new clinical trials and expanding our laboratory capabilities.

Selling, general and administrative expenses

Selling, general and administrative expenses consist primarily of costs for our sales and marketing, finance, legal, human resources, business development and general management functions, as well as professional services, such as legal, consulting and accounting services. We expect selling, general and administrative expenses to increase in future periods as we commercialize products and future product candidates and as our needs for sales, marketing and administrative personnel grow. Other selling, general and administrative expenses include facility-related costs, fees and expenses associated with obtaining and maintaining patents, clinical and economic studies and publications, marketing expenses, and travel expenses. We expense all selling, general and administrative expenses as incurred.

Interest expense, net

Interest expense, net, consists primarily of interest expense on our notes payable and the amortization of deferred financing costs, partially offset by interest earned on our cash and cash equivalents.

Other income, net

Other income, net, consists of dividend and other investment income, government grant income and the gain or loss associated with the change in the fair value of our liability for warrants to purchase redeemable securities.

Critical Accounting Policies and Use of Estimates

We have prepared our condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States. Our preparation of these condensed consolidated financial statements requires us to make estimates, assumptions, and judgments that affect the reported amounts of assets, liabilities, expenses, and related disclosures at the date of the condensed consolidated financial statements, as well as revenue and expenses recorded during those periods. We evaluated our estimates and judgments on an ongoing basis. We based our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could therefore differ materially from these estimates under different assumptions or conditions.

The items that we disclosed as our critical accounting policies and estimates in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2016 remain materially consistent. For a description of those critical accounting policies, please refer to our Annual Report on Form 10-K filing for the year ended December 31, 2016.

Results of Operations for the Three Months Ended June 30, 2017 and 2016


	Three Months Ended June 30,
	2017			2016			Change
	(in thousands)
Revenue:
Product revenue	$	735		$	151		$	584
Research revenue		221			839			(618	)

Total revenue		956			990			(34	)
Costs and expenses:
Cost of product revenue		1,989			1,781			208
Research and development		7,112			6,369			743
Selling, general and administrative		5,759			6,143			(384	)

Total costs and expenses		14,860			14,293			567

Loss from operations		(13,904	)		(13,303	)		(601	)
Interest expense, net		(1,654	)		(805	)		(849	)
Other income, net		102			62			40

Net loss	$	(15,456	)	$	(14,046	)	$	(1,410	)

Product revenue

Product revenue was $0.7 million for the three months ended June 30, 2017 compared to $0.2 million for the three months ended June 30, 2016, an increase of $0.6 million or 387%. The increase was driven by an increase in sales volume of our products, primarily the sale of T2Candida consumable diagnostic tests, driven from increased usage of consumable diagnostic tests in the installed base and growth in our installed T2Dx Instrument base, as well as sales of our instruments. Product revenue during the three months ended June 30, 2016 was affected by an approximately $0.1 million decrease due to the voluntary product recall.

Research revenue

Research revenue was $0.2 million for the three months ended June 30, 2017, compared to $0.8 million for the three months ended June 30, 2016, a decrease of $0.6 million or 74%. The decrease was primarily the result of lower revenue from service delivered under our Co-Development Agreement with Canon US Life Sciences, which decreased $0.6 million over the prior year period, as well as a decrease in revenue from research and development agreements utilizing T2MR technology with other third parties.

Cost of product revenue

Cost of product revenue was $2.0 million for the three months ended June 30, 2017, compared to $1.8 million for the three months ended June 30, 2016, an increase of $0.2 million. The increase was primarily due to increased product revenue and continued expansion of manufacturing activities. Cost of product revenue for the three months ended June 30, 2017 also included $0.6 million of cost to provide maintenance and technical support services to customers and $0.2 million of depreciation related to the T2Dx Instruments placed at customer locations pursuant to reagent rental agreements, as compared to $0.7 million and $0.1 million, respectively, for the three months ended June 30, 2016.

Research and development expenses

Research and development expenses were $7.1 million for the three months ended June 30, 2017, compared to $6.4 million for the three months ended June 30, 2016, an increase of $0.7 million. Clinical and preclinical expenses increased by $0.5 million primarily due to the T2Bacteria clinical trial, facilities related expenses increased by $0.2 million, primarily from increased depreciation, and outside service expenditures and travel expenses increased by $0.3 million, primarily from increased work on the T2Bacteria clinical trial. Partially offsetting these increases is a decrease in payroll and related expenses of $0.2 million related to headcount reduction and a decrease in other research and development expenses of $0.1 million, which includes lower prototype and lab related expenses.

Selling, general and administrative expenses

Selling, general and administrative expenses were $5.8 million for the three months ended June 30, 2017, compared to $6.1 million for the three months ended June 30, 2016, a decrease of $0.3 million. The decrease was due primarily to decreased payroll and related expenses of approximately $0.2 million, due to a reduction in headcount, decreased travel expenses of $0.1 million related to headcount reduction, and decreased legal expenses of $0.1 million. These decreases were partially offset by increased facility and other selling, general and administrative expenses of $0.1 million.

Interest expense, net

Interest expense, net, was $1.7 million for the three months ended June 30, 2017, compared to $0.8 million for the three months ended June 30, 2016. Interest expense, net, increased by $0.8 million primarily from the refinancing of debt with CRG.

Other income, net

Other income, net, was $102,000 of net income for the three months ended June 30, 2017, compared to $62,000 for the three months ended June 30, 2016. Other income, net, increased by $40,000 due primarily to increased dividend and other investment income.

Results of Operations for the Six Months Ended June 30, 2017 and 2016


	Six Months Ended June 30,
	2017			2016			Change
	(in thousands)
Revenue:
Product revenue	$	1,366		$	588		$	778
Research revenue		531			1,498			(967	)

Total revenue		1,897			2,086			(189	)
Costs and expenses:
Cost of product revenue		3,617			2,807			810
Research and development		13,697			12,958			739
Selling, general and administrative		11,633			12,347			(714	)

Total costs and expenses		28,947			28,112			835

Loss from operations		(27,050	)		(26,026	)		(1,024	)
Interest expense, net		(3,291	)		(1,540	)		(1,751	)
Other income, net		181			94			87

Net loss	$	(30,160	)	$	(27,472	)	$	(2,688	)

Product revenue

Product revenue was $1.4 million for the six months ended June 30, 2017 compared to $0.6 million for the six months ended June 30, 2016, an increase of $0.8 million or 132%. The increase was driven by an increase in sales volume of our products, primarily the sale of T2Candida consumable diagnostic tests, driven from increased usage of consumable diagnostic tests in the installed base and growth in our installed T2Dx Instrument base, as well as sales of our instruments. The six months ended June 30, 2016 was affected by an approximately $0.1 million decrease due to the voluntary product recall.

Research revenue

Research revenue was $0.5 million for the six months ended June 30, 2017, compared to $1.5 million for the six months ended June 30, 2016, a decrease of $1.0 million or 65%. The decrease was primarily the result of lower revenue from services delivered under our Co-Development Agreement with Canon US Life Sciences, which decreased $0.8 million over the prior year period, as well as a decrease in revenue from research and development agreements utilizing T2MR technology with other third parties.

Cost of product revenue

Cost of product revenue was $3.6 million for the six months ended June 30, 2017, compared to $2.8 million for the six months ended June 30, 2016, an increase of $0.8 million. The increase was due to increased product revenue and continued expansion of manufacturing activities. Cost of product revenue for the six months ended June 30, 2017 also included $1.2 million of cost to provide maintenance and technical support services to customers and $0.4 million of depreciation related to the T2Dx Instruments placed at customer locations pursuant to reagent rental agreements, as compared to $1.3 million and $0.2 million, respectively, for the six months ended June 30, 2016.

Research and development expenses

Research and development expenses were $13.7 million for the six months ended June 30, 2017, compared to $13.0 million for the six months ended June 30, 2016, an increase of $0.7 million. Clinical and preclinical expenses increased by $1.0 million primarily due to the T2Bacteria clinical trial, facilities related expenses increased by $0.4 million, primarily from increased depreciation and travel increased by $0.1 million, primarily from increased work on the clinical trial. Partially offsetting these increases are decreases in payroll and related expenses of $0.5 million related to headcount reductions and a decrease in other research and development expenses of $0.3 million, which includes lower prototype and lab related expenses.

Selling, general and administrative expenses

Selling, general and administrative expenses were $11.6 million for the six months ended June 30, 2017, compared to $12.3 million for the six months ended June 30, 2016, a decrease of $0.7 million. The decrease was due primarily to decreased payroll and related expenses of approximately $0.8 million, due to a reduction in headcount, decreased travel expenses of $0.2 million related to headcount reduction, and decreased legal expenses of $0.2 million. These decreases were partially offset by increased outside services expenditures of $0.3 million and increased facility and other selling, general and administrative expenses of $0.2 million.

Interest expense, net

Interest expense, net, was $3.3 million for the six months ended June 30, 2017, compared to $1.5 million for the six months ended June 30, 2016. Interest expense, net, increased by $1.8 million primarily from the refinancing of debt with CRG.

Other income, net

Other income, net, was $0.2 million of net income for the six months ended June 30, 2017, compared to $0.1 million for the six months ended June 30, 2016. Other income, net, increased by $0.1 million due primarily to increased dividend and other investment income.

Liquidity and Capital Resources

We have incurred losses and cumulative negative cash flows from operations since our inception, and as of June 30, 2017, and December 31, 2016 we had an accumulated deficit of $233.8 million and $203.7 million respectively. We anticipate that we will continue to incur losses for at least the next few years. We expect that our operating expenses will continue to

increase and, as a result, we will need additional capital to fund our operations, which we may raise through a combination of equity offerings, debt financings, other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements.

We have historically funded our operations principally from the sale of common stock and preferred stock, the incurrence of indebtedness, and revenue from research and development agreements.

Plan of operations and future funding requirements

As of June 30, 2017 and December 31, 2016 we had cash and cash equivalents of approximately $46.1 million and $73.5 million respectively. Currently, our funds are primarily held in money market funds invested in U.S. government agency securities. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, costs related to our products, clinical trials, laboratory and related supplies, supplies and materials used in manufacturing, legal and other regulatory expenses and general overhead costs.

Management believes that the existing cash and cash equivalents at June 30, 2017, together with the additional remaining liquidity on our Term Loan Agreement of up to an additional $10.0 million, will be sufficient to fund our current operating plan for 12 months from the date the financial statements are issued. The borrowing on the Term Loan Agreement is available at any time through July 27, 2018, and is subject to certain conditions including that we receive 510(k) clearance for the marketing of T2Bacteria^TM by the FDA by April 30, 2018 (see Note 5 to our unaudited condensed consolidated financial statements for details). Because certain elements of our plan are outside of our control they cannot be considered probable, as defined by ASU 2014-15, Presentation of Financial Statements - Going Concern. Should our current operating plan not materialize as expected, including our ability to draw additional borrowings on the Term Loan Agreement on a timely basis, we would delay certain research projects and capital expenditures and reduce or eliminate certain future operating expenses in order to fund operations at reduced levels to continue as a going concern for a period of 12 months from the date the financial statements are issued.

Until such time as we can generate substantial product revenue, we expect to finance our cash needs, beyond what is currently available or on hand, through a combination of equity offerings, debt financings and revenue from potential research and development and other collaboration agreements. If we raise additional funds in the future, we may need to relinquish valuable rights to our technologies, future revenue streams or grant licenses on terms that may not be favorable to us.

Cash flows

The following is a summary of cash flows for each of the periods set forth below:


	Six Months Ended June 30,
	2017			2016
	(in thousands)
Net cash (used in) provided by:
Operating activities	$	(24,979	)	$	(24,787	)
Investing activities		(2,468	)		(3,173	)
Financing activities		93			4,516

Net decrease in cash and cash equivalents	$	(27,354	)	$	(23,444	)

Net cash used in operating activities

Net cash used in operating activities was approximately $25.0 million for the six months ended June 30, 2017, and consisted primarily of a net loss of $30.2 million adjusted for non-cash items including stock-based compensation expense of $2.6 million, depreciation and amortization expense of $1.4 million, non-cash interest expense of $1.3 million, loss on sale of T2 owned equipment of $0.1 million, offset by deferred rent of $0.1 million, and a net change in operating assets and liabilities of $0.2 million, primarily related to an increase in accrued expenses and accounts payable of $0.5 million, an increase in accounts receivable of $0.7 million primarily related to a milestone invoice from our Co-Development Agreement with Allergan Sales, LLC. of $0.5 million, an increase in inventory of $0.2 million to support our commercial demand, and an increase in deferred revenue of $0.1 million, partially offset by a decrease in prepaid expenses and other assets of $0.2 million.

Net cash used in operating activities was approximately $24.8 million for the six months ended June 30, 2016, and consisted primarily of a net loss of $27.5 million adjusted for non-cash items including depreciation and amortization expense of $1.1 million, stock-based compensation expense of $2.5 million, non-cash interest expense of $0.3 million, deferred rent of $0.1 million, and a net change in operating assets and liabilities (use of cash) of $1.1 million, primarily related to an increase in inventory of $0.8 million to support our commercial demand and a decrease in deferred revenue of approximately $0.9 million primarily related to the recognition of revenue from our Co-Development Agreement with Canon US Life Sciences, partially offset by a decrease in prepaid expenses of $0.3 million related to the amortization of insurance premiums and an increase in accrued expenses of $0.2 million related to increased clinical study accruals.

Net cash used in investing activities

Net cash used in investing activities was approximately $2.5 million for the six months ended June 30, 2017 and consisted of costs to acquire components of and manufacture T2-owned instruments of $2.3 million, which are classified as property and equipment, $0.3 million of purchases of laboratory and manufacturing equipment and other property and equipment, less $0.1 million cash received from sale of T2-owned instruments.

Net cash used in investing activities was approximately $3.2 million for the six months ended June 30, 2016 and consisted of costs to acquire components of and manufacture Company-owned instruments of $2.5 million, which are classified as property and equipment, and $0.7 million of purchases of laboratory and manufacturing equipment incurred to support commercialization efforts and research and development programs.

Net cash provided by financing activities

Net cash provided by financing activities was approximately $0.1 million for the six months ended June 30, 2017, and consisted primarily of $0.6 million of repayments of notes payable, partially offset by $0.7 million of proceeds from the exercise of stock options and sale of common stock under our 2014 Employee Stock Purchase Plan.

Net cash provided by financing activities was approximately $4.5 million for the six months ended June 30, 2016, and consisted of $4.6 million of proceeds from our Credit Facility and $0.7 million of proceeds from the exercise of stock options and sale of common stock under our 2014 Employee Stock Purchase Plan. Partially offsetting these sources of cash were $0.4 million of repayments of notes payable and $0.4 million of payments of issuance costs from our December 2015 secondary offering.

Borrowing Arrangements

Term Loan Agreement

In December 2016, we entered into a Term Loan Agreement (the “Term Loan Agreement”) with CRG. We borrowed $40.0 million pursuant to the Term Loan Agreement and may borrow up to an additional $10.0 million at any time through and including July 27, 2018, provided that, among other conditions, we receive 510(k) clearance for the marketing of T2Bacteria^TM by the FDA on or before April 30, 2018, or the Approval Milestone. The Term Loan Agreement has a six-year term with three years (through December 30, 2019) of interest-only payments, which period shall be extended to four years (through December 30, 2020) if we achieve the Approval Milestone, after which quarterly principal and interest payments will be due through the December 30, 2022 maturity date. Interest on the amounts borrowed under the Term Loan Agreement accrues at an annual fixed rate of (a) prior to the Approval Milestone, 12.5%, 4.0% of which may be deferred during the interest-only period by adding such amount to the aggregate principal loan amount and (b) following the Approval Milestone, 11.5%, 3.5% of which may be deferred during the interest-only period by adding such amount to the aggregate principal loan amount. In addition, if we achieve certain financial performance metrics, the loan will convert to interest-only

until the December 30, 2022 maturity, at which time all unpaid principal and accrued unpaid interest will be due and payable. We are required to pay CRG a financing fee based on the loan principal amount drawn. We are also required to pay a final payment fee of 8.0% of the principal outstanding upon repayment.

We may prepay all or a portion of the outstanding principal and accrued unpaid interest under the Term Loan Agreement at any time upon prior notice subject to a prepayment fee during the first five years of the term and no prepayment fee thereafter. As security for our obligations under the Term Loan Agreement we entered into a security agreement with CRG whereby we granted a lien on substantially all of its assets, including intellectual property. The Term Loan Agreement also contains customary affirmative and negative covenants for a credit facility of this size and type. The Term Loan Agreement also requires us to achieve certain revenue targets, whereby we are required to pay double the amount of any shortfall as an acceleration of principal payments. The Term Loan Agreement includes a subjective acceleration clause whereby an event of default, including a material adverse change in the business, operations, or conditions (financial or otherwise), could result in the acceleration of the obligations under the Term Loan Agreement. Under certain circumstances, a default interest rate of an additional 4.0% per annum will apply at the election of CRG on all outstanding obligations during the occurrence and continuance of an event of default. CRG has not exercised its right under this clause, as there have been no such events. We believe the likelihood of CRG exercising this right is remote.

We assessed the terms and features of the Term Loan Agreement in order to identify any potential embedded features that would require bifurcation or any beneficial conversion features. As part of this analysis, we assessed the economic characteristics and risks of the Term Loan Agreement, including put and call features. We determined that the features of the Term Loan Agreement are either clearly and closely associated with a debt host and do not require bifurcation as a derivative liability, or the fair value of the feature is immaterial. Included in these features are principal payment acceleration clauses triggered by a developmental milestone. Should our assessment of this milestone change, there could be a non-cash charge in operations. We will continue to reassess the features to determine if they require separate accounting on a quarterly basis.

In December 2016, pursuant to the Term Loan Agreement, we made an initial draw of $39.2 million, net of financing fees. We used approximately $28.0 million of the initial proceeds to repay approximately $27.5 million of outstanding debt pursuant to the Loan and Security Agreement and to repay approximately $0.5 million of outstanding debt pursuant to the Promissory Note. Upon the repayment of all amounts owed by us under these agreements, all commitments were terminated and all security interests granted by us were released.

Equipment Lease Credit Facility

In October 2015, we signed a $10.0 million Equipment Lease Credit Facility, or the Credit Facility, with Essex Capital Corporation (the “Lessor”) to fund capital equipment needs. As one of the conditions of the Term Loan Agreement, the Credit Facility is capped at a maximum of $5.0 million. Under the Credit Facility, Essex will fund capital equipment purchases presented by us. We will repay the amounts borrowed in 36 equal monthly installments from the date of the amount funded. At the end of the 36 month lease term, we have the option to (a) repurchase the leased equipment at the lesser of fair market value or 10% of the original equipment value, (b) extend the applicable lease for a specified period of time, which will not be less than one year, or (c) return the leased equipment to the Lessor.

In April 2016 and June 2016, we completed the first two draws under the Credit Facility, of $2.1 million and $2.5 million, respectively. We will make monthly payments of $67,000 under the first draw and $79,000 under the second draw. The borrowings under the Credit Facility are treated as capital leases. The amortization of the assets conveyed under the Credit Facility is included as a component of depreciation expense.

Contractual Obligations and Commitments

There were no material changes to our contractual obligations and commitments from those described under Management’s Discussion and Analysis of Financial Condition and Results of Operations in the Annual Report on Form 10-K for the year ended December 31, 2016.

Off-Balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are exposed to market risk related to changes in interest rates. As of June 30, 2017 and December 31, 2016, we had cash and cash equivalents of $46.1 million and $73.5 million, respectively, held primarily in money market funds consisting of U.S. government agency securities. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments are in short-term securities. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate one percent change in interest rates would not have a material effect on the fair market value of our portfolio. As of June 30, 2017 and December 31, 2016, we had no outstanding debt exposed to variable market interest rates.

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

Management of the Company, with the participation of the Chief Executive Officer and the Chief Financial Officer, evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended) as of June 30, 2017. The Company’s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported on a timely basis and that such information is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, as appropriate, to allow timely decisions regarding disclosure. Based upon this evaluation, the Chief Executive Officer and the Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were effective as of June 30, 2017.

(b) Changes in Internal Control over Financial Reporting

There have been no material changes to the Company’s internal control over financial reporting during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II.

OTHER INFORMATION

Item 1. Legal Proceedings

We may be from time to time subject to various claims and legal actions during the ordinary course of our business. There are currently no claims or legal actions, individually or in the aggregate, that would have a material adverse effect on our results of operations or financial condition.

Item 1A. Risk Factors

In addition to the other information set forth in this report, you should carefully consider the factors discussed in “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2016, which could materially affect our business, financial condition or future results. There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2016.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None

Item 6. Exhibits, Financial Statement Schedules


Exhibit Number		Exhibit Description

3.1		Restated Certificate of Incorporation of the Company, as amended (incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K (File No. 001-36571) filed on August 12, 2014)

3.2		Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.2 of the Company’s Form 8-K (File No. 001-36571) filed on August 12, 2014)

10.1		Employment Letter Agreement, dated May 1, 2017, by and between the Company and Darlene Deptula-Hicks. (incorporated by reference to Exhibit 10.1 of the Company’s Form 10Q (File No. 001-36571) filed on May 8, 2017)

10.2		Change of Control Severance Agreement, dated May 1, 2017 by and between the Company and Darlene Deptula-Hicks. (incorporated by reference to Exhibit 10.2 of the Company’s Form 10Q (File No. 001-36571) filed on May 8, 2017)

10.3*		Amendment to Co-Development, Collaboration and Co-Marketing Agreement by and between the Company and Allergan Sales, LLC, dated June 1, 2017.

31.1*		Certification of principle executive officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*		Certification of principal financial officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1**		Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2**		Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.1*		The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, formatted in XBRL: (i) Condensed Consolidated Balance Sheets (unaudited), (ii) Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited), (iii) Condensed Consolidated Statements of Cash Flows (unaudited), and (v) Notes of Condensed Consolidated Financial Statements.

*	Filed herewith

**	Furnished herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	T2 BIOSYSTEMS, INC.

Date: August 3, 2017	By:	/s/ JOHN MCDONOUGH
		John McDonough
		President, Chief Executive Officer and Director
		(principal executive officer)

Date: August 3, 2017	By:	/s/ DARLENE DEPTULA-HICKS
		Darlene Deptula-Hicks
		SVP and Chief Financial Officer
		(principal financial officer)

EX-10.3 2 d411451dex103.htm EX-10.3 EX-10.3

Exhibit 10.3

AMENDMENT

CO-DEVELOPMENT, COLLABORATION AND

CO-MARKETING AGREEMENT

THIS AMENDMENT TO CO-DEVELOPMENT, COLLABORATION AND CO-MARKETING AGREEMENT (this “Amendment”) is entered into on June 1, 2017 (the “Amendment Effective Date”), by and between T2 Biosystems, Inc., a Delaware corporation (“T2 Bio”), and Allergan Sales, LLC, a Delaware limited liability company (“Allergan”). Capitalized terms used herein without definition shall have the meaning ascribed thereto in the Agreement (as defined below).

RECITALS

A. T2 Bio and Allergan have entered into that certain Co-Development, Collaboration and Co-Marketing Agreement, dated as of November 1, 2016 (the “Agreement”).

B. T2 Bio and Allergan mutually desire to amend the Agreement to delete all references to the T2Bacteria II Panel, modify the definition of T2GNR Panel to include Enterobacter spp., include the T2Bacteria Panel in T2 Bio’s manufacturing and distribution obligations and modify the Project Plan.

C. T2 Bio and Allergan mutually desire to amend the Agreement to allow Allergan to co-market the T2Bacteria Panel for research use only prior to receipt of regulatory approval for the panel.

NOW, THEREFORE, in consideration of the foregoing and the mutual promises made herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree to amend the Agreement in accordance with Section 12.13 of the Agreement as follows:

1. AMENDMENT OF RECITALS. The first Recital in the Agreement is hereby deleted in its entirety and replaced with the following:

“WHEREAS, T2 Bio agrees to develop, in collaboration with Allergan, a direct detection diagnostic test panel of [****] directly in whole blood (the “T2GNR Panel”), as further described below in this Agreement; and”

2. DELETION OF REFERENCES TO T2BACTERIA II PANEL. All references to the defined term “T2Bacteria II Panel” wherever occurring in the Agreement are hereby deleted.

3. AMENDMENT OF DEFINITION OF DEVELOPED PRODUCTS. The defined term “Developed Products” in Section 1.4 of the Agreement is hereby deleted in its entirety and replaced with the following, and all references to the term “Developed Products” wherever occurring in the Agreement are hereby amended to reference the defined term “Developed Product”:

“1.4 “Developed Product” means the T2GNR Panel developed pursuant to the Project Plan.”

4. AMENDMENT OF MILESTONE PAYMENTS. Section 3.2 of the Agreement is hereby deleted in its entirety and replaced with the following:

“3.2 Milestone Payments. Upon the achievement of a milestone described in clause (a) or (b) of this Section 3.2, T2 Bio shall provide to Allergan written notification of and supporting documentation for the achievement of the applicable milestone. In addition, in connection with the delivery of a panel cartridge described in clause (c) of this Section 3.2, T2 Bio shall provide to Allergan supporting documentation demonstrating that such panel cartridge meets the applicable specifications set forth in the Project Plan. Allergan shall make the following non-refundable payments to T2 Bio within forty-five (45) calendar days of receipt of notice of the achievement of the milestone described in clause (a) or (b) or receipt of the panel cartridge described in clause (c); provided, however, that Allergan shall within twenty (20) calendar days of receiving such notice or panel cartridge, as applicable, and supporting documentation from T2 Bio, notify T2 Bio in writing in the event Allergan believes that such milestone has not been achieved, in which case the Parties shall discuss in good faith whether such milestone has been met and, if the Parties cannot reach agreement on such matter, the question of whether such milestone has been achieved shall be decided by a Third Party with relevant expertise selected by mutual agreement of the Parties, with the costs of such Third Party being borne by the Party against which the determination of such Third Party has been made.

(a) $500,000 upon achievement of [****];

(b) $500,000 upon achievement of [****]; and

5. AMENDMENT OF PURCHASE OF CERTAIN T2 BIO PRODUCTS. Section 3.3 of the Agreement is hereby amended as follows:

Notwithstanding Section 2 of this Amendment, reference to the defined term “T2Bacteria II Panel” in Section 3.3(a) of the Agreement is hereby amended to reference the defined term “T2Bacteria Panel.”

6. AMENDMENT OF MANUFACTURING AND DISTRIBUTION OBLIGATIONS. Sections 6.1 and 6.2 of the Agreement are hereby deleted in their entirety and replaced with the following:

“6.1 Manufacturing. T2 Bio shall have the exclusive right and shall use commercially reasonable efforts during the Term to manufacture (x) the T2Dx Instrument, (y) the T2Bacteria Panel upon the T2Bacteria Panel receiving regulatory approval from the FDA, EMA, or other regulatory body and (z) the Developed Product upon the Developed Product receiving regulatory approval from the FDA, EMA, or other regulatory body.

6.2 Distribution. T2 Bio shall have the exclusive right, subject to Section 6.3, and shall use commercially reasonable efforts during the Term, to sell and distribute the T2Bacteria Panel and the Developed Product worldwide, including through its direct sales force or through Third Party distributors following receipt of regulatory approval from the FDA, EMA, or other regulatory body. In the event a Joint Account or Allergan Account does not have a T2Dx Instrument and wishes to purchase the T2Bacteria Panel or a Developed Product, T2 Bio shall offer to sell and, if applicable, sell a T2Dx Instrument to such account on T2 Bio’s customary terms.”

7. AMENDMENT OF CO-MARKETING RIGHT. Section 6.3(b) of the Agreement is hereby amended by inserting the following language at the end of clause (C), immediately following the word “body”:

“; provided, however, that, upon prior written notice to T2 Bio, Allergan may co-market the T2Bacteria Panel prior to any such regulatory approval as a research use only product and only in accordance with all applicable laws and regulations”

8. AMENDMENT OF EXHIBIT A (PROJECT PLAN). Exhibit A to the Agreement is hereby deleted in its entirety and replaced with the Exhibit A attached to this Amendment.

9. COUNTERPARTS. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. In addition, fully executed instruments bearing one or more, or all signatures, that have been converted to electronic format (e.g., PDF) and thereafter fixed in a tangible copy before or after being electronically transmitted (e.g., by fax or e-mail) shall be effective in all respects and treated the same as original hand written signatures placed on hard copies.

10. NO OTHER AMENDMENTS. Except to the extent amended hereby, all of the definitions, terms, provisions and conditions set forth in the Agreement are hereby ratified and confirmed and shall remain in full force and effect. The Agreement and this Amendment shall be read and construed together as a single agreement and the term “Agreement” shall henceforth be deemed a reference to the Agreement, as amended by this Amendment. In making proof of this Amendment, it shall not be necessary to produce or account for more than one such counterpart.

[Remainder of this page intentionally left blank.]

IN WITNESS WHEREOF, the Parties have duly authorized and caused this Amendment to be executed as of the Amendment Effective Date.


T2 BIOSYSTEMS, INC.

By:		/s/ John McDonough
Name:		John McDonough
Title:		CEO & President

ALLERGAN SALES, LLC


By:		/s/ A. Robert Bailey
Name:		A. Robert Bailey
Title:		President

Exhibit A

[****]

EX-31.1 3 d411451dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION

PURSUANT TO 17 CFR 240.13a-14

PROMULGATED UNDER

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, John McDonough, certify that:

1. I have reviewed this quarterly report on Form 10-Q of T2 Biosystems, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ John McDonough

John McDonough

President, Chief Executive Officer and Director

(principal executive officer)

Date: August 3, 2017

EX-31.2 4 d411451dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION

PURSUANT TO 17 CFR 240.13a-14

PROMULGATED UNDER

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Darlene Deptula-Hicks, certify that:

1. I have reviewed this quarterly report on Form 10-Q of T2 Biosystems, Inc.;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Darlene Deptula-Hicks

Darlene Deptula-Hicks

SVP and Chief Financial Officer

(principal accounting and financial officer)

Date: August 3, 2017

EX-32.1 5 d411451dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of T2 Biosystems, Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John McDonough, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ John McDonough

John McDonough

President and Chief Executive Officer

(principal executive officer)

Date: August 3, 2017

This certification accompanies each Report pursuant to §906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of §18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement required by §906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 6 d411451dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of T2 Biosystems, Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Darlene Deptula-Hicks, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


/s/ Darlene Deptula-Hicks
Darlene Deptula-Hicks
Chief Financial Officer (principal accounting officer and financial officer)

Date: August 3, 2017

EX-101.INS 7 ttoo-20170630.xml XBRL INSTANCE DOCUMENT 6500000 8500000

10000000

5000000

0.10 4000000 30764319

50218000

149000

6.56

0.199

4701000

48789000

981000

545000

7783000

246141000

1660000

63777000

46134000

200000000

30763919

0.001

30763919

32000

2494000

771000

248000

2234000

6100000

1014000

82000

463000

469000

63777000

10468000

39908000

41273000

1365000

717000

218000

305000

0.001

10000000

660000

14510000

22293000

260000

-233848000

12325000

1205000

1200000

146066

2200000

5.43

597220

918000

7.69

918000

3761002

918000

2309906

7.25

4006148

7.67

823529

960529

0.04

2953000

43181000

5000000 2000000 3000000 2

2700000

38141000

10000000

34000

3132000

46394000

260000

46394000

260000

20000

2000

1488000

4078000

200000

3372000

910000

409000

743000

160000

10933000

7800000

73662000

4908000

75438000

327000

884000

7066000

242997000

962000

89568000

73488000

200000000

30482712

0.001

30482712

30000

2445000

792000

301000

2479000

803000

63000

389000

351000

89568000

9885000

39504000

40773000

1269000

699000

281000

49000

0.001

10000000

820000

13589000

20655000

260000

-203689000

39338000

846000

146066

166066

5.83

272195

4091000

4042627

8.20

16887000

56601000

10000000 0.08

0.125

0.115

3000000

37031000

45000

3742000

73748000

260000

73748000

260000

1299000

4516000

200000

3353000

897000

409000

708000

154000

9119000

5700000

8.06

528958

1800000

2000000 1 2000000 1

39700000

0.199

6055341

false

2455000

5132326

51000

<div> Basis of Presentation The Company’s financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP as defined in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). The Company’s condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, T2 Biosystems Securities Corporation. All intercompany balances and transactions have been eliminated. We have evaluated subsequent events from June 30, 2017 through the date of the issuance of these consolidated financial statements and have determined that no material subsequent events have occurred that would affect the information presented in these consolidated financial statements. </div>

<div> 10. Co-Development Agreements Canon US Life Sciences On September 21, 2016, Canon became a related party when the Company sold the Canon Shares for an aggregate cash purchase price of $39.7 million, which represented 19.9% of the outstanding shares of common stock of the Company. On February 3, 2015, the Company entered into a Co-Development Partnership Agreement (the “Co-Development Agreement”) with Canon U.S. Life Sciences, Inc. (“Canon US Life Sciences”) to develop a diagnostic test panel to rapidly detect Lyme disease. Under the terms of the Co-Development Agreement, the Company received an upfront payment of $2.0 million from Canon US Life Sciences, and the agreement includes an additional $6.5 million of consideration upon achieving certain development and regulatory milestones for total aggregate payments of up to $8.5 million. In October 2015, the Company achieved a specified technical requirement and received $1.5 million related to the achievement of the milestone. The Company is eligible to receive an additional $5.0 million under the arrangement, in two milestone payments of $2.0 million and $3.0 million, related to the achievement of additional development and regulatory milestones. All payments under the Co-Development Agreement are non-refundable once received. The Company will retain exclusive worldwide commercialization rights of any products developed under the Co-Development Agreement, including sales, marketing and distribution and Canon US Life Sciences will not receive any commercial rights and will be entitled to only receive royalty payments on the sales of all products developed under the Co-Development Agreement. Either party may terminate the Co-Development Agreement upon the occurrence of a material breach by the other party (subject to a cure period). The Company evaluated the deliverables under the Co-Development Agreement and determined that the Co-Development Agreement included one unit of accounting, the research and development services, as the joint research and development committee deliverable was deemed to be de minimis. The Company is recognizing revenue for research and development services as a component of research revenue in the condensed consolidated financial statements as the services are delivered using the proportional performance method of accounting, limited to payments earned. Costs incurred to deliver the services under the Co-Development Agreement are recorded as research and development expense in the condensed consolidated financial statements. The Company recorded revenue of $0.0 and $0.6 million during the three months ended June 30, 2017 and June 30, 2016, respectively, and recorded revenue of $0.3 million and $1.1 million during the six months ended June 30, 2017 and 2016, under the Co-Development Agreement, and expects to record revenue over the next two years, provided development milestones are achieved. Allergan Sales, LLC On November 1, 2016, the Company entered into a Co-Development, Collaboration and Co-Marketing Agreement (the “Allergan Agreement”) with Allergan Sales, LLC (“Allergan Sales”) to develop (1) a direct detection diagnostic test panel that adds one additional bacteria species to the existing T2Bacteria product candidate (the “T2Bacteria II Panel”), and (2) a direct detection diagnostic test panel for testing drug resistance directly in whole blood (the “T2GNR Panel” and, together with the T2Bacteria II Panel, the “Developed Products”). In addition, both the Company and Allergan Sales will participate in a joint research and development committee and Allergan Sales will receive the right to cooperatively market the T2Candida, T2Bacteria, and the Developed Products under the Allergan Agreement to certain agreed-upon customers. On June 1, 2017 the Company and Allergan Sales entered into an Amendment to the Allergan Agreement which primarily modified the project plan to combine the T2Bacteria II Panel and T2GNR Panel into one test panel. Under the terms of the Allergan Agreement, the Company received an upfront payment of $2.0 million from Allergan Sales and will receive additional milestone payments upon achieving certain developmental milestones for total aggregate payments of up to $4.0 million. All payments under the Allergan Agreement are non-refundable once received. The Company will retain exclusive worldwide commercialization rights of any products developed under the Allergan Agreement, including distribution, subject to Allergan Sales’ right to co-market the Developed Products. Allergan Sales, at its election, may co-market T2Candida, T2Bacteria and the Developed Products worldwide to certain agreed-upon customers and will receive royalty based on its sales for a period of time. The Company evaluated the deliverables under the Allergan Agreement and determined that the Allergan Agreement included two units of accounting, the research and development services for the T2Bacteria II Panel and the research and development services for the T2GNR Panel, as the joint research and development committee and right to cooperatively market deliverables were deemed to be de minimus. The Company is recognizing revenue for research and development services as a component of research revenue in the consolidated financial statements as the services are delivered using the proportional performance method of accounting, limited to payments earned. Costs incurred to deliver the services under the Allergan Agreement are recorded as research and development expense in the consolidated financial statements. The Company recorded revenue of $0.2 million for the three and six months ended June 30, 2017, under the Allergan Agreement and expects to record revenue over the next two years, provided development and regulatory milestones are achieved. </div>

3617000

<div> Cost of Product Revenue Cost of product revenue includes the cost of materials, direct labor and manufacturing overhead costs used in the manufacture of consumable diagnostic tests sold to customers and related license and royalty fees. Cost of product revenue also includes depreciation on revenue generating T2Dx systems that have been placed with customers under reagent rental agreements; costs of materials, direct labor and manufacturing overhead costs on the T2Dx systems sold to customers; and other costs such as customer support costs, royalties and license fees, warranty and repair and maintenance expense on the T2Dx systems that have been placed with customers under reagent rental agreements. </div>

28947000

--12-31

<div> 5. Notes Payable Future principal payments on the notes payable are as follows (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Term loan agreement, net of deferred issuance costs of $2.7 million and $3.0 million, respectively </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">38,141</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">37,031</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Equipment lease credit facility, net of deferred issuance cost of $34 and $45 thousand, respectively </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,132</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,742</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total notes payable </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">41,273</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">40,773</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Less: current portion of notes payable </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,365</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,269</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Notes payable, net of current portion </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">39,908</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">39,504</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   Term Loan Agreement In December 2016, the Company entered into a Term Loan Agreement (the “Term Loan Agreement”) with CRG Servicing LLC (“CRG”). The Company initially borrowed $40.0 million pursuant to the Term Loan Agreement and may borrow up to an additional $10.0 million at any time through and including July 27, 2018, provided that, among other conditions, the Company receives 510(k) clearance for the marketing of T2BacteriaTM by the FDA on or before April 30, 2018 (the “Approval Milestone”). The Term Loan Agreement has a six-year term with three years (through December 30, 2019) of interest-only payments, which period shall be extended to four years (through December 30, 2020) if the Company achieves the Approval Milestone, after which quarterly principal and interest payments will be due through the December 30, 2022 maturity date. Interest on the amounts borrowed under the Term Loan Agreement accrues at an annual fixed rate of (a) prior to the Approval Milestone, 12.5%, 4.0% of which may be deferred during the interest-only period by adding such amount to the aggregate principal loan amount and (b) following the Approval Milestone, 11.5%, 3.5% of which may be deferred during the interest-only period by adding such amount to the aggregate principal loan amount. In addition, if the Company achieves certain financial performance metrics, the loan will convert to interest-only until the December 30, 2022 maturity, at which time all unpaid principal and accrued unpaid interest will be due and payable. The Company is required to pay CRG a financing fee based on the loan principal amount drawn. The Company is also required to pay a final payment fee of 8.0% of the principal outstanding upon repayment. The Company may prepay all or a portion of the outstanding principal and accrued unpaid interest under the Term Loan Agreement at any time upon prior notice subject to a prepayment fee during the first five years of the term and no prepayment fee thereafter. As security for its obligations under the Term Loan Agreement the Company entered into a security agreement with CRG whereby the Company granted a lien on substantially all of its assets, including intellectual property. The Term Loan Agreement also contains customary affirmative and negative covenants for a credit facility of this size and type. The Term Loan Agreement also requires the Company to achieve certain revenue targets, whereby the Company is required to pay double the amount of any shortfall as an acceleration of principal payments. The Term Loan Agreement includes a subjective acceleration clause whereby an event of default, including a material adverse change in the business, operations, or conditions (financial or otherwise), could result in the acceleration of the obligations under the Term Loan Agreement. Under certain circumstances, a default interest rate of an additional 4.0% per annum will apply at the election of CRG on all outstanding obligations during the occurrence and continuance of an event of default. CRG has not exercised its right under this clause, as there have been no such events. The Company believes the likelihood of CRG exercising this right is remote. The Company assessed the terms and features of the Term Loan Agreement in order to identify any potential embedded features that would require bifurcation or any beneficial conversion features. As part of this analysis, the Company assessed the economic characteristics and risks of the Term Loan Agreement, including put and call features. The Company determined that the features of the Term Loan Agreement are either clearly and closely associated with a debt host and do not require bifurcation as a derivative liability, or the fair value of the feature is immaterial. Included in these features are principal payment acceleration clauses triggered by a developmental milestone. Should the Company’s assessment of this milestone change, there could be a non-cash charge in operations. The Company will continue to reassess the features to determine if they require separate accounting on a quarterly basis. In December 2016, pursuant to the Term Loan Agreement, the Company made an initial draw of $39.2 million, net of financing fees. The Company used approximately $28.0 million of the initial proceeds to repay approximately $27.5 million of outstanding debt pursuant to the Loan and Security Agreement and to repay approximately $0.5 million of outstanding debt pursuant to the Promissory Note. Upon the repayment of all amounts owed by the Company under these agreements, all commitments were terminated and all security interests granted by the Company were released. In connection with the Term Loan Agreement entered into in December 2016, the Company issued to CRG four separate warrants to purchase a total of 528,958 shares of the Company’s common stock. The warrants are exercisable any time prior to December 30, 2026 at a price of $8.06 per share, with typical provisions for termination upon a change of control or a sale of all or substantially all of the assets of the Company. The warrants are classified within shareholders’ equity, and the proceeds were allocated between the debt and warrants based on their relative fair value. The fair value of the warrants was determined by the Black Scholes Merton option pricing model. The fair value of the warrants at issuance on December 30, 2016 was $1.8 million.   Equipment Lease Credit Facility In October 2015, the Company signed a $10.0 million Credit Facility with Essex Capital Corporation (the “Lessor”) to fund capital equipment needs. As one of the conditions of the Term Loan Agreement, the Credit Facility is capped at a maximum of $5.0 million. Under the Credit Facility, Essex will fund capital equipment purchases presented by the Company. The Company will repay the amounts borrowed in 36 equal monthly installments from the date of the amount funded. At the end of the 36 month lease term, the Company has the option to (a) repurchase the leased equipment at the lesser of fair market value or 10% of the original equipment value, (b) extend the applicable lease for a specified period of time, which will not be less than one year, or (c) return the leased equipment to the Lessor. In April 2016 and June 2016, the Company completed the first two draws under the Credit Facility, of $2.1 million and $2.5 million, respectively. The Company will make monthly payments of $67,000 under the first draw and $79,000 under the second draw. The borrowings under the Credit Facility are treated as capital leases. The amortization of the assets conveyed under the Credit Facility is included as a component of depreciation expense. </div>

1432000

-0.99

<div> 9. Net Loss Per Share The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock method, because their effect would have been anti-dilutive for the periods presented:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="60%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Options to purchase common shares </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,006,148</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,167,295</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,006,148</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,167,295</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Restricted stock units </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">597,220</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">597,220</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Warrants to purchase common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">528,958</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">528,958</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,132,326</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,167,295</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,132,326</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,167,295</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

P2Y0M18D

<div> 7. Stock-Based Compensation <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Stock Incentive Plans <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> 2006 Stock Incentive Plan <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company’s 2006 Stock Option Plan (“2006 Plan”) was established for granting stock incentive awards to directors, officers, employees and consultants of the Company. Upon closing of the Company’s IPO in August 2014, the Company ceased granting stock incentive awards under the 2006 Plan. The 2006 Plan provided for the grant of incentive and non-qualified stock options and restricted stock grants as determined by the Company’s board of directors. Under the 2006 Plan, stock options were generally granted with exercise prices equal to or greater than the fair value of the common stock as determined by the board of directors, expired no later than 10 years from the date of grant, and vest over various periods not exceeding 4 years. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> 2014 Stock Incentive Plan <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company’s 2014 Plan (“2014 Plan”, and together with the 2006 Plan, the “Stock Incentive Plans”), provides for the issuance of shares of common stock in the form of stock options, awards of restricted stock, awards of restricted stock units, performance awards, dividend equivalent awards, stock payment awards and stock appreciation rights to directors, officers, employees and consultants of the Company. Since the establishment of the 2014 Plan, the Company has only granted stock options and restricted stock units. Generally, stock options are granted with exercise prices equal to or greater than the fair value of the common stock on the date of grant, expire no later than 10 years from the date of grant, and vest over various periods not exceeding 4 years. <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The number of shares reserved for future issuance under the 2014 Plan is the sum of (1) 823,529 shares, (2) any shares that were granted under the 2006 Plan which are forfeited, lapsed unexercised or are settled in cash subsequent to the effective date of the 2014 Plan and (3) an annual increase on the first day of each calendar year beginning January 1, 2015 and ending on January 1, 2024, equal to the lesser of (A) 4% of the shares outstanding (on an as-converted basis) on the final day of the immediately preceding calendar year, and (B) such smaller number of shares determined by the Company’s Board of Directors. As of June 30, 2017 there were 960,529 shares available for future grant under the 2014 Plan. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Stock Options <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> During the six months ended June 30, 2017 and 2016, the Company granted stock options with an aggregate fair value of $2.3 million and $5.8 million, respectively, which are being amortized into compensation expense over the vesting period of the stock options as the services are being provided. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The following is a summary of stock option activity under the Plans (in thousands, except share and per share amounts): <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="55%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted-Average Exercise Price Per Share</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted-Average Remaining Contractual Term (In years)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at December 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,042,627</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8.20</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.05</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,091</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">743,200</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.30</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.00</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(193,630</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.33</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">500</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Forfeited </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(483,274</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.03</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Cancelled </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(102,775</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14.93</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Outstanding at June 30, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,006,148</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.67</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.98</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">918</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Exercisable at June 30, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,309,906</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.25</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.54</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">918</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Vested or expected to vest at June 30, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,761,002</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.69</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.83</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">918</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Included in the stock options outstanding as of December 31, 2016 are 166,066 options to purchase common stock granted to certain executive officers of the Company that vest upon the achievement of certain performance conditions, which include the attainment of specified operating result and regulatory targets, by December 31, 2017, of which 20,000 options to purchase common stock upon the achievement of certain performance conditions were forfeited during the year ended December 31, 2016. There are 146,066 performance based stock options outstanding at June 30, 2017 and December 31, 2016. The Company will continually evaluate the probability of achievement of each performance condition and will commence recognition of stock-based compensation expense on these awards in the period the achievement of each performance condition is deemed probable, including a catch-up adjustment from the grant date. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The weighted-average fair values of stock options granted in the six month periods ended June 30, 2017 and 2016 were $3.11 per share and $4.90 per share, respectively, and were calculated using the following estimated assumptions: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Six months ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Weighted-average risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.99</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.45</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Expected dividend yield </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Expected volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">63</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">60</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Expected terms </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.0 years</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.0 years</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The total fair values of stock options that vested during the six months ended June 30, 2017 and 2016 were $2.0 million and $2.5 million, respectively. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> As of June 30, 2017, there was $6.1 million of total unrecognized compensation cost related to unvested stock options granted under the Stock Incentive Plans, including the unrecognized compensation expense of stock options with performance conditions deemed probable of vesting. Total unrecognized compensation cost will be adjusted for future changes in the estimated forfeiture rate. The Company expects to recognize that cost over a remaining weighted-average period of 2.5 years as of June 30, 2017. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Restricted Stock Units <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> During the six months ended June 30, 2017, the Company awarded shares of restricted stock units to certain employees and directors at no cost to them, which cannot be sold, assigned, transferred or pledged during the restriction period. The restricted stock and restricted stock units vest through the passage of time, assuming continued employment. Restricted stock units are not included in issued and outstanding common stock until the shares are vested and released. The fair value of the award at the time of the grant is expensed on a straight line basis. The granted restricted stock units had an aggregate fair value of $1.8 million, which are being amortized into compensation expense over the vesting period of the options as the services are being provided. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The following is a summary of restricted stock unit activity under the 2014 Plan (in thousands, except share and per share amounts): <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="71%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted-Average Grant Date Fair Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Nonvested at December 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">272,195</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.83</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">357,925</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.16</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Vested </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Forfeited </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(32,900</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.80</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Canceled </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Nonvested at June 30, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">597,220</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.43</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> There was no vesting of restricted stock units during the six months ended June 30, 2017. As of June 30, 2017, there was $2.2 million of total unrecognized compensation cost related to unvested restricted stock units granted under the Stock Incentive Plans. Total unrecognized compensation cost will be adjusted for future forfeitures . The Company expects to recognize that cost over a remaining weighted-average period of 1.8 years as of June 30, 2017. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Stock-Based Compensation Expense <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The following table summarizes the stock-based compensation expense resulting from awards granted under stock incentive plans, including the 2014 ESPP, that was recorded in the Company’s results of operations for the periods presented (in thousands): <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Cost of product revenue </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">33</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">65</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">59</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">393</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">341</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">691</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">610</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Selling, general and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">902</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">826</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,699</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,793</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Total stock-based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,331</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,200</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,455</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,462</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> For the three months ended June 30, 2017 and 2016, $53,000 and $37,000 of stock-based compensation expenses was capitalized as part of inventory or T2 instruments and components, respectively. For the six months ended June 30, 2017 and 2016, $86,000 and $65,000 of stock-based compensation expenses was capitalized as part of inventory or T2 instruments and components, respectively. </div>

Q2 2017 10-Q

<div> Net Loss Per Share Basic net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net loss per share calculation, stock options and unvested restricted stock are considered to be common stock equivalents, but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share applicable to common stockholders was the same for all periods presented. </div>

2017-06-30 T2 Biosystems, Inc.

<div> 3. Fair Value Measurements The Company measures the following financial assets at fair value on a recurring basis. There were no transfers between levels of the fair value hierarchy during any of the periods presented. The following tables set forth the Company’s financial assets carried at fair value categorized using the lowest level of input applicable to each financial instrument as of June 30, 2017 and December 31, 2016 (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="56%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Balance at June 30, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Quoted Prices in Active Markets for Identical Assets (Level 1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant Other Observable Inputs (Level 2)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant Unobservable Inputs (Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom" colspan="5"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Cash </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,953</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,953</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Money market funds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">43,181</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">43,181</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Restricted cash </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">260</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">260</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">46,394</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">46,394</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Balance at December 31, 2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Quoted Prices in Active Markets for Identical Assets (Level 1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant Other Observable Inputs (Level 2)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant Unobservable Inputs (Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom" colspan="5"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Cash </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,887</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,887</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Money market funds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">56,601</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">56,601</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Restricted cash </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">260</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">260</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">73,748</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">73,748</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> For certain financial instruments, including accounts payable and accrued expenses, the carrying amounts approximate their fair values as of June 30, 2017 and December 31, 2016 because of their short-term nature. At June 30, 2017 and December 31, 2016, the carrying value of the Company’s debt approximated fair value, which was determined using Level 3 inputs, using market quotes from brokers and is based on current rates offered for similar debt (Note 5). </div>

0001492674 Accelerated Filer

-107000

<div> Guarantees As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while each such officer or director is, or was, serving at the Company’s request in such capacity. The term of the indemnification is the officer’s or director’s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors’ and officers’ liability insurance coverage that limits its exposure and enables the Company to recover a portion of any future amounts paid. The Company leases office, laboratory and manufacturing space under noncancelable operating leases. The Company has standard indemnification arrangements under the leases that require it to indemnify the landlords against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation or nonperformance of any covenant or condition of the Company’s leases. In the ordinary course of business, the Company enters into indemnification agreements with certain suppliers and business partners where the Company has certain indemnification obligations limited to the costs, expenses, fines, suits, claims, demands, liabilities and actions directly resulting from the Company’s gross negligence or willful misconduct, and in certain instances, breaches, violations or nonperformance of covenants or conditions under the agreements. As of June 30, 2017 and December 31, 2016, the Company had not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established. </div>

48000

654000

212000

698000

-230000

-225000

-3291000

1981000

<div> 1. Nature of Business T2 Biosystems, Inc. (the “Company”) was incorporated on April 27, 2006 as a Delaware corporation with operations based in Lexington, Massachusetts. The Company is an in vitro diagnostics company that has developed an innovative and proprietary technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company is using its T2 Magnetic Resonance technology (“T2MR”) to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (“CFU/mL”). The Company’s initial development efforts target sepsis and lyme disease, which are areas of significant unmet medical need in which existing therapies could be more effective with improved diagnostics. On September 22, 2014, the Company received market clearance from the U.S. Food and Drug Administration (“FDA”) for its first two products, the T2Dx Instrument (the “T2Dx”) and T2Candida Panel (“T2Candida”). On June 30, 2017 the Company received CE Mark for its T2Bacteria Panel (“T2Bacteria”). Liquidity At June 30, 2017, the Company had cash and cash equivalents of $46.1 million and an accumulated deficit of $233.8 million. The future success of the Company is dependent on its ability to successfully commercialize its FDA approved products, obtain regulatory clearance for and successfully launch its future product candidates, including T2Bacteria, obtain additional capital and ultimately attain profitable operations. Historically, the Company has funded its operations primarily through its August 2014 initial public offering, its December 2015 secondary public offering, its September 2016 private investment in public equity (“PIPE”) financing, private placements of redeemable convertible preferred stock and through debt financing arrangements. The Company is subject to a number of risks similar to other newly commercial life science companies, including, but not limited to commercially launching the Company’s products, development and market acceptance of the Company’s product candidates, development by its competitors of new technological innovations, protection of proprietary technology, and raising additional capital. Having obtained authorization from the FDA to market T2Dx and T2Candida, the Company has incurred significant commercialization expenses related to product sales, marketing, manufacturing and distribution. In addition, the Company expects that costs and expenses may increase as it continues the research and development of other product candidates and maintains, expands and protects its intellectual property portfolio. The Company may seek to fund its operations through public equity or private equity or debt financings, as well as other sources. However, the Company may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. The Company’s failure to raise capital or enter into such other arrangements if and when needed would have a negative impact on the Company’s business, results of operations and financial condition and the Company’s ability to develop and commercialize T2Dx, T2Candida, T2Bacteria and other product candidates. Management believes that its existing cash and cash equivalents at June 30, 2017, together with the additional remaining liquidity on the Company’s Term Loan Agreement of up to an additional $10.0 million, will be sufficient to allow the Company to fund its current operating plan for 12 months from the date the financial statements are issued. The borrowing on the Term Loan Agreement is available at any time through July 27, 2018, and is subject to certain conditions including that the Company receive 510(k) clearance for the marketing of T2BacteriaTM by the U.S. Food and Drug Administration (“FDA”) by April 30, 2018 (see Note 5). Because certain elements of the Company’s plan are outside of the Company’s control they cannot be considered probable, as defined by ASU 2014-15, Presentation of Financial Statements - Going Concern. Should the Company’s current operating plan not materialize as expected, including the Company’s ability to draw additional borrowings on the Term Loan Agreement on a timely basis, the Company would delay certain research projects and capital expenditures and reduce or eliminate certain future operating expenses in order to fund operations at reduced levels for the Company to continue as a going concern for a period of 12 months from the date the financial statements are issued.   For more information, refer to the section titled “Liquidity and Capital Resources” in Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations and the section entitled “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2016, for additional risks associated with our capital needs. </div>

-2468000

-27354000

93000

-24979000

-30160000

-27050000

<div> Recent Accounting Standards From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. Accounting Standards Adopted In August 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” which is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its financial obligations as they become due within one year after the date that the financial statements are issued (or are available to be issued). ASU No. 2014-15 provides guidance to an organization’s management, with principles and definitions intended to reduce diversity in the timing and content of disclosures commonly provided by organizations in the footnotes of their financial statements. ASU No. 2014-15 was effective for annual reporting periods ending after December 15, 2016, and for annual and interim periods thereafter. This standard has been adopted and the Company does not believe it is required to make any additional disclosures. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory (“ASU 2015-11”). The standard simplifies the subsequent measurement of inventory by requiring inventory to be measured at the lower of cost and net realizable value for entities using the first-in-first out method of valuing inventory. ASU 2015-11 eliminates other measures required by current guidance to determine net realizable value. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016 and interim periods within those fiscal years and early adoption is permitted. The Company’s adoption of this standard did not have a material effect on its condensed consolidated financial statements. In March 2016, the FASB released ASU No. 2016-09 Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”) which is intended to simplify income tax accounting for excess tax benefits, accounting for forfeitures, and employer statutory withholding. Under the current guidance, excess tax benefits that result from an award vesting or settling are recognized in additional paid-in capital in the period that they reduce cash taxes payable. This requires the provision to be computed on a with and without option basis and may result in net operating loss and credit carryforwards on the balance sheet being less than what is available on the tax return. Under the new guidance, the income tax effects of awards will be recognized as a component of income tax expense when the awards vest or are settled (regardless if cash taxes are reduced). For interim reporting purposes, companies will account for excess tax benefits and tax deficiencies as discrete items in the period during which they occurred. The guidance is effective for public entities for fiscal years beginning after December 15, 2016, and interim periods within those years. Early adoption is permitted, however all of the guidance included in the update must be applied when adopted. The Company must use a modified retrospective transition method for adopting and record the cumulative effect of all unrecognized benefits and any change in valuation allowances at the end of the prior tax period as an adjustment to retained earnings. The Company’s adoption of this standard did not have a material effect on its condensed consolidated financial statements and prior periods have not been adjusted. As a result, the Company established a net operating loss deferred tax asset of $1.2 million to account for prior period excess tax benefits through retained earnings, however an offsetting valuation allowance of $1.2 million will also be established through retained earnings because it is not more likely than not that the deferred tax asset will be realized due to historical and expected future losses, such that there is no impact on the Company’s condensed consolidated financial statements. The Company also elected to maintain the use of estimated forfeitures in the calculation of stock based compensation. In March 2016, the FASB issued ASU No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments (“ASU 2016-06”), which applies to all issuers of or investors in debt instruments with embedded call or put options. ASU 2016-06 clarifies the requirements for assessing whether contingent call or put options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts. Entities performing the assessment under the guidance of ASU 2016-06 are required to assess the embedded call or put options solely in accordance with the four-step decision process. In addition, ASU 2016-06 clarifies what steps are required when assessing whether the economic characteristics and risks of call or put options are clearly and closely related to the economic characteristics and risks of their debt hosts. ASU 2016-06 is effective for financial statements issued for fiscal years beginning after December 15, 2016 and interim periods within those fiscal years using the modified retrospective method for existing debt instruments. The Company’s adoption of this standard did not have a material effect on its condensed consolidated financial statements. Accounting Standards Issued, Not Adopted In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASC 2016-15”), which provides guidance on the classification of certain specific cash flow issues including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of certain insurance claims and distributions received from equity method investees. The standard requires the use of a retrospective approach to all periods presented, but may be applied prospectively if retrospective application would be impracticable. The guidance is effective for public entities for fiscal years beginning after December 15, 2017, and interim periods within those years, and early application is permitted. The Company is currently evaluating the impact of its pending adoption of ASU 2016-15 on the Company’s consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (“ASU 2016-02”), which applies to all leases. Under ASU 2016-02, a right-of-use asset and lease obligation will be recorded for all leases, whether operating or financing leases, while the statement of operations will reflect lease expense for operating leases and amortization and interest expense for financing leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 and interim periods within those years, which is the year ended December 31, 2019 for the Company. Entities are required to use a modified retrospective approach of adoption for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. Full retrospective application is prohibited. The Company is evaluating the new guidance and the expected effect on the Company’s consolidated financial statements. In June 2014, the FASB issued amended guidance, ASU No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which is applicable to revenue recognition that will now be effective for the Company for the year ending December 31, 2018, as a result of the deferral of the effective date adopted by the FASB in July 2015. The new guidance must be adopted using either a full retrospective approach for all periods presented or a modified retrospective approach. Early adoption prior to the original adoption date of ASU 2014-09 is not permitted. The new guidance applies a more principles-based approach to revenue recognition. The Company currently anticipates adoption of the new standard effective January 1, 2018 under the modified retrospective method. The Company’s revenue is primarily comprised of product sales and research services, and the Company is in the process of determining the impact of the new standard on its financial statements. </div>

181000

1291000

2468000

<div> Property and equipment consists of the following (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Office and computer equipment </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">409</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">409</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Software </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">743</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">708</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Laboratory equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,078</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,516</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Furniture </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">200</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">200</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Manufacturing equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">910</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">897</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Manufacturing tooling and molds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">160</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">154</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> T2-owned instruments and components </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,933</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,119</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Leasehold improvements </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,372</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,353</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Construction in progress </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,488</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,299</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,293</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20,655</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Less accumulated depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,783</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,066</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Property and equipment, net </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,510</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,589</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

531000

620000

13697000

<div> Research and Development Costs Costs incurred in the research and development of the Company’s product candidates are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including activities associated with performing services under research revenue arrangements, and include salaries and benefits, stock compensation, research-related facility and overhead costs, laboratory supplies, equipment and contract services. </div>

<div> The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock method, because their effect would have been anti-dilutive for the periods presented:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="60%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Options to purchase common shares </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,006,148</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,167,295</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,006,148</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,167,295</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Restricted stock units </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">597,220</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">597,220</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Warrants to purchase common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">528,958</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">528,958</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,132,326</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,167,295</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,132,326</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,167,295</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Revenue Recognition The Company generates revenue from product sales, which includes the sale of instruments, consumable diagnostic tests and related services, and research and development agreements with third parties. The Company recognizes revenue in accordance with FASB ASC Topic 605, Revenue Recognition (“ASC 605”). Accordingly, the Company recognizes revenue when all of the following criteria have been met:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="8%"> </td> <td valign="top" width="5%" align="left">i.</td> <td valign="top" align="left">Persuasive evidence of an arrangement exists</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="8%"> </td> <td valign="top" width="5%" align="left">ii.</td> <td valign="top" align="left">Delivery has occurred or services have been rendered</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="8%"> </td> <td valign="top" width="5%" align="left">iii.</td> <td valign="top" align="left">The seller’s price to the buyer is fixed or determinable</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="8%"> </td> <td valign="top" width="5%" align="left">iv.</td> <td valign="top" align="left">Collectability is reasonably assured</td> </tr> </table> If any of the above criteria have not been met, the Company defers revenue until such time each of the criteria have been satisfied. Product revenue is generated by the sale of instruments and consumable diagnostic tests predominantly through the Company’s direct sales force in the United States and distributors in geographic regions outside the United States. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including its distributors. Payment terms granted to distributors are the same as those granted to end-user customers and payments are not dependent upon the distributors’ receipt of payment from their end-user customers. The Company either sells instruments to customers and international distributors, or retains title and places the instrument at the customer site pursuant to a reagent rental agreement. When the instrument is directly purchased by a customer, the Company recognizes revenue when all applicable revenue recognition criteria are met. When the instrument is placed under a reagent rental agreement, the Company’s customers generally agree to fixed term agreements, which can be extended, certain of which may include minimum purchase commitments and/or incremental charges on each consumable diagnostic test purchased, which varies based on the volume of test cartridges purchased. Revenue from the sale of consumable diagnostic tests, which includes the incremental charge, is recognized upon delivery or shipment as a component of product revenue in the Company’s consolidated statements of operations and comprehensive loss. Direct sales of instruments include warranty, maintenance and technical support services for one year following the installation of the purchased instrument (“Maintenance Services”). After the completion of the initial Maintenance Services period, customers have the option to renew the Maintenance Services for additional one year periods in exchange for additional consideration. In addition, the Company may provide training to customers. The Company defers revenue from the initial sale of the instrument equal to the relative fair value of the one year of Maintenance Services and training and recognizes the amounts ratably over the service delivery period. The Company warrants that consumable diagnostic tests will be free from defects, when handled according to product specifications, for the stated life of the product. To fulfill valid warranty claims, the Company either provides a credit to its customers on future orders or provides a replacement product. Accordingly, the Company defers revenue associated with the estimated defect rates of the consumable diagnostic tests. The Company does not offer rights of return for instruments or consumable diagnostic tests. Shipping and handling costs incurred associated with products sold to customers are recorded as a cost of product revenue in the consolidated statement of operations and comprehensive loss. Shipping and handling costs billed to customers in connection with a product sale are recorded as a component of product revenue in the consolidated statements of operations and comprehensive loss. For multiple-element arrangements, the Company identifies the deliverables included within each agreement and evaluates which deliverables represent separate units of accounting. The determination that multiple elements in an arrangement meet the criteria for separate units of accounting requires the Company’s management to exercise judgment. The Company accounts for those components as separate elements when the following criteria are met: (1) the delivered items have value to the customer on a stand-alone basis; and, (2) if there is a general right of return relative to the delivered items, delivery or performance of the undelivered items is considered probable and within its control. The consideration received is allocated among the separate units of accounting based on a selling price hierarchy. The selling price hierarchy is based on: (1) vendor specific objective evidence (“VSOE”), if available; (2) third party evidence of selling price if VSOE is not available; or (3) best estimated selling price (“BESP”) if neither VSOE nor third party evidence is available. The Company generally expects that it will not be able to establish selling price using third-party evidence due to the nature of our products and the markets in which the Company competes, and, as such, the Company typically will determine selling price using VSOE or BESP. When the Company establishes selling price using BESP, consideration is given to both market and Company-specific factors, including the cost to produce the deliverable and the anticipated margin on that deliverable, as well as the characteristics of markets in which the deliverable is sold. Revenue earned from activities performed pursuant to research and development agreements is reported as research revenue in the consolidated statements of operations and comprehensive loss, using the proportional performance method as the work is completed, limited to payments earned, and the related costs are expensed as incurred as research and development expense. The timing of receipt of cash from the Company’s research and development agreements generally differs from when revenue is recognized. </div>

<div> Future principal payments on the notes payable are as follows (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Term loan agreement, net of deferred issuance costs of $2.7 million and $3.0 million, respectively </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">38,141</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">37,031</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Equipment lease credit facility, net of deferred issuance cost of $34 and $45 thousand, respectively </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,132</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,742</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total notes payable </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">41,273</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">40,773</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Less: current portion of notes payable </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,365</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,269</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Notes payable, net of current portion </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">39,908</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">39,504</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   </div>

<div> The following table summarizes the stock-based compensation expense resulting from awards granted under stock incentive plans, including the 2014 ESPP, that was recorded in the Company’s results of operations for the periods presented (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Cost of product revenue </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">33</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">65</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">59</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">393</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">341</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">691</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">610</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Selling, general and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">902</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">826</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,699</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,793</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total stock-based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,331</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,200</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,455</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,462</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Inventories are stated at the lower of cost or net realizable value on a first-in, first-out basis and are comprised of the following (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Raw materials </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">463</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">389</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Work-in-process </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">469</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">351</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Finished goods </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">82</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">63</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total inventories, net </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,014</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">803</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

1897000

<div> Accrued expenses consist of the following (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accrued payroll and compensation </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,234</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,479</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accrued research and development expenses </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,205</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">846</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accrued professional services </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">545</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">884</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Other accrued expenses </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">717</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">699</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total accrued expenses </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,701</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,908</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The following is a summary of restricted stock unit activity under the 2014 Plan (in thousands, except share and per share amounts):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="71%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted-Average Grant Date Fair Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Nonvested at December 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">272,195</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.83</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">357,925</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.16</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Vested </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Forfeited </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(32,900</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.80</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Canceled </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Nonvested at June 30, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">597,220</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.43</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div>

1366000

<div> The following is a summary of stock option activity under the Plans (in thousands, except share and per share amounts):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="55%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted-Average Exercise Price Per Share</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted-Average Remaining Contractual Term (In years)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at December 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,042,627</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8.20</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.05</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,091</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">743,200</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.30</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.00</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(193,630</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.33</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">500</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Forfeited </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(483,274</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.03</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Cancelled </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(102,775</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14.93</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Outstanding at June 30, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,006,148</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.67</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.98</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">918</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Exercisable at June 30, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,309,906</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.25</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.54</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">918</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Vested or expected to vest at June 30, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,761,002</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.69</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.83</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">918</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div>

<div> The weighted-average fair values of stock options granted in the six month periods ended June 30, 2017 and 2016 were $3.11 per share and $4.90 per share, respectively, and were calculated using the following estimated assumptions:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Six months ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Weighted-average risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.99</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.45</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Expected dividend yield </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Expected volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">63</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">60</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Expected terms </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.0 years</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.0 years</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> </div>

<div> Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is the Chief Executive Officer. The Company views its operations and manages its business in one operating segment, which is the business of developing and, upon regulatory clearance, launching commercially its diagnostic products aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. </div>

<div> The Company measures the following financial assets at fair value on a recurring basis. There were no transfers between levels of the fair value hierarchy during any of the periods presented. The following tables set forth the Company’s financial assets carried at fair value categorized using the lowest level of input applicable to each financial instrument as of June 30, 2017 and December 31, 2016 (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="56%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Balance at June 30, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Quoted Prices in Active Markets for Identical Assets (Level 1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant Other Observable Inputs (Level 2)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant Unobservable Inputs (Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom" colspan="5"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Cash </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,953</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,953</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Money market funds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">43,181</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">43,181</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Restricted cash </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">260</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">260</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">46,394</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">46,394</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Balance at December 31, 2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Quoted Prices in Active Markets for Identical Assets (Level 1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant Other Observable Inputs (Level 2)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant Unobservable Inputs (Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom" colspan="5"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Cash </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,887</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,887</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Money market funds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">56,601</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">56,601</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Restricted cash </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">260</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">260</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">73,748</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">73,748</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

2550000

11633000

2000000

<div> 6. Stockholders’ Equity Private Investment in Public Equity Financing On September 21, 2016, Canon U.S.A., Inc. (“Canon”) became a related party when the Company sold 6,055,341 shares of its common stock (the “Canon Shares”) to Canon at $6.56 per share, the closing price on this date, for an aggregate cash purchase price of $39.7 million. As of September 21, 2016, the Canon Shares represented 19.9% of the outstanding shares of common stock of the Company. In connection with the sale of the Canon Shares, the Company agreed to grant Canon certain board designation rights, including the right to initially appoint a Class I director to the Company’s board of directors. On March 20, 2017, the Company filed with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-3 for purposes of registering the resale of the Canon Shares with the SEC. </div>

74000

<div> 2. Summary of Significant Accounting Policies Basis of Presentation The Company’s financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP as defined in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). The Company’s condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, T2 Biosystems Securities Corporation. All intercompany balances and transactions have been eliminated. We have evaluated subsequent events from June 30, 2017 through the date of the issuance of these consolidated financial statements and have determined that no material subsequent events have occurred that would affect the information presented in these consolidated financial statements. Unaudited Interim Financial Information Certain information and footnote disclosures normally included in the Company’s annual financial statements have been condensed or omitted. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016. The accompanying interim condensed consolidated balance sheet as of June 30, 2017, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2017 and 2016, the condensed consolidated statements of cash flows for the three and six months ended June 30, 2017 and 2016 and the related financial data and other information disclosed in these notes are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual financial statements, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of June 30, 2017, and the results of its operations and its cash flows for the three and six months ended June 30, 2017 and 2016. The results for the three and six months ended June 30, 2017 are not necessarily indicative of the results to be expected for the year ending December 31, 2017, any other interim periods, or any future year or period. Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is the Chief Executive Officer. The Company views its operations and manages its business in one operating segment, which is the business of developing and, upon regulatory clearance, launching commercially its diagnostic products aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier.   Net Loss Per Share Basic net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net loss per share calculation, stock options and unvested restricted stock are considered to be common stock equivalents, but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share applicable to common stockholders was the same for all periods presented. Guarantees As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while each such officer or director is, or was, serving at the Company’s request in such capacity. The term of the indemnification is the officer’s or director’s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors’ and officers’ liability insurance coverage that limits its exposure and enables the Company to recover a portion of any future amounts paid. The Company leases office, laboratory and manufacturing space under noncancelable operating leases. The Company has standard indemnification arrangements under the leases that require it to indemnify the landlords against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation or nonperformance of any covenant or condition of the Company’s leases. In the ordinary course of business, the Company enters into indemnification agreements with certain suppliers and business partners where the Company has certain indemnification obligations limited to the costs, expenses, fines, suits, claims, demands, liabilities and actions directly resulting from the Company’s gross negligence or willful misconduct, and in certain instances, breaches, violations or nonperformance of covenants or conditions under the agreements. As of June 30, 2017 and December 31, 2016, the Company had not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established. Revenue Recognition The Company generates revenue from product sales, which includes the sale of instruments, consumable diagnostic tests and related services, and research and development agreements with third parties. The Company recognizes revenue in accordance with FASB ASC Topic 605, Revenue Recognition (“ASC 605”). Accordingly, the Company recognizes revenue when all of the following criteria have been met:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="8%"> </td> <td valign="top" width="5%" align="left">i.</td> <td valign="top" align="left">Persuasive evidence of an arrangement exists</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="8%"> </td> <td valign="top" width="5%" align="left">ii.</td> <td valign="top" align="left">Delivery has occurred or services have been rendered</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="8%"> </td> <td valign="top" width="5%" align="left">iii.</td> <td valign="top" align="left">The seller’s price to the buyer is fixed or determinable</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="8%"> </td> <td valign="top" width="5%" align="left">iv.</td> <td valign="top" align="left">Collectability is reasonably assured</td> </tr> </table> If any of the above criteria have not been met, the Company defers revenue until such time each of the criteria have been satisfied. Product revenue is generated by the sale of instruments and consumable diagnostic tests predominantly through the Company’s direct sales force in the United States and distributors in geographic regions outside the United States. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including its distributors. Payment terms granted to distributors are the same as those granted to end-user customers and payments are not dependent upon the distributors’ receipt of payment from their end-user customers. The Company either sells instruments to customers and international distributors, or retains title and places the instrument at the customer site pursuant to a reagent rental agreement. When the instrument is directly purchased by a customer, the Company recognizes revenue when all applicable revenue recognition criteria are met. When the instrument is placed under a reagent rental agreement, the Company’s customers generally agree to fixed term agreements, which can be extended, certain of which may include minimum purchase commitments and/or incremental charges on each consumable diagnostic test purchased, which varies based on the volume of test cartridges purchased. Revenue from the sale of consumable diagnostic tests, which includes the incremental charge, is recognized upon delivery or shipment as a component of product revenue in the Company’s consolidated statements of operations and comprehensive loss. Direct sales of instruments include warranty, maintenance and technical support services for one year following the installation of the purchased instrument (“Maintenance Services”). After the completion of the initial Maintenance Services period, customers have the option to renew the Maintenance Services for additional one year periods in exchange for additional consideration. In addition, the Company may provide training to customers. The Company defers revenue from the initial sale of the instrument equal to the relative fair value of the one year of Maintenance Services and training and recognizes the amounts ratably over the service delivery period. The Company warrants that consumable diagnostic tests will be free from defects, when handled according to product specifications, for the stated life of the product. To fulfill valid warranty claims, the Company either provides a credit to its customers on future orders or provides a replacement product. Accordingly, the Company defers revenue associated with the estimated defect rates of the consumable diagnostic tests. The Company does not offer rights of return for instruments or consumable diagnostic tests. Shipping and handling costs incurred associated with products sold to customers are recorded as a cost of product revenue in the consolidated statement of operations and comprehensive loss. Shipping and handling costs billed to customers in connection with a product sale are recorded as a component of product revenue in the consolidated statements of operations and comprehensive loss. For multiple-element arrangements, the Company identifies the deliverables included within each agreement and evaluates which deliverables represent separate units of accounting. The determination that multiple elements in an arrangement meet the criteria for separate units of accounting requires the Company’s management to exercise judgment. The Company accounts for those components as separate elements when the following criteria are met: (1) the delivered items have value to the customer on a stand-alone basis; and, (2) if there is a general right of return relative to the delivered items, delivery or performance of the undelivered items is considered probable and within its control. The consideration received is allocated among the separate units of accounting based on a selling price hierarchy. The selling price hierarchy is based on: (1) vendor specific objective evidence (“VSOE”), if available; (2) third party evidence of selling price if VSOE is not available; or (3) best estimated selling price (“BESP”) if neither VSOE nor third party evidence is available. The Company generally expects that it will not be able to establish selling price using third-party evidence due to the nature of our products and the markets in which the Company competes, and, as such, the Company typically will determine selling price using VSOE or BESP. When the Company establishes selling price using BESP, consideration is given to both market and Company-specific factors, including the cost to produce the deliverable and the anticipated margin on that deliverable, as well as the characteristics of markets in which the deliverable is sold. Revenue earned from activities performed pursuant to research and development agreements is reported as research revenue in the consolidated statements of operations and comprehensive loss, using the proportional performance method as the work is completed, limited to payments earned, and the related costs are expensed as incurred as research and development expense. The timing of receipt of cash from the Company’s research and development agreements generally differs from when revenue is recognized.   Product Recall In July 2016, the Company initiated a voluntary recall and replacement of its T2Candida cartridges at certain customer sites because T2Candida was experiencing higher than normal invalid test rates as the T2Candida cartridges aged. As of June 30, 2016, as a result of this voluntary recall, the Company deferred revenue totaling $149,000 and recorded additional costs of product revenue of $41,000 related to returned products, which are no longer usable. As of June 30, 2017, the Company had $20,000 of deferred revenue and $2,000 of warranty reserve remaining, both related to this voluntary recall. The impact of the voluntary recall on T2Candida cartridges in inventory was not material to the condensed consolidated financial statements. Cost of Product Revenue Cost of product revenue includes the cost of materials, direct labor and manufacturing overhead costs used in the manufacture of consumable diagnostic tests sold to customers and related license and royalty fees. Cost of product revenue also includes depreciation on revenue generating T2Dx systems that have been placed with customers under reagent rental agreements; costs of materials, direct labor and manufacturing overhead costs on the T2Dx systems sold to customers; and other costs such as customer support costs, royalties and license fees, warranty and repair and maintenance expense on the T2Dx systems that have been placed with customers under reagent rental agreements. Research and Development Costs Costs incurred in the research and development of the Company’s product candidates are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including activities associated with performing services under research revenue arrangements, and include salaries and benefits, stock compensation, research-related facility and overhead costs, laboratory supplies, equipment and contract services. Recent Accounting Standards From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. Accounting Standards Adopted In August 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” which is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its financial obligations as they become due within one year after the date that the financial statements are issued (or are available to be issued). ASU No. 2014-15 provides guidance to an organization’s management, with principles and definitions intended to reduce diversity in the timing and content of disclosures commonly provided by organizations in the footnotes of their financial statements. ASU No. 2014-15 was effective for annual reporting periods ending after December 15, 2016, and for annual and interim periods thereafter. This standard has been adopted and the Company does not believe it is required to make any additional disclosures. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory (“ASU 2015-11”). The standard simplifies the subsequent measurement of inventory by requiring inventory to be measured at the lower of cost and net realizable value for entities using the first-in-first out method of valuing inventory. ASU 2015-11 eliminates other measures required by current guidance to determine net realizable value. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016 and interim periods within those fiscal years and early adoption is permitted. The Company’s adoption of this standard did not have a material effect on its condensed consolidated financial statements. In March 2016, the FASB released ASU No. 2016-09 Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”) which is intended to simplify income tax accounting for excess tax benefits, accounting for forfeitures, and employer statutory withholding. Under the current guidance, excess tax benefits that result from an award vesting or settling are recognized in additional paid-in capital in the period that they reduce cash taxes payable. This requires the provision to be computed on a with and without option basis and may result in net operating loss and credit carryforwards on the balance sheet being less than what is available on the tax return. Under the new guidance, the income tax effects of awards will be recognized as a component of income tax expense when the awards vest or are settled (regardless if cash taxes are reduced). For interim reporting purposes, companies will account for excess tax benefits and tax deficiencies as discrete items in the period during which they occurred. The guidance is effective for public entities for fiscal years beginning after December 15, 2016, and interim periods within those years. Early adoption is permitted, however all of the guidance included in the update must be applied when adopted. The Company must use a modified retrospective transition method for adopting and record the cumulative effect of all unrecognized benefits and any change in valuation allowances at the end of the prior tax period as an adjustment to retained earnings. The Company’s adoption of this standard did not have a material effect on its condensed consolidated financial statements and prior periods have not been adjusted. As a result, the Company established a net operating loss deferred tax asset of $1.2 million to account for prior period excess tax benefits through retained earnings, however an offsetting valuation allowance of $1.2 million will also be established through retained earnings because it is not more likely than not that the deferred tax asset will be realized due to historical and expected future losses, such that there is no impact on the Company’s condensed consolidated financial statements. The Company also elected to maintain the use of estimated forfeitures in the calculation of stock based compensation. In March 2016, the FASB issued ASU No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments (“ASU 2016-06”), which applies to all issuers of or investors in debt instruments with embedded call or put options. ASU 2016-06 clarifies the requirements for assessing whether contingent call or put options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts. Entities performing the assessment under the guidance of ASU 2016-06 are required to assess the embedded call or put options solely in accordance with the four-step decision process. In addition, ASU 2016-06 clarifies what steps are required when assessing whether the economic characteristics and risks of call or put options are clearly and closely related to the economic characteristics and risks of their debt hosts. ASU 2016-06 is effective for financial statements issued for fiscal years beginning after December 15, 2016 and interim periods within those fiscal years using the modified retrospective method for existing debt instruments. The Company’s adoption of this standard did not have a material effect on its condensed consolidated financial statements. Accounting Standards Issued, Not Adopted In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASC 2016-15”), which provides guidance on the classification of certain specific cash flow issues including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of certain insurance claims and distributions received from equity method investees. The standard requires the use of a retrospective approach to all periods presented, but may be applied prospectively if retrospective application would be impracticable. The guidance is effective for public entities for fiscal years beginning after December 15, 2017, and interim periods within those years, and early application is permitted. The Company is currently evaluating the impact of its pending adoption of ASU 2016-15 on the Company’s consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (“ASU 2016-02”), which applies to all leases. Under ASU 2016-02, a right-of-use asset and lease obligation will be recorded for all leases, whether operating or financing leases, while the statement of operations will reflect lease expense for operating leases and amortization and interest expense for financing leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 and interim periods within those years, which is the year ended December 31, 2019 for the Company. Entities are required to use a modified retrospective approach of adoption for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. Full retrospective application is prohibited. The Company is evaluating the new guidance and the expected effect on the Company’s consolidated financial statements. In June 2014, the FASB issued amended guidance, ASU No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which is applicable to revenue recognition that will now be effective for the Company for the year ending December 31, 2018, as a result of the deferral of the effective date adopted by the FASB in July 2015. The new guidance must be adopted using either a full retrospective approach for all periods presented or a modified retrospective approach. Early adoption prior to the original adoption date of ASU 2014-09 is not permitted. The new guidance applies a more principles-based approach to revenue recognition. The Company currently anticipates adoption of the new standard effective January 1, 2018 under the modified retrospective method. The Company’s revenue is primarily comprised of product sales and research services, and the Company is in the process of determining the impact of the new standard on its financial statements. </div>

<div> 11. Subsequent Events. None </div>

<div> 4. Supplemental Balance Sheet Information Inventories Inventories are stated at the lower of cost or net realizable value on a first-in, first-out basis and are comprised of the following (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Raw materials </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">463</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">389</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Work-in-process </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">469</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">351</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Finished goods </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">82</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">63</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total inventories, net </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,014</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">803</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Property and Equipment Property and equipment consists of the following (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Office and computer equipment </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">409</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">409</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Software </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">743</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">708</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Laboratory equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,078</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,516</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Furniture </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">200</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">200</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Manufacturing equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">910</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">897</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Manufacturing tooling and molds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">160</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">154</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> T2-owned instruments and components </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,933</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,119</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Leasehold improvements </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,372</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,353</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Construction in progress </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,488</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,299</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,293</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20,655</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Less accumulated depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,783</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,066</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Property and equipment, net </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,510</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,589</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Construction in progress is primarily comprised of equipment and leasehold improvement construction projects that have not been placed in service. T2-owned instruments and components is comprised of raw materials and work-in-process inventory that are expected to be used or used to produce Company-owned instruments, based on our business model and forecast, and completed instruments that will be used for internal research and development, clinical studies or reagent rental agreements with customers. Completed T2-owned instruments are placed in service once installation procedures are completed and are depreciated over five years. The Company has approximately $7.8 million and $5.7 million of T2-owned instruments installed and depreciating as of June 30, 2017 and December 31, 2016, respectively. Depreciation expense for T2-owned instruments placed at customer sites pursuant to reagent rental agreements is recorded as a component of cost of product revenue and totaled approximately $0.2 million and $0.2 million for the three months ended June 30, 2017 and 2016, respectively, and $0.4 million and $0.2 million for the six months ended June 30, 2017 and 2016, respectively. Depreciation expense for T2-owned instruments used for internal research and development and clinical studies is recorded as a component of research and development expense. Accrued Expenses Accrued expenses consist of the following (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accrued payroll and compensation </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,234</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,479</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accrued research and development expenses </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,205</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">846</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accrued professional services </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">545</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">884</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Other accrued expenses </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">717</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">699</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total accrued expenses </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,701</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,908</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

TTOO

30595933

<div> 8. Warrants In connection with the Term Loan Agreement entered into in December 2016, the Company issued to CRG four separate warrants to purchase a total of 528,958 shares of the Company’s common stock. The warrants are exercisable any time prior to December 30, 2026 at a price of $8.06 per share, with typical provisions for termination upon a change of control or a sale of all or substantially all of the assets of the Company. The warrants are classified within shareholders’ equity, and the proceeds were allocated between the debt and warrants based on their relative fair value. The fair value of the warrants was determined by the Black-Scholes-Merton option pricing model. The fair value of the warrants at issuance on December 30, 2016 was $1.8 million. </div> <div> Unaudited Interim Financial Information Certain information and footnote disclosures normally included in the Company’s annual financial statements have been condensed or omitted. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016. The accompanying interim condensed consolidated balance sheet as of June 30, 2017, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2017 and 2016, the condensed consolidated statements of cash flows for the three and six months ended June 30, 2017 and 2016 and the related financial data and other information disclosed in these notes are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual financial statements, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of June 30, 2017, and the results of its operations and its cash flows for the three and six months ended June 30, 2017 and 2016. The results for the three and six months ended June 30, 2017 are not necessarily indicative of the results to be expected for the year ending December 31, 2017, any other interim periods, or any future year or period. </div> 713000 <div> Product Recall In July 2016, the Company initiated a voluntary recall and replacement of its T2Candida cartridges at certain customer sites because T2Candida was experiencing higher than normal invalid test rates as the T2Candida cartridges aged. As of June 30, 2016, as a result of this voluntary recall, the Company deferred revenue totaling $149,000 and recorded additional costs of product revenue of $41,000 related to returned products, which are no longer usable. As of June 30, 2017, the Company had $20,000 of deferred revenue and $2,000 of warranty reserve remaining, both related to this voluntary recall. The impact of the voluntary recall on T2Candida cartridges in inventory was not material to the condensed consolidated financial statements. </div>

4006148

597220

528958

P1Y0M29D

32900

357925

5.80

5.16

0 0 1800000 2300000

P6Y0M0D

102775

P6Y11M23D

2.33

0.00

0.0199

P5Y6M14D

483274

3.11

9.03

5.30

0.63

14.93

P6Y9M29D

500000

743200

193630

P6Y0M0D

P10Y0M0D

P4Y0M0D

P10Y0M0D

P4Y0M0D

300000

200000

65000

691000

1699000

P1Y P1Y

86000

400000

P5Y

P12M

2462000

4167295

184000

2807000

28112000

1068000

-1.13

-879000

-81000

752000

-49000

228000

-276000

-1540000

1146000

-3173000

-23444000

4516000

-24787000

-27472000

-26026000

94000

308000

3173000

385000

4593000

1498000

392000

12958000

2086000

588000

2527000

12347000

2500000

123000

24270041

700000

4167295

5800000

P6Y0M0D

0.00

0.0145

4.90

0.60

1100000

59000

610000

1793000

41000

65000

200000

67000000

2100000

79000000

2500000

1500000

P36M

P1Y

P6Y

39200000

40000000

28000000 P3Y P4Y P5Y 0.040 0.040 0.035

27500000

500000

20000

P7Y0M18D

1200000

4167295

1781000

14293000

-0.58

-805000

-14046000

-13303000

62000

839000

6369000

990000

151000

6143000

24321310

4167295

600000

33000

341000

826000

37000

200000

1331000

5132326

1989000

14860000

-0.50

-1654000

-15456000

-13904000

102000

221000

7112000

956000

735000

5759000

30661200

4006148

597220

528958

200000

36000

393000

902000

53000

200000

0001492674 ttoo:T2OwnedInstrumentsInServiceMember 2017-04-01 2017-06-30 0001492674 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-04-01 2017-06-30 0001492674 us-gaap:ResearchAndDevelopmentExpenseMember 2017-04-01 2017-06-30 0001492674 us-gaap:CostOfSalesMember 2017-04-01 2017-06-30 0001492674 ttoo:AllerganSalesMemberttoo:CoDevelopmentPartnershipAgreementMember 2017-04-01 2017-06-30 0001492674 ttoo:CanonU.S.LifeSciencesIncMemberttoo:CoDevelopmentPartnershipAgreementMember 2017-04-01 2017-06-30 0001492674 us-gaap:WarrantMember 2017-04-01 2017-06-30 0001492674 us-gaap:RestrictedStockUnitsRSUMember 2017-04-01 2017-06-30 0001492674 us-gaap:EmployeeStockOptionMember 2017-04-01 2017-06-30 0001492674 2017-04-01 2017-06-30 0001492674 ttoo:T2OwnedInstrumentsInServiceMember 2016-04-01 2016-06-30 0001492674 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-04-01 2016-06-30 0001492674 us-gaap:ResearchAndDevelopmentExpenseMember 2016-04-01 2016-06-30 0001492674 us-gaap:CostOfSalesMember 2016-04-01 2016-06-30 0001492674 ttoo:CanonU.S.LifeSciencesIncMemberttoo:CoDevelopmentPartnershipAgreementMember 2016-04-01 2016-06-30 0001492674 us-gaap:EmployeeStockOptionMember 2016-04-01 2016-06-30 0001492674 2016-04-01 2016-06-30 0001492674 ttoo:EmployeeAndNonemployeeStockOptionsMemberttoo:StockOptionPlans2006And2014Member 2016-01-01 2016-12-31 0001492674 us-gaap:PerformanceSharesMemberus-gaap:ExecutiveOfficerMember 2016-01-01 2016-12-31 0001492674 us-gaap:CommonStockMember 2016-12-01 2016-12-31 0001492674 ttoo:PromissoryNoteMember 2016-12-01 2016-12-31 0001492674 ttoo:LoanAndSecurityAgreementMember 2016-12-01 2016-12-31 0001492674 ttoo:FollowingApprovalMilestoneMemberttoo:CRGServicingLLCMemberttoo:TermLoanAgreementMember 2016-12-01 2016-12-31 0001492674 ttoo:PriortoApprovalMilestoneMemberttoo:CRGServicingLLCMemberttoo:TermLoanAgreementMember 2016-12-01 2016-12-31 0001492674 ttoo:CRGServicingLLCMemberttoo:TermLoanAgreementMember 2016-12-01 2016-12-31 0001492674 us-gaap:CapitalLeaseObligationsMember 2015-10-01 2015-10-31 0001492674 ttoo:CanonU.S.LifeSciencesIncMemberttoo:CoDevelopmentPartnershipAgreementMember 2015-10-01 2015-10-31 0001492674 us-gaap:CapitalLeaseObligationsMember 2016-06-01 2016-06-30 0001492674 us-gaap:CapitalLeaseObligationsMember 2016-04-01 2016-04-30 0001492674 ttoo:T2OwnedInstrumentsInServiceMember 2016-01-01 2016-06-30 0001492674 ttoo:T2CandidaMember 2016-01-01 2016-06-30 0001492674 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-06-30 0001492674 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-06-30 0001492674 us-gaap:CostOfSalesMember 2016-01-01 2016-06-30 0001492674 ttoo:CanonU.S.LifeSciencesIncMemberttoo:CoDevelopmentPartnershipAgreementMember 2016-01-01 2016-06-30 0001492674 ttoo:EmployeeAndNonemployeeStockOptionsMemberttoo:StockOptionPlans2006And2014Member 2016-01-01 2016-06-30 0001492674 ttoo:EmployeeAndNonemployeeStockOptionsMemberttoo:StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember 2016-01-01 2016-06-30 0001492674 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-06-30 0001492674 2016-01-01 2016-06-30 0001492674 us-gaap:MinimumMember 2017-01-01 2017-06-30 0001492674 ttoo:T2OwnedInstrumentsInServiceMember 2017-01-01 2017-06-30 0001492674 ttoo:T2DxMember 2017-01-01 2017-06-30 0001492674 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-06-30 0001492674 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-06-30 0001492674 us-gaap:CostOfSalesMember 2017-01-01 2017-06-30 0001492674 ttoo:AllerganSalesMemberttoo:CoDevelopmentPartnershipAgreementMember 2017-01-01 2017-06-30 0001492674 ttoo:CanonU.S.LifeSciencesIncMemberttoo:CoDevelopmentPartnershipAgreementMember 2017-01-01 2017-06-30 0001492674 ttoo:EmployeeAndNonemployeeStockOptionsMemberttoo:StockOptionPlan2014Memberus-gaap:MaximumMember 2017-01-01 2017-06-30 0001492674 ttoo:EmployeeAndNonemployeeStockOptionsMemberttoo:StockOptionPlan2006Memberus-gaap:MaximumMember 2017-01-01 2017-06-30 0001492674 ttoo:EmployeeAndNonemployeeStockOptionsMemberttoo:StockOptionPlans2006And2014Member 2017-01-01 2017-06-30 0001492674 ttoo:EmployeeAndNonemployeeStockOptionsMemberttoo:StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember 2017-01-01 2017-06-30 0001492674 us-gaap:RestrictedStockUnitsRSUMemberttoo:StockOptionPlans2006And2014Member 2017-01-01 2017-06-30 0001492674 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-06-30 0001492674 us-gaap:WarrantMember 2017-01-01 2017-06-30 0001492674 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-06-30 0001492674 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-06-30 0001492674 2017-01-01 2017-06-30 0001492674 us-gaap:PrivatePlacementMember 2016-09-21 2016-09-21 0001492674 ttoo:AllerganSalesMemberttoo:CoDevelopmentPartnershipAgreementMember 2016-11-01 2016-11-01 0001492674 ttoo:CanonU.S.LifeSciencesIncMemberttoo:CoDevelopmentPartnershipAgreementMember 2015-02-03 2015-02-03 0001492674 us-gaap:CommonStockMember 2016-12-31 0001492674 ttoo:T2OwnedInstrumentsInServiceMember 2016-12-31 0001492674 ttoo:T2DxInstrumentsAndComponentsMember 2016-12-31 0001492674 us-gaap:ToolsDiesAndMoldsMember 2016-12-31 0001492674 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2016-12-31 0001492674 us-gaap:OfficeEquipmentMember 2016-12-31 0001492674 us-gaap:ManufacturingFacilityMember 2016-12-31 0001492674 us-gaap:LeaseholdImprovementsMember 2016-12-31 0001492674 us-gaap:FurnitureAndFixturesMember 2016-12-31 0001492674 us-gaap:EquipmentMember 2016-12-31 0001492674 us-gaap:ConstructionInProgressMember 2016-12-31 0001492674 us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001492674 us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001492674 ttoo:EquipmentLeaseCreditFacilityMemberus-gaap:LineOfCreditMember 2016-12-31 0001492674 ttoo:TermLoanAgreementMemberus-gaap:MediumTermNotesMember 2016-12-31 0001492674 ttoo:FollowingApprovalMilestoneMemberttoo:CRGServicingLLCMemberttoo:TermLoanAgreementMember 2016-12-31 0001492674 ttoo:PriortoApprovalMilestoneMemberttoo:CRGServicingLLCMemberttoo:TermLoanAgreementMember 2016-12-31 0001492674 ttoo:CRGServicingLLCMemberttoo:TermLoanAgreementMember 2016-12-31 0001492674 us-gaap:MoneyMarketFundsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001492674 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001492674 us-gaap:CashMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001492674 us-gaap:CashMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001492674 ttoo:EmployeeAndNonemployeeStockOptionsMemberttoo:StockOptionPlans2006And2014Member 2016-12-31 0001492674 us-gaap:RestrictedStockUnitsRSUMember 2016-12-31 0001492674 us-gaap:PerformanceSharesMemberus-gaap:ExecutiveOfficerMember 2016-12-31 0001492674 us-gaap:PerformanceSharesMember 2016-12-31 0001492674 2016-12-31 0001492674 2015-12-31 0001492674 ttoo:T2OwnedInstrumentsInServiceMember 2017-06-30 0001492674 ttoo:T2DxInstrumentsAndComponentsMember 2017-06-30 0001492674 us-gaap:ToolsDiesAndMoldsMember 2017-06-30 0001492674 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2017-06-30 0001492674 us-gaap:OfficeEquipmentMember 2017-06-30 0001492674 us-gaap:ManufacturingFacilityMember 2017-06-30 0001492674 us-gaap:LeaseholdImprovementsMember 2017-06-30 0001492674 us-gaap:FurnitureAndFixturesMember 2017-06-30 0001492674 us-gaap:EquipmentMember 2017-06-30 0001492674 us-gaap:ConstructionInProgressMember 2017-06-30 0001492674 ttoo:T2CandidaMember 2017-06-30 0001492674 us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0001492674 us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0001492674 ttoo:EquipmentLeaseCreditFacilityMemberus-gaap:LineOfCreditMember 2017-06-30 0001492674 ttoo:LoanAndSecurityAgreementMember 2017-06-30 0001492674 ttoo:TermLoanAgreementMemberus-gaap:MediumTermNotesMember 2017-06-30 0001492674 ttoo:CanonU.S.LifeSciencesIncMemberttoo:CoDevelopmentPartnershipAgreementMember 2017-06-30 0001492674 us-gaap:MoneyMarketFundsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0001492674 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0001492674 us-gaap:CashMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0001492674 us-gaap:CashMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0001492674 ttoo:EmployeeAndNonemployeeStockOptionsMemberttoo:StockOptionPlan2014Member 2017-06-30 0001492674 ttoo:EmployeeAndNonemployeeStockOptionsMemberttoo:StockOptionPlans2006And2014Member 2017-06-30 0001492674 us-gaap:RestrictedStockUnitsRSUMember 2017-06-30 0001492674 us-gaap:PerformanceSharesMember 2017-06-30 0001492674 ttoo:AccountingStandardsUpdate201609ExcessTaxBenefitComponentMemberus-gaap:RetainedEarningsMember 2017-06-30 0001492674 2017-06-30 0001492674 us-gaap:PrivatePlacementMember 2016-09-21 0001492674 ttoo:T2CandidaMember 2016-06-30 0001492674 2016-06-30 0001492674 2017-08-02 0001492674 ttoo:AllerganSalesMemberttoo:CoDevelopmentPartnershipAgreementMember 2016-11-01 0001492674 us-gaap:CapitalLeaseObligationsMember 2015-10-31 0001492674 ttoo:CanonU.S.LifeSciencesIncMemberttoo:CoDevelopmentPartnershipAgreementMember 2015-02-03 iso4217:USD pure shares iso4217:USD shares ttoo:Item ttoo:specie ttoo:Segment ttoo:Draw ttoo:Warrant

EX-101.SCH 8 ttoo-20170630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Statement of Cash Flows link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - Nature of Business link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Supplemental Balance Sheet Information link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Notes Payable link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Warrants link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Net Loss Per Share link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Co-Development Agreements link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Supplemental Balance Sheet Information (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Notes Payable (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Net Loss Per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Nature of Business - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities at Fair value on a Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Supplemental Balance Sheet Information - Schedule of Inventory (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Supplemental Balance Sheet Information - Schedule of Property and Equipment (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Supplemental Balance Sheet Information - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Supplemental Balance Sheet Information - Components of Accrued Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Notes Payable - Schedule of Debt (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Notes Payable - Schedule of Debt (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Notes Payable - Term Loan Agreement - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Notes Payable - Equipment Lease Credit Facility - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Stock-Based Compensation - Schedule of Estimated Assumptions Used to Calculate Weighted-Average Fair Value of Options Granted (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Stock-Based Compensation - Schedule of Nonvested Restricted Stock Units Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense for Stock Options Granted that was Recorded in the Company's Results of Operations (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Warrants - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - Co-Development Agreements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 9 ttoo-20170630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 ttoo-20170630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 ttoo-20170630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Policies [Abstract] Accounting Policies [Abstract] Accounting Standards Update 2016-09, Excess Tax Benefit Component [Member] Accounting Standards Update 201609 Excess Tax Benefit Component [Member] Accounting Standards Update 201609 Excess Tax Benefit Component [Member] Accounts Payable, Current Accounts payable Accounts Receivable, Net, Current Accounts receivable Accrued Liabilities, Current Accrued expenses and other current liabilities Total accrued expenses Accrued Liabilities, Current [Abstract] Accrued Liabilities, Current [Abstract] Accrued Professional Fees, Current Accrued professional services Carrying value as of the balance sheet date of obligations incurred and payable for research and development expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Research and Development Expenses Current Accrued research and development expenses Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less accumulated depreciation and amortization Additional Paid in Capital, Common Stock Additional paid-in capital Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Allergan Sales [Member] Allergan Sales [Member] Allergan Sales [Member] Allocated Share-based Compensation Expense Stock-based compensation expense Amendment Flag Amendment Flag Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive securities excluded from the computation of diluted net loss per share Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Assets Total assets Assets [Abstract] Assets Assets, Current Total current assets Assets, Current [Abstract] Current assets: Assets, Fair Value Disclosure Total assets Assets, Fair Value Disclosure [Abstract] Assets: Award Type [Axis] Award Type [Axis] Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Represents the information pertaining to Canon U.S. Life Sciences, Inc. Canon U.S. Life Sciences Inc [Member] Canon U.S. Life Sciences Inc [Member] Capital Expenditures Incurred but Not yet Paid Accrued property and equipment Repurchase price as percentage of original equipment value that the equipment purchased under the terms of the capital lease obligation may be repurchased by lessee. Capital Lease Obligation Repurchase Price As Percentage Of Original Equipment Value Repurchase price as percentage of original equipment value that the equipment under lease may be repurchased by lessee Capital Lease Obligations [Member] Capital Lease Obligations [Member] Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and cash equivalents Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents, Fair Value Disclosure Cash Cash [Member] Cash [Member] Class of Stock [Domain] Class of Stock [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price of warrants Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Class of Warrant or Right, Number of Securities Called by Warrants or Rights Number of shares issuable for warrants outstanding Number of shares issuable for warrants outstanding (in shares) Class of Warrant or Right [Table] Class of Warrant or Right [Table] Represents information pertaining to a Co-Development Partnership Agreement with a third party to develop certain products. Co Development Partnership Agreement [Member] Co Development Partnership Agreement [Member] Amount of additional consideration receivable upon achievement of additional development and regulatory milestones under collaborative arrangement. Collaborative Arrangement Additional Consideration Receivable Upon Achievement Of Additional Development And Regulatory Milestones Additional consideration receivable upon achievement of additional development and regulatory milestones Amount of the first milestone payment due for additional consideration receivable upon achievement of additional development and regulatory milestones under collaborative arrangement. Collaborative Arrangement Additional Consideration Receivable Upon Achievement Of Additional Development And Regulatory Milestones Payment One Additional consideration receivable upon achievement of development and regulatory milestones, payment one Amount of the second milestone payment due for additional consideration receivable upon achievement of additional development and regulatory milestones under collaborative arrangement. Collaborative Arrangement Additional Consideration Receivable Upon Achievement Of Additional Development And Regulatory Milestones Payment Two Additional consideration receivable upon achievement of development and regulatory milestones, payment two Amount of additional consideration receivable upon achievement of certain development and regulatory milestones under collaborative arrangement. Collaborative Arrangement Additional Consideration Receivable Upon Achievement Of Certain Development And Regulatory Milestones Additional consideration receivable upon achievement of certain development and regulatory milestones Amount of aggregate consideration receivable under collaborative arrangement. Collaborative Arrangement Aggregate Consideration Aggregate consideration receivable Collaborative Arrangement Disclosure [Text Block] Co-Development Agreements Represents the number of milestone payments receivable upon achievement of specified requirements under collaborative arrangement. Collaborative Arrangement Number Of Milestone Payments Number of milestone payments Number of units under arrangement. Collaborative Arrangement Number Of Units Number of units Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Upfront payment amount received upon entry into collaborative arrangement. Collaborative Arrangement Up Front Payment Received Upfront payment Commitments and Contingencies Commitments and contingencies Common Stock, Capital Shares Reserved for Future Issuance Shares available for future issuance under stock incentive plan Common Stock [Member] Common Stock [Member] Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Value, Issued Common stock, $0.001 par value; 200,000,000 shares authorized; 30,763,919 and 30,482,712 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively Construction in Progress [Member] Construction in Progress [Member] Cost of Goods Sold Cost of product revenue Costs of product revenue Cost of Goods Sold, Depreciation Depreciation expense recorded as a component of cost of product revenue Cost of Sales [Member] Cost of Product Revenue [Member] Cost of Sales, Policy [Policy Text Block] Cost of Product Revenue Costs and Expenses Total costs and expenses Costs and Expenses [Abstract] Costs and expenses: Counterparty Name [Axis] Counterparty Name [Axis] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] CRG Servicing LLC [Member] CRG Servicing LLC [Member] CRG Servicing LLC [Member] Cumulative Effect of New Accounting Principle in Period of Adoption Cumulative effect of new accounting principle in period of adoption Current Fiscal Year End Date Current Fiscal Year End Date Debt Covenant Terms [Axis] Debt Covenant Terms [Axis] Debt Covenant Terms [Axis] Debt Covenant Terms [Domain] Debt Covenant Terms [Domain] Debt Covenant Terms [Domain] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Disclosure [Text Block] Notes Payable Debt Instrument [Axis] Debt Instrument [Axis] Contractual deferred interest rate during interest only payments for funds borrowed, under the debt agreement. Debt Instrument Deferred Interest Rate Interest Only Payment Deferred interest rate (as a percent) Additional interest rate on all outstanding obligations during the occurrence and continuance of an event of default. Debt Instrument Event Of Default Additional Interest Rate Additional interest rate, event of default (as a percent) Extended period of time between issuance and maturity of debt instrument of interest only payments, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Debt Instrument Extended Term Interest Only Payments Debt instrument, extended term interest only payments (in years) Final fee as a percentage of the amount of principal outstanding upon repayment. Debt Instrument Final Payment Fee Percentage Final fee as a percentage of the principal outstanding (as a percent) Debt Instrument, Interest Rate, Stated Percentage Annual fixed rate (as a percent) Debt Instrument [Line Items] Debt Instrument Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Prepayment fee period of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Debt Instrument Prepayment Fee Term Debt instrument, prepayment fee term (in years) Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument, Term Debt term (in months) Debt term (in years) Period of time between issuance and maturity of debt instrument of interest only payments, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Debt Instrument Term Of Interest Only Payments Debt instrument, term of interest-only payments (in years) Debt Issuance Costs, Net Deferred issuance costs Deferred Rent Credit, Current Current portion of lease incentives Deferred Rent Credit, Noncurrent Lease incentives, net of current portion Deferred Revenue, Current Deferred revenue Depreciation, Depletion and Amortization Depreciation and amortization Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-Based Compensation Document and entity information. Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] Earnings Per Share [Abstract] Earnings Per Share, Basic and Diluted Net loss per share - basic and diluted Earnings Per Share, Policy [Policy Text Block] Net Loss Per Share Earnings Per Share [Text Block] Net Loss Per Share Employee and nonemployee stock options. Employee And Nonemployee Stock Options [Member] Stock Options [Member] Employee-related Liabilities, Current Accrued payroll and compensation Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Stock-based compensation expense Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Weighted-average period Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Unrecognized compensation cost related to unvested stock options Employee Stock Option [Member] Options to Purchase Common Shares [Member] Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equipment Lease Credit Facility [Member] Equipment Lease Credit Facility [Member] Equipment Lease Credit Facility [Member] Equipment [Member] Laboratory Equipment [Member] Equity [Abstract] Equity [Abstract] Equity Component [Domain] Equity Component [Domain] Estimate of Fair Value Measurement [Member] Estimate of Fair Value Measurement [Member] Executive Officer [Member] Executive Officer [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Measurement Basis [Axis] Measurement Basis [Axis] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value Measurements Fair Value, Inputs, Level 1 [Member] Level 1 [Member] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value, Measurements, Recurring [Member] Recurring [Member] Following Approval Milestone [Member] Following Approval Milestone [Member] Following Approval Milestone [Member] Furniture and Fixtures [Member] Furniture [Member] Gain (Loss) on Disposition of Property Plant Equipment Loss on sale of T2 owned equipment Guarantees, Indemnifications and Warranties Policies [Policy Text Block] Guarantees Income Statement [Abstract] Income Statement [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued expenses and other liabilities Increase (Decrease) in Deferred Revenue Deferred revenue Increase (Decrease) in Inventories Inventories, net Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Interest Income (Expense), Nonoperating, Net Interest expense, net Interest Paid Cash paid for interest Inventory, Finished Goods, Net of Reserves Finished goods Inventory, Net Inventories, net Total inventories, net Inventory, Raw Materials, Net of Reserves Raw materials Inventory, Work in Process, Net of Reserves Work-in-process Leasehold Improvements [Member] Leasehold Improvements [Member] Liabilities and Equity Total liabilities and stockholders' equity Liabilities and Equity [Abstract] Liabilities and stockholders' equity Liabilities, Current Total current liabilities Liabilities, Current [Abstract] Current liabilities: The contingent increase above the maximum borrowing capacity under the credit facility, if any one or more of the existing banks or new banks agree to provide such increased commitment amount. Line Of Credit Facility Contingent Increase Additional Borrowing Capacity Line of credit, additional borrowing capacity Line of Credit Facility, Current Borrowing Capacity Initial borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Maximum borrowings available (up to) Line of Credit Facility, Periodic Payment Amount of monthly payment Line of Credit Facility, Remaining Borrowing Capacity Remaining borrowing capacity Line of Credit [Member] Line of Credit [Member] Represents information pertaining to the loan and security agreement. Loan And Security Agreement [Member] Loan and Security Agreement [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Notes Payable, Noncurrent Notes payable, net of current portion The term following the installation of the purchased product for maintenance services which include warranty, maintenance, and technical support services, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Maintenance Service Period Maintenance Services period (in years) The additional term for maintenance services on purchased product (which include warranty, maintenance, and technical support services) that may be purchased for additional consideration, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Maintenance Service Term Of Additional Period Additional period for Maintenance Service option (in years) Manufacturing Facility [Member] Manufacturing Equipment [Member] Maximum [Member] Maximum [Member] Medium-term Notes [Member] Medium-term Notes [Member] Represents the minimum lease period to extend the lease, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Minimum Lease Period For Renewal Minimum lease period to extend lease (in years) Minimum [Member] Minimum [Member] Money Market Funds [Member] Money Market Funds [Member] Nature of Operations [Text Block] Nature of Business Net Cash Provided by (Used in) Continuing Operations Net decrease in cash and cash equivalents Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash flows from financing activities Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Cash flows from investing activities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash flows from operating activities Net Income (Loss) Attributable to Parent Net loss Net loss and comprehensive loss New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Standards Noncash Investing and Financing Items [Abstract] Supplemental disclosures of noncash investing and financing activities Notes Payable Total notes payable Notes Payable, Current Current portion of notes payable Less: current portion of notes payable The number of additional bacteria species added. Number Of Additional Bacteria Species Added Number of additional bacteria species added to existing product candidate Represents the number of draws on the Equipment Lease Credit Facility during the period. Number Of Draws On Credit Facility Number of draws The period over which the operating plan will be sufficiently funded by cash resources. Number Of Months Operating Plan Sufficiently Funded By Cash Resources Period over which cash resources will be sufficient to allow Company to fund current operating plan EX-101.PRE 12 ttoo-20170630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2017	Aug. 02, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2
Trading Symbol	TTOO
Entity Registrant Name	T2 Biosystems, Inc.
Entity Central Index Key	0001492674
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		30,764,319

XML 14 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 46,134	$ 73,488
Accounts receivable	981	327
Prepaid expenses and other current assets	660	820
Inventories, net	1,014	803
Total current assets	48,789	75,438
Property and equipment, net	14,510	13,589
Restricted cash	260	260
Other assets	218	281
Total assets	63,777	89,568
Current liabilities:
Accounts payable	1,660	962
Accrued expenses and other current liabilities	4,701	4,908
Current portion of notes payable	1,365	1,269
Deferred revenue	2,494	2,445
Current portion of lease incentives	248	301
Total current liabilities	10,468	9,885
Notes payable, net of current portion	39,908	39,504
Lease incentives, net of current portion	771	792
Other liabilities	305	49
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at June 30, 2017 and December 31, 2016
Common stock, $0.001 par value; 200,000,000 shares authorized; 30,763,919 and 30,482,712 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively	32	30
Additional paid-in capital	246,141	242,997
Accumulated deficit	(233,848)	(203,689)
Total stockholders' equity	12,325	39,338
Total liabilities and stockholders' equity	$ 63,777	$ 89,568

XML 15 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	30,763,919	30,482,712
Common stock, shares outstanding	30,763,919	30,482,712

XML 16 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenue:
Product revenue	$ 735	$ 151	$ 1,366	$ 588
Research revenue	221	839	531	1,498
Total revenue	956	990	1,897	2,086
Costs and expenses:
Cost of product revenue	1,989	1,781	3,617	2,807
Research and development	7,112	6,369	13,697	12,958
Selling, general and administrative	5,759	6,143	11,633	12,347
Total costs and expenses	14,860	14,293	28,947	28,112
Loss from operations	(13,904)	(13,303)	(27,050)	(26,026)
Interest expense, net	(1,654)	(805)	(3,291)	(1,540)
Other income, net	102	62	181	94
Net loss and comprehensive loss	$ (15,456)	$ (14,046)	$ (30,160)	$ (27,472)
Net loss per share - basic and diluted	$ (0.50)	$ (0.58)	$ (0.99)	$ (1.13)
Weighted-average number of common shares used in computing net loss per share - basic and diluted	30,661,200	24,321,310	30,595,933	24,270,041

XML 17 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities
Net loss	$ (30,160)	$ (27,472)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,432	1,068
Stock-based compensation expense	2,550	2,527
Loss on sale of T2 owned equipment	107
Non-cash interest expense	1,291	308
Deferred rent	(74)	(123)
Changes in operating assets and liabilities:
Accounts receivable	(654)	81
Prepaid expenses and other assets	225	276
Inventories, net	(212)	(752)
Accounts payable	698	(49)
Accrued expenses and other liabilities	(230)	228
Deferred revenue	48	(879)
Net cash used in operating activities	(24,979)	(24,787)
Cash flows from investing activities
Purchases and manufacture of property and equipment	(2,468)	(3,173)
Net cash used in investing activities	(2,468)	(3,173)
Cash flows from financing activities
Payment of offering costs for issuance of common stock in public offering		(385)
Proceeds from issuance of common stock and stock options exercises, net	713	700
Proceeds from notes payable, net of issuance costs		4,593
Repayments of note payable	(620)	(392)
Net cash provided by financing activities	93	4,516
Net decrease in cash and cash equivalents	(27,354)	(23,444)
Cash and cash equivalents at beginning of period	73,488	73,662
Cash and cash equivalents at end of period	46,134	50,218
Supplemental disclosures of cash flow information
Cash paid for interest	1,981	1,146
Supplemental disclosures of noncash investing and financing activities
Accrued property and equipment	$ 51	$ 184

XML 18 R6.htm IDEA: XBRL DOCUMENT

Nature of Business	6 Months Ended
Nature of Business	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business	1. Nature of Business T2 Biosystems, Inc. (the “Company”) was incorporated on April 27, 2006 as a Delaware corporation with operations based in Lexington, Massachusetts. The Company is an in vitro diagnostics company that has developed an innovative and proprietary technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company is using its T2 Magnetic Resonance technology (“T2MR”) to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (“CFU/mL”). The Company’s initial development efforts target sepsis and lyme disease, which are areas of significant unmet medical need in which existing therapies could be more effective with improved diagnostics. On September 22, 2014, the Company received market clearance from the U.S. Food and Drug Administration (“FDA”) for its first two products, the T2Dx Instrument (the “T2Dx”) and T2Candida Panel (“T2Candida”). On June 30, 2017 the Company received CE Mark for its T2Bacteria Panel (“T2Bacteria”). Liquidity At June 30, 2017, the Company had cash and cash equivalents of $46.1 million and an accumulated deficit of $233.8 million. The future success of the Company is dependent on its ability to successfully commercialize its FDA approved products, obtain regulatory clearance for and successfully launch its future product candidates, including T2Bacteria, obtain additional capital and ultimately attain profitable operations. Historically, the Company has funded its operations primarily through its August 2014 initial public offering, its December 2015 secondary public offering, its September 2016 private investment in public equity (“PIPE”) financing, private placements of redeemable convertible preferred stock and through debt financing arrangements. The Company is subject to a number of risks similar to other newly commercial life science companies, including, but not limited to commercially launching the Company’s products, development and market acceptance of the Company’s product candidates, development by its competitors of new technological innovations, protection of proprietary technology, and raising additional capital. Having obtained authorization from the FDA to market T2Dx and T2Candida, the Company has incurred significant commercialization expenses related to product sales, marketing, manufacturing and distribution. In addition, the Company expects that costs and expenses may increase as it continues the research and development of other product candidates and maintains, expands and protects its intellectual property portfolio. The Company may seek to fund its operations through public equity or private equity or debt financings, as well as other sources. However, the Company may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. The Company’s failure to raise capital or enter into such other arrangements if and when needed would have a negative impact on the Company’s business, results of operations and financial condition and the Company’s ability to develop and commercialize T2Dx, T2Candida, T2Bacteria and other product candidates. Management believes that its existing cash and cash equivalents at June 30, 2017, together with the additional remaining liquidity on the Company’s Term Loan Agreement of up to an additional $10.0 million, will be sufficient to allow the Company to fund its current operating plan for 12 months from the date the financial statements are issued. The borrowing on the Term Loan Agreement is available at any time through July 27, 2018, and is subject to certain conditions including that the Company receive 510(k) clearance for the marketing of T2Bacteria^TM by the U.S. Food and Drug Administration (“FDA”) by April 30, 2018 (see Note 5). Because certain elements of the Company’s plan are outside of the Company’s control they cannot be considered probable, as defined by ASU 2014-15, Presentation of Financial Statements - Going Concern. Should the Company’s current operating plan not materialize as expected, including the Company’s ability to draw additional borrowings on the Term Loan Agreement on a timely basis, the Company would delay certain research projects and capital expenditures and reduce or eliminate certain future operating expenses in order to fund operations at reduced levels for the Company to continue as a going concern for a period of 12 months from the date the financial statements are issued. For more information, refer to the section titled “Liquidity and Capital Resources” in Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations and the section entitled “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2016, for additional risks associated with our capital needs.

XML 19 R7.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

Unaudited Interim Financial Information

Segment Information

Net Loss Per Share

Guarantees

Revenue Recognition

Persuasive evidence of an arrangement exists

ii.

Delivery has occurred or services have been rendered

iii.

The seller’s price to the buyer is fixed or determinable

iv.

Collectability is reasonably assured

If any of the above criteria have not been met, the Company defers revenue until such time each of the criteria have been satisfied.

Product revenue is generated by the sale of instruments and consumable diagnostic tests predominantly through the Company’s direct sales force in the United States and distributors in geographic regions outside the United States. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including its distributors. Payment terms granted to distributors are the same as those granted to end-user customers and payments are not dependent upon the distributors’ receipt of payment from their end-user customers. The Company either sells instruments to customers and international distributors, or retains title and places the instrument at the customer site pursuant to a reagent rental agreement. When the instrument is directly purchased by a customer, the Company recognizes revenue when all applicable revenue recognition criteria are met. When the instrument is placed under a reagent rental agreement, the Company’s customers generally agree to fixed term agreements, which can be extended, certain of which may include minimum purchase commitments and/or incremental charges on each consumable diagnostic test purchased, which varies based on the volume of test cartridges purchased. Revenue from the sale of consumable diagnostic tests, which includes the incremental charge, is recognized upon delivery or shipment as a component of product revenue in the Company’s consolidated statements of operations and comprehensive loss.

The Company does not offer rights of return for instruments or consumable diagnostic tests.

Product Recall

Cost of Product Revenue

Research and Development Costs

Recent Accounting Standards

Accounting Standards Adopted

In March 2016, the FASB released ASU No. 2016-09 Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”) which is intended to simplify income tax accounting for excess tax benefits, accounting for forfeitures, and employer statutory withholding. Under the current guidance, excess tax benefits that result from an award vesting or settling are recognized in additional paid-in capital in the period that they reduce cash taxes payable. This requires the provision to be computed on a with and without option basis and may result in net operating loss and credit carryforwards on the balance sheet being less than what is available on the tax return. Under the new guidance, the income tax effects of awards will be recognized as a component of income tax expense when the awards vest or are settled (regardless if cash taxes are reduced). For interim reporting purposes, companies will account for excess tax benefits and tax deficiencies as discrete items in the period during which they occurred. The guidance is effective for public entities for fiscal years beginning after December 15, 2016, and interim periods within those years. Early adoption is permitted, however all of the guidance included in the update must be applied when adopted. The Company must use a modified retrospective transition method for adopting and record the cumulative effect of all unrecognized benefits and any change in valuation allowances at the end of the prior tax period as an adjustment to retained earnings. The Company’s adoption of this standard did not have a material effect on its condensed consolidated financial statements and prior periods have not been adjusted. As a result, the Company established a net operating loss deferred tax asset of $1.2 million to account for prior period excess tax benefits through retained earnings, however an offsetting valuation allowance of $1.2 million will also be established through retained earnings because it is not more likely than not that the deferred tax asset will be realized due to historical and expected future losses, such that there is no impact on the Company’s condensed consolidated financial statements. The Company also elected to maintain the use of estimated forfeitures in the calculation of stock based compensation.

Accounting Standards Issued, Not Adopted

XML 20 R8.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

6 Months Ended

Jun. 30, 2017

Fair Value Disclosures [Abstract]

Fair Value Measurements

3. Fair Value Measurements


	Balance at June 30, 2017		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash	$	2,953	$	2,953	$	—	$	—
Money market funds		43,181		43,181		—		—
Restricted cash		260		260		—		—

Total	$	46,394	$	46,394	$	—	$	—


	Balance at December 31, 2016		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash	$	16,887	$	16,887	$	—	$	—
Money market funds		56,601		56,601		—		—
Restricted cash		260		260		—		—

Total	$	73,748	$	73,748	$	—	$	—

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 21 R9.htm IDEA: XBRL DOCUMENT

Supplemental Balance Sheet Information

6 Months Ended

Jun. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Supplemental Balance Sheet Information

4. Supplemental Balance Sheet Information

Inventories

Inventories are stated at the lower of cost or net realizable value on a first-in, first-out basis and are comprised of the following (in thousands):


	June 30, 2017		December 31, 2016
Raw materials	$	463	$	389
Work-in-process		469		351
Finished goods		82		63

Total inventories, net	$	1,014	$	803

Property and Equipment

Property and equipment consists of the following (in thousands):


	June 30, 2017			December 31, 2016
Office and computer equipment	$	409		$	409
Software		743			708
Laboratory equipment		4,078			4,516
Furniture		200			200
Manufacturing equipment		910			897
Manufacturing tooling and molds		160			154
T2-owned instruments and components		10,933			9,119
Leasehold improvements		3,372			3,353
Construction in progress		1,488			1,299

		22,293			20,655
Less accumulated depreciation and amortization		(7,783	)		(7,066	)

Property and equipment, net	$	14,510		$	13,589

Accrued Expenses

Accrued expenses consist of the following (in thousands):


	June 30, 2017		December 31, 2016
Accrued payroll and compensation	$	2,234	$	2,479
Accrued research and development expenses		1,205		846
Accrued professional services		545		884
Other accrued expenses		717		699

Total accrued expenses	$	4,701	$	4,908

XML 22 R10.htm IDEA: XBRL DOCUMENT

Notes Payable

6 Months Ended

Jun. 30, 2017

Debt Disclosure [Abstract]

Notes Payable

5. Notes Payable

Future principal payments on the notes payable are as follows (in thousands):


	June 30, 2017			December 31, 2016
Term loan agreement, net of deferred issuance costs of $2.7 million and $3.0 million, respectively	$	38,141		$	37,031
Equipment lease credit facility, net of deferred issuance cost of $34 and $45 thousand, respectively		3,132			3,742

Total notes payable		41,273			40,773
Less: current portion of notes payable		(1,365	)		(1,269	)

Notes payable, net of current portion	$	39,908		$	39,504

Term Loan Agreement

Equipment Lease Credit Facility

XML 23 R11.htm IDEA: XBRL DOCUMENT

Stockholders' Equity	6 Months Ended
Stockholders' Equity	Jun. 30, 2017
Equity [Abstract]
Stockholders' Equity	6. Stockholders’ Equity Private Investment in Public Equity Financing On September 21, 2016, Canon U.S.A., Inc. (“Canon”) became a related party when the Company sold 6,055,341 shares of its common stock (the “Canon Shares”) to Canon at $6.56 per share, the closing price on this date, for an aggregate cash purchase price of $39.7 million. As of September 21, 2016, the Canon Shares represented 19.9% of the outstanding shares of common stock of the Company. In connection with the sale of the Canon Shares, the Company agreed to grant Canon certain board designation rights, including the right to initially appoint a Class I director to the Company’s board of directors. On March 20, 2017, the Company filed with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-3 for purposes of registering the resale of the Canon Shares with the SEC.

XML 24 R12.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

6 Months Ended

Jun. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation

7. Stock-Based Compensation

Stock Incentive Plans

2006 Stock Incentive Plan

2014 Stock Incentive Plan

Stock Options

The following is a summary of stock option activity under the Plans (in thousands, except share and per share amounts):


	Number of Shares			Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term (In years)		Aggregate Intrinsic Value
Outstanding at December 31, 2016		4,042,627		$	8.20		7.05	$	4,091
Granted		743,200			5.30		6.00
Exercised		(193,630	)		2.33				500
Forfeited		(483,274	)		9.03
Cancelled		(102,775	)		14.93

Outstanding at June 30, 2017		4,006,148			7.67		6.98		918

Exercisable at June 30, 2017		2,309,906			7.25		5.54		918

Vested or expected to vest at June 30, 2017		3,761,002			7.69		6.83		918


	Six months ended
	June 30,
	2017			2016
Weighted-average risk-free interest rate		1.99	%		1.45	%
Expected dividend yield		—	%		—	%
Expected volatility		63	%		60	%
Expected terms		6.0 years			6.0 years

The total fair values of stock options that vested during the six months ended June 30, 2017 and 2016 were $2.0 million and $2.5 million, respectively.

Restricted Stock Units

The following is a summary of restricted stock unit activity under the 2014 Plan (in thousands, except share and per share amounts):


	Number of Shares			Weighted-Average Grant Date Fair Value
Nonvested at December 31, 2016		272,195			5.83
Granted		357,925			5.16
Vested		—			—
Forfeited		(32,900	)		5.80
Canceled		—			—

Nonvested at June 30, 2017		597,220			5.43

Stock-Based Compensation Expense


	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Cost of product revenue	$	36	$	33	$	65	$	59
Research and development		393		341		691		610
Selling, general and administrative		902		826		1,699		1,793

Total stock-based compensation expense	$	1,331	$	1,200	$	2,455	$	2,462

XML 25 R13.htm IDEA: XBRL DOCUMENT

Warrants	6 Months Ended
Warrants	Jun. 30, 2017
Text Block [Abstract]
Warrants	8. Warrants In connection with the Term Loan Agreement entered into in December 2016, the Company issued to CRG four separate warrants to purchase a total of 528,958 shares of the Company’s common stock. The warrants are exercisable any time prior to December 30, 2026 at a price of $8.06 per share, with typical provisions for termination upon a change of control or a sale of all or substantially all of the assets of the Company. The warrants are classified within shareholders’ equity, and the proceeds were allocated between the debt and warrants based on their relative fair value. The fair value of the warrants was determined by the Black-Scholes-Merton option pricing model. The fair value of the warrants at issuance on December 30, 2016 was $1.8 million.

XML 26 R14.htm IDEA: XBRL DOCUMENT

Net Loss Per Share

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Net Loss Per Share

9. Net Loss Per Share


	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Options to purchase common shares		4,006,148		4,167,295		4,006,148		4,167,295
Restricted stock units		597,220		—		597,220		—
Warrants to purchase common stock		528,958		—		528,958		—

Total		5,132,326		4,167,295		5,132,326		4,167,295

XML 27 R15.htm IDEA: XBRL DOCUMENT

Co-Development Agreements	6 Months Ended
Co-Development Agreements	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Co-Development Agreements	10. Co-Development Agreements Canon US Life Sciences On September 21, 2016, Canon became a related party when the Company sold the Canon Shares for an aggregate cash purchase price of $39.7 million, which represented 19.9% of the outstanding shares of common stock of the Company. On February 3, 2015, the Company entered into a Co-Development Partnership Agreement (the “Co-Development Agreement”) with Canon U.S. Life Sciences, Inc. (“Canon US Life Sciences”) to develop a diagnostic test panel to rapidly detect Lyme disease. Under the terms of the Co-Development Agreement, the Company received an upfront payment of $2.0 million from Canon US Life Sciences, and the agreement includes an additional $6.5 million of consideration upon achieving certain development and regulatory milestones for total aggregate payments of up to $8.5 million. In October 2015, the Company achieved a specified technical requirement and received $1.5 million related to the achievement of the milestone. The Company is eligible to receive an additional $5.0 million under the arrangement, in two milestone payments of $2.0 million and $3.0 million, related to the achievement of additional development and regulatory milestones. All payments under the Co-Development Agreement are non-refundable once received. The Company will retain exclusive worldwide commercialization rights of any products developed under the Co-Development Agreement, including sales, marketing and distribution and Canon US Life Sciences will not receive any commercial rights and will be entitled to only receive royalty payments on the sales of all products developed under the Co-Development Agreement. Either party may terminate the Co-Development Agreement upon the occurrence of a material breach by the other party (subject to a cure period). The Company evaluated the deliverables under the Co-Development Agreement and determined that the Co-Development Agreement included one unit of accounting, the research and development services, as the joint research and development committee deliverable was deemed to be de minimis. The Company is recognizing revenue for research and development services as a component of research revenue in the condensed consolidated financial statements as the services are delivered using the proportional performance method of accounting, limited to payments earned. Costs incurred to deliver the services under the Co-Development Agreement are recorded as research and development expense in the condensed consolidated financial statements. The Company recorded revenue of $0.0 and $0.6 million during the three months ended June 30, 2017 and June 30, 2016, respectively, and recorded revenue of $0.3 million and $1.1 million during the six months ended June 30, 2017 and 2016, under the Co-Development Agreement, and expects to record revenue over the next two years, provided development milestones are achieved. Allergan Sales, LLC On November 1, 2016, the Company entered into a Co-Development, Collaboration and Co-Marketing Agreement (the “Allergan Agreement”) with Allergan Sales, LLC (“Allergan Sales”) to develop (1) a direct detection diagnostic test panel that adds one additional bacteria species to the existing T2Bacteria product candidate (the “T2Bacteria II Panel”), and (2) a direct detection diagnostic test panel for testing drug resistance directly in whole blood (the “T2GNR Panel” and, together with the T2Bacteria II Panel, the “Developed Products”). In addition, both the Company and Allergan Sales will participate in a joint research and development committee and Allergan Sales will receive the right to cooperatively market the T2Candida, T2Bacteria, and the Developed Products under the Allergan Agreement to certain agreed-upon customers. On June 1, 2017 the Company and Allergan Sales entered into an Amendment to the Allergan Agreement which primarily modified the project plan to combine the T2Bacteria II Panel and T2GNR Panel into one test panel. Under the terms of the Allergan Agreement, the Company received an upfront payment of $2.0 million from Allergan Sales and will receive additional milestone payments upon achieving certain developmental milestones for total aggregate payments of up to $4.0 million. All payments under the Allergan Agreement are non-refundable once received. The Company will retain exclusive worldwide commercialization rights of any products developed under the Allergan Agreement, including distribution, subject to Allergan Sales’ right to co-market the Developed Products. Allergan Sales, at its election, may co-market T2Candida, T2Bacteria and the Developed Products worldwide to certain agreed-upon customers and will receive royalty based on its sales for a period of time. The Company evaluated the deliverables under the Allergan Agreement and determined that the Allergan Agreement included two units of accounting, the research and development services for the T2Bacteria II Panel and the research and development services for the T2GNR Panel, as the joint research and development committee and right to cooperatively market deliverables were deemed to be de minimus. The Company is recognizing revenue for research and development services as a component of research revenue in the consolidated financial statements as the services are delivered using the proportional performance method of accounting, limited to payments earned. Costs incurred to deliver the services under the Allergan Agreement are recorded as research and development expense in the consolidated financial statements. The Company recorded revenue of $0.2 million for the three and six months ended June 30, 2017, under the Allergan Agreement and expects to record revenue over the next two years, provided development and regulatory milestones are achieved.

XML 28 R16.htm IDEA: XBRL DOCUMENT

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	11. Subsequent Events. None

XML 29 R17.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Unaudited Interim Financial Information

Unaudited Interim Financial Information

Segment Information

Segment Information

Net Loss Per Share

Net Loss Per Share

Guarantees

Guarantees

Revenue Recognition

Revenue Recognition

Persuasive evidence of an arrangement exists

ii.

Delivery has occurred or services have been rendered

iii.

The seller’s price to the buyer is fixed or determinable

iv.

Collectability is reasonably assured

If any of the above criteria have not been met, the Company defers revenue until such time each of the criteria have been satisfied.

The Company does not offer rights of return for instruments or consumable diagnostic tests.

Product Recall

Product Recall

Cost of Product Revenue

Cost of Product Revenue

Research and Development Costs

Research and Development Costs

Recent Accounting Standards

Recent Accounting Standards

Accounting Standards Adopted

Accounting Standards Issued, Not Adopted

XML 30 R18.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2017

Fair Value Disclosures [Abstract]

Schedule of Financial Assets and Liabilities at Fair value on a Recurring Basis


	Balance at June 30, 2017		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash	$	2,953	$	2,953	$	—	$	—
Money market funds		43,181		43,181		—		—
Restricted cash		260		260		—		—

Total	$	46,394	$	46,394	$	—	$	—


	Balance at December 31, 2016		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash	$	16,887	$	16,887	$	—	$	—
Money market funds		56,601		56,601		—		—
Restricted cash		260		260		—		—

Total	$	73,748	$	73,748	$	—	$	—

XML 31 R19.htm IDEA: XBRL DOCUMENT

Supplemental Balance Sheet Information (Tables)

6 Months Ended

Jun. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Inventory

Inventories are stated at the lower of cost or net realizable value on a first-in, first-out basis and are comprised of the following (in thousands):


	June 30, 2017		December 31, 2016
Raw materials	$	463	$	389
Work-in-process		469		351
Finished goods		82		63

Total inventories, net	$	1,014	$	803

Schedule of Property and Equipment

Property and equipment consists of the following (in thousands):


	June 30, 2017			December 31, 2016
Office and computer equipment	$	409		$	409
Software		743			708
Laboratory equipment		4,078			4,516
Furniture		200			200
Manufacturing equipment		910			897
Manufacturing tooling and molds		160			154
T2-owned instruments and components		10,933			9,119
Leasehold improvements		3,372			3,353
Construction in progress		1,488			1,299

		22,293			20,655
Less accumulated depreciation and amortization		(7,783	)		(7,066	)

Property and equipment, net	$	14,510		$	13,589

Components of Accrued Expenses

Accrued expenses consist of the following (in thousands):


	June 30, 2017		December 31, 2016
Accrued payroll and compensation	$	2,234	$	2,479
Accrued research and development expenses		1,205		846
Accrued professional services		545		884
Other accrued expenses		717		699

Total accrued expenses	$	4,701	$	4,908

XML 32 R20.htm IDEA: XBRL DOCUMENT

Notes Payable (Tables)

6 Months Ended

Jun. 30, 2017

Debt Disclosure [Abstract]

Schedule of Debt

Future principal payments on the notes payable are as follows (in thousands):


	June 30, 2017			December 31, 2016
Term loan agreement, net of deferred issuance costs of $2.7 million and $3.0 million, respectively	$	38,141		$	37,031
Equipment lease credit facility, net of deferred issuance cost of $34 and $45 thousand, respectively		3,132			3,742

Total notes payable		41,273			40,773
Less: current portion of notes payable		(1,365	)		(1,269	)

Notes payable, net of current portion	$	39,908		$	39,504

XML 33 R21.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of Stock Option Activity

The following is a summary of stock option activity under the Plans (in thousands, except share and per share amounts):


	Number of Shares			Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term (In years)		Aggregate Intrinsic Value
Outstanding at December 31, 2016		4,042,627		$	8.20		7.05	$	4,091
Granted		743,200			5.30		6.00
Exercised		(193,630	)		2.33				500
Forfeited		(483,274	)		9.03
Cancelled		(102,775	)		14.93

Outstanding at June 30, 2017		4,006,148			7.67		6.98		918

Exercisable at June 30, 2017		2,309,906			7.25		5.54		918

Vested or expected to vest at June 30, 2017		3,761,002			7.69		6.83		918

Schedule of Estimated Assumptions Used to Calculate Weighted-Average Fair Value of Options Granted


	Six months ended
	June 30,
	2017			2016
Weighted-average risk-free interest rate		1.99	%		1.45	%
Expected dividend yield		—	%		—	%
Expected volatility		63	%		60	%
Expected terms		6.0 years			6.0 years

Schedule of Nonvested Restricted Stock Units Activity

The following is a summary of restricted stock unit activity under the 2014 Plan (in thousands, except share and per share amounts):


	Number of Shares			Weighted-Average Grant Date Fair Value
Nonvested at December 31, 2016		272,195			5.83
Granted		357,925			5.16
Vested		—			—
Forfeited		(32,900	)		5.80
Canceled		—			—

Nonvested at June 30, 2017		597,220			5.43

Summary of Stock-Based Compensation Expense for Stock Options Granted that was Recorded in the Company's Results of Operations


	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Cost of product revenue	$	36	$	33	$	65	$	59
Research and development		393		341		691		610
Selling, general and administrative		902		826		1,699		1,793

Total stock-based compensation expense	$	1,331	$	1,200	$	2,455	$	2,462

XML 34 R22.htm IDEA: XBRL DOCUMENT

Net Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share


	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Options to purchase common shares		4,006,148		4,167,295		4,006,148		4,167,295
Restricted stock units		597,220		—		597,220		—
Warrants to purchase common stock		528,958		—		528,958		—

Total		5,132,326		4,167,295		5,132,326		4,167,295

XML 35 R23.htm IDEA: XBRL DOCUMENT

Nature of Business - Additional Information (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016	Jun. 30, 2016	Dec. 31, 2015
Debt Instrument
Cash and cash equivalents	$ 46,134	$ 73,488	$ 50,218	$ 73,662
Accumulated deficit	$ (233,848)	$ (203,689)
Minimum [Member]
Debt Instrument
Period over which cash resources will be sufficient to allow Company to fund current operating plan	12 months
Loan and Security Agreement [Member]
Debt Instrument
Remaining borrowing capacity	$ 10,000

XML 36 R24.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2017 USD ($)	Jun. 30, 2016 USD ($)	Jun. 30, 2017 USD ($) Segment	Jun. 30, 2016 USD ($)	Dec. 31, 2016 USD ($)
Product Information [Line Items]
Number of operating segments \| Segment			1
Deferred revenue	$ 2,494,000		$ 2,494,000		$ 2,445,000
Costs of product revenue	1,989,000	$ 1,781,000	3,617,000	$ 2,807,000
T2 Candida [Member]
Product Information [Line Items]
Deferred revenue	20,000	$ 149,000	20,000	149,000
Costs of product revenue				$ 41,000
Remaining warranty reserve	2,000		$ 2,000
T2 Dx [Member]
Product Information [Line Items]
Maintenance Services period (in years)			1 year
Additional period for Maintenance Service option (in years)			1 year
Accounting Standards Update 201609 Excess Tax Benefit Component [Member] \| Retained Earnings [Member]
Product Information [Line Items]
Cumulative effect of new accounting principle in period of adoption	$ 1,200,000		$ 1,200,000

XML 37 R25.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Financial Assets and Liabilities at Fair value on a Recurring Basis (Detail) - Estimate of Fair Value Measurement [Member] - Recurring [Member] - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Assets:
Restricted cash	$ 260	$ 260
Total assets	46,394	73,748
Cash [Member]
Assets:
Cash	2,953	16,887
Money Market Funds [Member]
Assets:
Cash	43,181	56,601
Level 1 [Member]
Assets:
Restricted cash	260	260
Total assets	46,394	73,748
Level 1 [Member] \| Cash [Member]
Assets:
Cash	2,953	16,887
Level 1 [Member] \| Money Market Funds [Member]
Assets:
Cash	$ 43,181	$ 56,601

XML 38 R26.htm IDEA: XBRL DOCUMENT

Supplemental Balance Sheet Information - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Balance Sheet Related Disclosures [Abstract]
Raw materials	$ 463	$ 389
Work-in-process	469	351
Finished goods	82	63
Total inventories, net	$ 1,014	$ 803

XML 39 R27.htm IDEA: XBRL DOCUMENT

Supplemental Balance Sheet Information - Schedule of Property and Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 22,293	$ 20,655
Less accumulated depreciation and amortization	(7,783)	(7,066)
Property and equipment, net	14,510	13,589
Office and Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	409	409
Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	743	708
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	4,078	4,516
Furniture [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	200	200
Manufacturing Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	910	897
Manufacturing Tooling and Molds [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	160	154
T2-Owned Instruments and Components [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	10,933	9,119
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	3,372	3,353
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,488	$ 1,299

XML 40 R28.htm IDEA: XBRL DOCUMENT

Supplemental Balance Sheet Information - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Supplemental Balance Sheet Information [Line Items]
Property and equipment, gross	$ 22,293		$ 22,293		$ 20,655
T2 Owned Instruments in Service [Member]
Supplemental Balance Sheet Information [Line Items]
Property and equipment, gross	7,800		$ 7,800		$ 5,700
Estimated useful lives (in years)			5 years
Depreciation expense recorded as a component of cost of product revenue	$ 200	$ 200	$ 400	$ 200

XML 41 R29.htm IDEA: XBRL DOCUMENT

Supplemental Balance Sheet Information - Components of Accrued Expenses (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Accrued Liabilities, Current [Abstract]
Accrued payroll and compensation	$ 2,234	$ 2,479
Accrued research and development expenses	1,205	846
Accrued professional services	545	884
Other accrued expenses	717	699
Total accrued expenses	$ 4,701	$ 4,908

XML 42 R30.htm IDEA: XBRL DOCUMENT

Notes Payable - Schedule of Debt (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Debt Instrument
Total notes payable	$ 41,273	$ 40,773
Less: current portion of notes payable	(1,365)	(1,269)
Notes payable, net of current portion	39,908	39,504
Medium-term Notes [Member] \| Term Loan Agreement [Member]
Debt Instrument
Total notes payable	38,141	37,031
Line of Credit [Member] \| Equipment Lease Credit Facility [Member]
Debt Instrument
Total notes payable	$ 3,132	$ 3,742

XML 43 R31.htm IDEA: XBRL DOCUMENT

Notes Payable - Schedule of Debt (Parenthetical) (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Term Loan Agreement [Member] \| Medium-term Notes [Member]
Debt Instrument
Deferred issuance costs	$ 2,700	$ 3,000
Equipment Lease Credit Facility [Member] \| Line of Credit [Member]
Debt Instrument
Deferred issuance costs	$ 34	$ 45

XML 44 R32.htm IDEA: XBRL DOCUMENT

Notes Payable - Term Loan Agreement - Additional Information (Detail) $ / shares in Units, $ in Thousands	1 Months Ended	6 Months Ended
	Dec. 31, 2016 USD ($) Warrant $ / shares shares	Jun. 30, 2017 USD ($)	Jun. 30, 2016 USD ($)
Debt Instrument
Proceeds from issuance of note payable, net			$ 4,593
Repayments of note payable		$ 620	$ 392
Common Stock [Member]
Debt Instrument
Number of warrants \| Warrant	4
Number of shares issuable for warrants outstanding (in shares) \| shares	528,958
Exercise price of warrants \| $ / shares	$ 8.06
Fair market value of warrants	$ 1,800
Loan and Security Agreement [Member]
Debt Instrument
Repayments of note payable	27,500
Promissory Note [Member]
Debt Instrument
Repayments of note payable	500
CRG Servicing LLC [Member] \| Term Loan Agreement [Member]
Debt Instrument
Proceeds from issuance of long-term debt	40,000
Line of credit, additional borrowing capacity	$ 10,000
Debt term (in years)	6 years
Debt instrument, term of interest-only payments (in years)	3 years
Debt instrument, extended term interest only payments (in years)	4 years
Final fee as a percentage of the principal outstanding (as a percent)	8.00%
Debt instrument, prepayment fee term (in years)	5 years
Additional interest rate, event of default (as a percent)	4.00%
Proceeds from issuance of note payable, net	$ 39,200
Portion of proceeds used for debt repayment	$ 28,000
CRG Servicing LLC [Member] \| Term Loan Agreement [Member] \| Prior to Approval Milestone [Member]
Debt Instrument
Annual fixed rate (as a percent)	12.50%
Deferred interest rate (as a percent)	4.00%
CRG Servicing LLC [Member] \| Term Loan Agreement [Member] \| Following Approval Milestone [Member]
Debt Instrument
Annual fixed rate (as a percent)	11.50%
Deferred interest rate (as a percent)	3.50%

XML 45 R33.htm IDEA: XBRL DOCUMENT

Notes Payable - Equipment Lease Credit Facility - Additional Information (Detail) - Capital Lease Obligations [Member]	1 Months Ended
	Jun. 30, 2016 USD ($) Draw	Apr. 30, 2016 USD ($)	Oct. 31, 2015 USD ($)
Debt Instrument
Initial borrowing capacity			$ 10,000,000
Maximum borrowings available (up to)			$ 5,000,000
Debt term (in months)			36 months
Repurchase price as percentage of original equipment value that the equipment under lease may be repurchased by lessee			10.00%
Minimum lease period to extend lease (in years)			1 year
Amount of draw	$ 2,500,000	$ 2,100,000
Amount of monthly payment	$ 79,000,000	$ 67,000,000
Number of draws \| Draw	2

XML 46 R34.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Additional Information (Detail) - Private Placement [Member] $ / shares in Units, $ in Millions	Sep. 21, 2016 USD ($) $ / shares shares
Class of Stock [Line Items]
Number of shares sold \| shares	6,055,341
Sale price of stock (in dollars per share) \| $ / shares	$ 6.56
Proceeds from private investment in public equity \| $	$ 39.7
Percentage of common shares outstanding (as a percentage)	19.90%

XML 47 R35.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Share-Based Compensation
Fair value of vested stock options			$ 2,000,000	$ 2,500,000
Unrecognized compensation cost related to unvested stock options	$ 6,100,000		$ 6,100,000
Weighted-average period			2 years 18 days
Stock-based compensation expense	$ 1,331,000	$ 1,200,000	$ 2,455,000	2,462,000
Performance-based awards [Member]
Share-Based Compensation
Outstanding, end of the period	146,066		146,066		146,066
Performance-based awards [Member] \| Executive Officer [Member]
Share-Based Compensation
Outstanding, end of the period					166,066
Forfeited performance stock based options					20,000
Restricted Stock Units [Member]
Share-Based Compensation
Unrecognized compensation cost related to unvested stock options	$ 2,200,000		$ 2,200,000
Weighted-average period			1 year 29 days
T2 Owned Instruments in Service [Member]
Share-Based Compensation
Stock-based compensation expense	$ 53,000	$ 37,000	$ 86,000	65,000
2014 Stock Option Plan [Member] \| Stock Options [Member]
Share-Based Compensation
Shares available for future issuance under stock incentive plan	823,529		823,529
Percentage of common shares outstanding	4.00%		4.00%
Shares available for grant	960,529		960,529
2006 and 2014 Stock Option Plans [Member] \| Stock Options [Member]
Share-Based Compensation
Aggregate fair value of options granted			$ 2,300,000	$ 5,800,000
2006 and 2014 Stock Option Plans [Member] \| Stock Options [Member]
Share-Based Compensation
Outstanding, end of the period	4,006,148		4,006,148		4,042,627
Forfeited performance stock based options			483,274
Weighted average fair value of options granted			$ 3.11	$ 4.90
2006 and 2014 Stock Option Plans [Member] \| Restricted Stock Units [Member]
Share-Based Compensation
Aggregate fair value of options granted			$ 1,800,000
Maximum [Member] \| 2006 Stock Option Plan [Member] \| Stock Options [Member]
Share-Based Compensation
Expiration period			10 years
Vesting period			4 years
Maximum [Member] \| 2014 Stock Option Plan [Member] \| Stock Options [Member]
Share-Based Compensation
Expiration period			10 years
Vesting period			4 years

XML 48 R36.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Summary of Stock Option Activity (Detail) - 2006 and 2014 Stock Option Plans [Member] - Stock Options [Member] - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Share-Based Compensation
Number of Shares Outstanding, beginning of the period	4,042,627
Number of Shares, Granted	743,200
Number of Shares, Exercised	(193,630)
Number of Shares, Forfeited	(483,274)
Number of Shares, Cancelled	(102,775)
Number of Shares Outstanding, end of the period	4,006,148	4,042,627
Number of Shares, Exercisable	2,309,906
Number of Shares, Vested or expected to vest	3,761,002
Weighted-Average Exercise Price Per Share Outstanding, beginning of the period	$ 8.20
Weighted-Average Exercise Price Per Share, Granted	5.30
Weighted-Average Exercise Price Per Share, Exercised	2.33
Weighted-Average Exercise Price Per Share, Forfeited	9.03
Weighted-Average Exercise Price Per Share, Cancelled	14.93
Weighted-Average Exercise Price Per Share Outstanding, end of the period	7.67	$ 8.20
Weighted-Average Exercise Price Per Share, Exercisable	7.25
Weighted-Average Exercise Price Per Share, Vested or expected to vest	$ 7.69
Weighted-Average Remaining Contractual Term, Granted	6 years
Weighted-Average Remaining Contractual Term, Outstanding Beginning balance	6 years 11 months 23 days	7 years 18 days
Weighted-Average Remaining Contractual Term, Exercisable	5 years 6 months 14 days
Weighted-Average Remaining Contractual Term, Vested or expected to vest	6 years 9 months 29 days
Aggregate Intrinsic Value, Outstanding, beginning of the period	$ 4,091
Aggregate Intrinsic Value, Exercised	500
Aggregate Intrinsic Value Outstanding, end of the period	918	$ 4,091
Aggregate Intrinsic Value, Exercisable	918
Aggregate Intrinsic Value, Vested or expected to vest	$ 918

XML 49 R37.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Schedule of Estimated Assumptions Used to Calculate Weighted-Average Fair Value of Options Granted (Detail) - Stock Options [Member] - 2006 and 2014 Stock Option Plans [Member]	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Share-Based Compensation
Weighted-average risk-free interest rate	1.99%	1.45%
Expected dividend yield	0.00%	0.00%
Expected volatility	63.00%	60.00%
Expected terms	6 years	6 years

XML 50 R38.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Schedule of Nonvested Restricted Stock Units Activity (Detail) - Restricted Stock Units [Member]	6 Months Ended
	Jun. 30, 2017 $ / shares shares
Share-Based Compensation
Number of Shares, Unvested restricted shares at the beginning of the period \| shares	272,195
Number of Shares, Restricted shares granted \| shares	357,925
Number of Shares, Restricted shares vested \| shares	0
Number of Shares, Restricted shares forfeited \| shares	(32,900)
Number of Shares, Canceled \| shares	0
Number of Shares, Unvested restricted shares at the end of the period \| shares	597,220
Weighted-Average Grant Date Fair Value, Unvested restricted shares at the beginning of the period \| $ / shares	$ 5.83
Weighted-Average Grant Date Fair Value, Granted \| $ / shares	5.16
Weighted-Average Grant Date Fair Value, Vested \| $ / shares	0
Weighted-Average Grant Date Fair Value, Forfeited \| $ / shares	5.80
Weighted-Average Grant Date Fair Value, Canceled \| $ / shares	0
Weighted-Average Grant Date Fair Value, Unvested restricted shares at the end of the period \| $ / shares	$ 5.43

XML 51 R39.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Summary of Stock-Based Compensation Expense for Stock Options Granted that was Recorded in the Company's Results of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Stock-based compensation expense
Stock-based compensation expense	$ 1,331	$ 1,200	$ 2,455	$ 2,462
Cost of Product Revenue [Member]
Stock-based compensation expense
Stock-based compensation expense	36	33	65	59
Research and Development [Member]
Stock-based compensation expense
Stock-based compensation expense	393	341	691	610
Selling, General and Administrative [Member]
Stock-based compensation expense
Stock-based compensation expense	$ 902	$ 826	$ 1,699	$ 1,793

XML 52 R40.htm IDEA: XBRL DOCUMENT

Warrants - Additional Information (Detail) - Common Stock [Member] $ / shares in Units, $ in Millions	1 Months Ended
	Dec. 31, 2016 USD ($) Warrant $ / shares shares
Class of Warrant or Right [Line Items]
Number of warrants \| Warrant	4
Number of shares issuable for warrants outstanding \| shares	528,958
Exercise price of warrants \| $ / shares	$ 8.06
Fair market value of warrants \| $	$ 1.8

XML 53 R41.htm IDEA: XBRL DOCUMENT

Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Antidilutive Securities
Anti-dilutive securities excluded from the computation of diluted net loss per share	5,132,326	4,167,295	5,132,326	4,167,295
Options to Purchase Common Shares [Member]
Antidilutive Securities
Anti-dilutive securities excluded from the computation of diluted net loss per share	4,006,148	4,167,295	4,006,148	4,167,295
Restricted Stock Units [Member]
Antidilutive Securities
Anti-dilutive securities excluded from the computation of diluted net loss per share	597,220		597,220
Warrants to Purchase Common Stock [Member]
Antidilutive Securities
Anti-dilutive securities excluded from the computation of diluted net loss per share	528,958		528,958

XML 54 R42.htm IDEA: XBRL DOCUMENT

Co-Development Agreements - Additional Information (Detail) $ in Thousands				1 Months Ended	3 Months Ended		6 Months Ended
	Nov. 01, 2016 USD ($) specie	Sep. 21, 2016 USD ($)	Feb. 03, 2015 USD ($) Item	Oct. 31, 2015 USD ($)	Jun. 30, 2017 USD ($) Item	Jun. 30, 2016 USD ($)	Jun. 30, 2017 USD ($) Item	Jun. 30, 2016 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues					$ 956	$ 990	$ 1,897	$ 2,086
Private Placement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from sale of shares in related party		$ 39,700
Percentage of outstanding shares at date of sale		19.90%
Co Development Partnership Agreement [Member] \| Canon U.S. Life Sciences Inc [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment			$ 2,000
Additional consideration receivable upon achievement of certain development and regulatory milestones			6,500
Aggregate consideration receivable			$ 8,500
Proceeds received for achievement of milestone				$ 1,500
Additional consideration receivable upon achievement of additional development and regulatory milestones					$ 5,000		$ 5,000
Number of milestone payments \| Item					2		2
Additional consideration receivable upon achievement of development and regulatory milestones, payment one					$ 2,000		$ 2,000
Additional consideration receivable upon achievement of development and regulatory milestones, payment two					3,000		3,000
Number of units \| Item			1
Revenues					0	$ 600	300	$ 1,100
Co Development Partnership Agreement [Member] \| Allergan Sales [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment	$ 2,000
Aggregate consideration receivable	$ 4,000
Revenues					$ 200		$ 200
Number of additional bacteria species added to existing product candidate \| specie	1

EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 57 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 59 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 122 217 1 false 50 0 false 9 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.t2biosystems.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.t2biosystems.com/taxonomy/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.t2biosystems.com/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 105 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.t2biosystems.com/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 106 - Statement - Condensed Consolidated Statement of Cash Flows Sheet http://www.t2biosystems.com/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows Condensed Consolidated Statement of Cash Flows Statements 5 false false R6.htm 107 - Disclosure - Nature of Business Sheet http://www.t2biosystems.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations Nature of Business Notes 6 false false R7.htm 108 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.t2biosystems.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Summary of Significant Accounting Policies Notes 7 false false R8.htm 109 - Disclosure - Fair Value Measurements Sheet http://www.t2biosystems.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value Measurements Notes 8 false false R9.htm 110 - Disclosure - Supplemental Balance Sheet Information Sheet http://www.t2biosystems.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock Supplemental Balance Sheet Information Notes 9 false false R10.htm 111 - Disclosure - Notes Payable Notes http://www.t2biosystems.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock Notes Payable Notes 10 false false R11.htm 112 - Disclosure - Stockholders' Equity Sheet http://www.t2biosystems.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Stockholders' Equity Notes 11 false false R12.htm 113 - Disclosure - Stock-Based Compensation Sheet http://www.t2biosystems.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock-Based Compensation Notes 12 false false R13.htm 114 - Disclosure - Warrants Sheet http://www.t2biosystems.com/taxonomy/role/NotesToFinancialStatementsWarrantsTextBlock Warrants Notes 13 false false R14.htm 115 - Disclosure - Net Loss Per Share Sheet http://www.t2biosystems.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Net Loss Per Share Notes 14 false false R15.htm 116 - Disclosure - Co-Development Agreements Sheet http://www.t2biosystems.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock Co-Development Agreements Notes 15 false false R16.htm 117 - Disclosure - Subsequent Events Sheet http://www.t2biosystems.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock Subsequent Events Notes 16 false false R17.htm 118 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.t2biosystems.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.t2biosystems.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock 17 false false R18.htm 119 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.t2biosystems.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables Fair Value Measurements (Tables) Tables http://www.t2biosystems.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock 18 false false R19.htm 120 - Disclosure - Supplemental Balance Sheet Information (Tables) Sheet http://www.t2biosystems.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlockTables Supplemental Balance Sheet Information (Tables) Tables http://www.t2biosystems.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock 19 false false R20.htm 121 - Disclosure - Notes Payable (Tables) Notes http://www.t2biosystems.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables Notes Payable (Tables) Tables http://www.t2biosystems.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock 20 false false R21.htm 122 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.t2biosystems.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Stock-Based Compensation (Tables) Tables http://www.t2biosystems.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock 21 false false R22.htm 123 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.t2biosystems.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Net Loss Per Share (Tables) Tables http://www.t2biosystems.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock 22 false false R23.htm 124 - Disclosure - Nature of Business - Additional Information (Detail) Sheet http://www.t2biosystems.com/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformation Nature of Business - Additional Information (Detail) Details 23 false false R24.htm 125 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.t2biosystems.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation Summary of Significant Accounting Policies - Additional Information (Detail) Details 24 false false R25.htm 126 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities at Fair value on a Recurring Basis (Detail) Sheet http://www.t2biosystems.com/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnARecurringBasis Fair Value Measurements - Schedule of Financial Assets and Liabilities at Fair value on a Recurring Basis (Detail) Details 25 false false R26.htm 127 - Disclosure - Supplemental Balance Sheet Information - Schedule of Inventory (Detail) Sheet http://www.t2biosystems.com/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfInventory Supplemental Balance Sheet Information - Schedule of Inventory (Detail) Details 26 false false R27.htm 128 - Disclosure - Supplemental Balance Sheet Information - Schedule of Property and Equipment (Detail) Sheet http://www.t2biosystems.com/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipment Supplemental Balance Sheet Information - Schedule of Property and Equipment (Detail) Details 27 false false R28.htm 129 - Disclosure - Supplemental Balance Sheet Information - Additional Information (Detail) Sheet http://www.t2biosystems.com/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformation Supplemental Balance Sheet Information - Additional Information (Detail) Details 28 false false R29.htm 130 - Disclosure - Supplemental Balance Sheet Information - Components of Accrued Expenses (Detail) Sheet http://www.t2biosystems.com/taxonomy/role/DisclosureSupplementalBalanceSheetInformationComponentsOfAccruedExpenses Supplemental Balance Sheet Information - Components of Accrued Expenses (Detail) Details 29 false false R30.htm 131 - Disclosure - Notes Payable - Schedule of Debt (Detail) Notes http://www.t2biosystems.com/taxonomy/role/DisclosureNotesPayableScheduleOfDebt Notes Payable - Schedule of Debt (Detail) Details 30 false false R31.htm 132 - Disclosure - Notes Payable - Schedule of Debt (Parenthetical) (Detail) Notes http://www.t2biosystems.com/taxonomy/role/DisclosureNotesPayableScheduleOfDebtParenthetical Notes Payable - Schedule of Debt (Parenthetical) (Detail) Details 31 false false R32.htm 133 - Disclosure - Notes Payable - Term Loan Agreement - Additional Information (Detail) Notes http://www.t2biosystems.com/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformation Notes Payable - Term Loan Agreement - Additional Information (Detail) Details 32 false false R33.htm 134 - Disclosure - Notes Payable - Equipment Lease Credit Facility - Additional Information (Detail) Notes http://www.t2biosystems.com/taxonomy/role/DisclosureNotesPayableEquipmentLeaseCreditFacilityAdditionalInformation Notes Payable - Equipment Lease Credit Facility - Additional Information (Detail) Details 33 false false R34.htm 135 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.t2biosystems.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation Stockholders' Equity - Additional Information (Detail) Details 34 false false R35.htm 136 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.t2biosystems.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation Stock-Based Compensation - Additional Information (Detail) Details 35 false false R36.htm 137 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail) Sheet http://www.t2biosystems.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivity Stock-Based Compensation - Summary of Stock Option Activity (Detail) Details 36 false false R37.htm 138 - Disclosure - Stock-Based Compensation - Schedule of Estimated Assumptions Used to Calculate Weighted-Average Fair Value of Options Granted (Detail) Sheet http://www.t2biosystems.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedAssumptionsUsedToCalculateWeightedAverageFairValueOfOptionsGranted Stock-Based Compensation - Schedule of Estimated Assumptions Used to Calculate Weighted-Average Fair Value of Options Granted (Detail) Details 37 false false R38.htm 139 - Disclosure - Stock-Based Compensation - Schedule of Nonvested Restricted Stock Units Activity (Detail) Sheet http://www.t2biosystems.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivity Stock-Based Compensation - Schedule of Nonvested Restricted Stock Units Activity (Detail) Details 38 false false R39.htm 140 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense for Stock Options Granted that was Recorded in the Company's Results of Operations (Detail) Sheet http://www.t2biosystems.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedThatWasRecordedInTheCompanysResultsOfOperations Stock-Based Compensation - Summary of Stock-Based Compensation Expense for Stock Options Granted that was Recorded in the Company's Results of Operations (Detail) Details 39 false false R40.htm 141 - Disclosure - Warrants - Additional Information (Detail) Sheet http://www.t2biosystems.com/taxonomy/role/DisclosureWarrantsAdditionalInformation Warrants - Additional Information (Detail) Details 40 false false R41.htm 142 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) Sheet http://www.t2biosystems.com/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) Details 41 false false R42.htm 143 - Disclosure - Co-Development Agreements - Additional Information (Detail) Sheet http://www.t2biosystems.com/taxonomy/role/DisclosureCoDevelopmentAgreementsAdditionalInformation Co-Development Agreements - Additional Information (Detail) Details 42 false false All Reports Book All Reports ttoo-20170630.xml ttoo-20170630.xsd ttoo-20170630_cal.xml ttoo-20170630_def.xml ttoo-20170630_lab.xml ttoo-20170630_pre.xml true true ZIP 61 0001193125-17-247725-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-17-247725-xbrl.zip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

Large accelerated filer

Accelerated filer

Non-accelerated filer

☐ (Do not check if a smaller reporting company)

Smaller reporting company

Emerging growth company